



Cochrane Editorial and Methods

Screening for breast cancer with mammography

--Manuscript Draft--

Manuscript Number:	COCHRANEEMD-2023-01113R1
Full Title:	Screening for breast cancer with mammography
Article Type:	Update: Intervention Review
Section/Category:	Central Editorial Service
Corresponding Author:	Peter C Gøtzsche Rigshospitalet Hørsholm, DENMARK
Order of Authors:	Peter C Gøtzsche Karsten Jørgensen

RevMan: review – intervention; 754799112511540913 (version 13.2)

Status: UNPUBLISHED DRAFT

medRxiv preprint doi: <https://doi.org/10.1101/2024.06.06.24308542>; this version posted June 6, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Screening for breast cancer with mammography

Table of contents

Abstract

Plain language summary

Summary of findings

Background

Description of the condition

Description of the intervention

How the intervention might work

Why it is important to do this review

Objectives

Methods

Criteria for considering studies for this review

Search methods for identification of studies

Data collection and analysis

Results

Description of studies

Risk of bias in included studies

Effects of interventions

Discussion

Summary of main results

Overall completeness and applicability of evidence

Quality of the evidence

Potential biases in the review process

Agreements and disagreements with other studies or reviews

Authors' conclusions

Acknowledgements

Data and analyses

What's new

History

Contributions of authors

Declarations of interest

Sources of support

Internal sources

External sources

Differences between protocol and review

Characteristics of studies

Characteristics of included studies [ordered by study ID]

Characteristics of excluded studies [ordered by study ID]

Characteristics of studies awaiting classification [ordered by study ID]

Appendices

Appendix 1. PubMed search strategy

Appendix 2. CENTRAL Search Strategy

Appendix 3. World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) Search Strategy

Appendix 4. Clinicaltrials.gov Search Strategy

References

References to studies included in this review

References to studies excluded from this review

References to studies awaiting assessment

Additional references

References to other published versions of this review

Additional tables

Editors: Cochrane Breast Cancer Group

Contact Person: Peter C Gøtzsche (pcg@scientificfreedom.dk)

Institute for Scientific Freedom, Hørsholm, Denmark

Peter C Gøtzsche [¹] Karsten Juhl Jørgensen [²]

[1] Institute for Scientific Freedom, Hørsholm, Denmark

[2] Cochrane Denmark and Centre for Evidence Based Medicine; this version posted June 6, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Citation

Gøtzsche PC, Jørgensen KJ. Screening for breast cancer with mammography. Cochrane Database of Systematic Reviews TBD, Issue TBD. Art. No.: CD001877. DOI: [10.1002/14651858.CD001877.pub6](https://doi.org/10.1002/14651858.CD001877.pub6).

Dates

Revision published: Issue TBD, TBD (TBD)

Version published (citation changed): Issue TBD, TBD (TBD)

Review first published: Issue 4, 2001

Protocol first published: Issue 1, 2000

Abstract

Background

A variety of estimates of the benefits and harms of mammographic screening for breast cancer have been published and national policies vary. This is an update of a review previously updated 2013 and originally published 2001.

Objectives

To assess the effect of screening for breast cancer with mammography on mortality and morbidity.

Search methods

For this 2023 update, we searched PubMed, CENTRAL, the Cochrane Breast Cancer Group Specialised Register, the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) and ClinicalTrials.gov up to 28 February 2023.

Selection criteria

Randomised clinical trials (RCTs) comparing mammographic screening with no mammographic screening.

Data collection and analysis

Two authors independently extracted data. Study authors were contacted for additional information. Our main outcomes of interest were deaths due to breast cancer, any cancer, and due to any cause, and harms measured as overdiagnosis, number of mastectomies, lumpectomies, use of radiotherapy and of chemotherapy. Certainty of evidence was assessed with GRADE.

Main results

Eight eligible trials from Europe and North America that compared women offered screening mammography with women not offered screening were included. We excluded a trial because the randomisation failed to produce comparable groups. The eligible trials included 600,000 women in the age range 39 to 74 years.

The trials with adequate randomisation did not show a benefit in terms of a reduction in breast cancer mortality at 13 years (risk ratio (RR) 0.90, 95% confidence interval (CI) 0.79 to 1.02; 33 vs 30 deaths from breast cancer per 10,000 women; 3 RCTs; 292,153 participants). The findings at 24 years were similar to those at 13 years. Our certainty in both estimates was downgraded 1 level to 'low' due to changes in technology and treatment (indirectness) and due to imprecision. The trials with suboptimal randomisation showed a reduction in breast cancer mortality at 13 years with an RR of 0.75 (95% CI 0.67 to 0.83; 4 RCTs; 306,937 participants; very low certainty evidence).

In women below age 50 years, the results from adequately randomised trials did not show a reduction in breast cancer mortality at 13 years of follow-up (RR 0.87, CI 0.73 to 1.03; 28 vs 24 deaths from breast cancer per 10,000 women; 3 RCTs; 218,697 participants, low certainty evidence), nor for women at least 50 years (RR 0.94, CI 0.77 to 1.15; 53 vs 50 deaths from breast cancer per 10,000 women; 2 RCTs; 74,261 participants, low certainty evidence). Only one trial included women aged 70 years and above and could not provide a reliable effect estimate.

We found that breast cancer mortality was an unreliable outcome that was biased in favour of screening, mainly because of the risk of differential misclassification of cause of death. The trials with inadequate randomisation did not find an effect of screening on total cancer mortality, including breast cancer (RR 1.00, 95% CI 0.98 to 1.04; 288 vs 288 cancer deaths per 10,000 women; 3 RCTs; 292,954 participants; moderate certainty evidence; the follow-up was 10.5 years for Canada, 9 years for Malmö and 23 years for the UK age trial). All-cause mortality was not reduced (RR 0.98, 95% CI 0.94 to 1.03 after 7 years; RR 0.99, 95% CI 0.95 to 1.03 after 13 years; 324 vs 328 deaths per 10,000 women; and RR 1.01, 95% CI 0.99 to 1.04 after 24 years; 773 vs 765 deaths per 10,000 women; 2 RCTs; 250,671 participants; moderate certainty evidence) in the adequately randomised trials.

There were more lumpectomies and mastectomies combined in the screened groups, likely reflecting overtreatment (RR 1.31, 95% CI 1.22 to 1.42; 164 vs 214 operations per 10,000 women; 2 RCTs; 132,321 participants; moderate certainty evidence), as were the number of mastectomies alone (RR 1.20, 95% CI 1.08 to 1.32; 122 vs 102 per 10,000 women; 2 RCTs; 132,321; moderate certainty evidence). The use of radiotherapy was similarly increased whereas there was no difference in the use of chemotherapy (data for each outcome available from only one adequately randomised trial; low certainty evidence). Breast screening increased the number of breast cancer diagnoses (overdiagnosis) (RR 1.25, CI 1.18 to 1.34, 142 vs 113 diagnoses at 7 to 9 years of follow-up; 3 RCTs, 292,979 participants; moderate certainty evidence) in trials that did not screen the control group after the intervention phase.

Authors' conclusions

Because of substantial changes in screening technology, treatment, and breast cancer awareness since the trials were done, the estimates from the trials are uncertain in today's setting. As breast cancer mortality is an unreliable outcome that is biased in favour of screening, it is noteworthy that screening did not reduce total cancer mortality or total mortality. Breast screening does not meet the criteria that population screening should be based on rigorously performed randomised trials that show that the benefits outweigh the harms. No studies have been completed in low income countries and one small study from Colombia has yet to provide data on long term outcomes. Women, clinicians and policy makers should consider the trade-offs and the uncertainties carefully when they decide whether or not to attend or support breast screening programmes.

Plain language summary

What are the benefits and harms of screening for breast cancer with mammography?

Key messages

1. The most reliable studies did not show that breast screening with mammography reduces your risk of dying from breast cancer. While other studies did show this, they are less reliable.
2. Breast screening detects cancers that would never have caused death or disease in the absence of screening (overdiagnosis). This increases your risk of having a breast or a lump in your breast removed needlessly (overtreatment). Breast screening also causes false positive results, which is when the mammogram raises a suspicion of breast cancer that is later put to rest. False positive tests are common and can negatively affect quality of life also after a serious diagnosis is ruled out.
3. Substantial changes in technology, treatment, and greater public awareness of breast cancer since the studies were done means that the effects of breast screening are uncertain and that any benefit is likely smaller today.

What is breast cancer?

Breast cancer is a common cancer in women. The risk increases with age. It is a highly variable disease, with some cases developing rapidly and aggressively while others grow slowly or not at all. This complicates screening, which is more likely to detect slow-growing than fast growing cancers.

How does breast screening work?

Screening with mammography uses X-ray imaging to find breast cancer before a lump is felt. Screening is therefore intended for women in whom breast cancer is not suspected. The idea is to detect cancer earlier, when a cure is more likely. However, as some cancers have spread before screen detection is possible, one cannot assume that earlier detection is beneficial.

What did we want to find out?

We wanted to find out if mammography screening reduces the risk of dying from breast cancer; if it reduces the need for treatment; if it reduces the risk of dying overall; and to which extent it causes harms in terms of overdiagnosis and overtreatment of breast cancers not destined to cause death or symptoms in the lifetime of the women.

What did we do?

We searched for studies that compared screening with no screening.

We compared and summarized the results of the studies and rated our confidence in the evidence, based on factors such as study methods, study context, and size. This review is the author's work, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

What did we find?

We found eight trials that involved 600,000 women in the age range 39 to 74 years. The design of some studies was more reliable than others, mainly due to the way women were distributed between the screening group and the control group, but also for other reasons. The most reliable studies showed that screening likely did not reduce the risk of dying from breast cancer, regardless of age group. Due to the age of the trials, our certainty of this result was assessed as 'low'. While other trials found a benefit from screening, their less reliable designs mean that our certainty in these results is even lower ('very low').

Neither our analysis of the most or of the least reliable trials showed that screening reduced the risk of dying when all causes were considered.

The trials indicated with moderate certainty that the risk of being overdiagnosed happened to about 1 in 5 of those diagnosed with breast cancer during the period they were offered screening.

What are the limitations of the evidence?

There were important differences in the estimated benefit (reduced risk of death from breast cancer) between well and less well designed trials. The main design limitation was that some trial randomised groups of women rather than individuals, which meant that the two groups did not have a comparable risk of getting breast cancer.

There has been substantial changes in technology and treatment since the trials were done, and increased awareness of breast cancer and the importance of seeking care as soon as possible. This means that the possible benefit of breast screening today is likely quite different from that in the trials. It is uncertain if mammography screening delivers an important benefit today but we are certain it causes serious harms, overdiagnosis and overtreatment and false positive results. The included trials were performed in Europe and North America and did not consider effects in minorities.

How up to date is the evidence?

This review updates our previous review but did not identify new trials. The evidence is up to date to February 2023.

Summary of findings

Summary of findings 1						
Summary of findings table - Screening with mammography compared to no screening with mammography for women not suspected of breast cancer (all age groups)						
Screening with mammography compared to no screening with mammography for women not suspected of breast cancer (all age groups)						
Patient or population: women not suspected of breast cancer (all age groups) Setting: population screening Intervention: screening with mammography Comparison: no screening with mammography						
Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	Nº of participants (studies)	Certainty of the evidence (GRADE)	Comments
	Risk with no screening with mammography	Risk with screening with mammography				
Deaths ascribed to breast cancer, 13 years follow up - Adequately randomised trials	33 per 10,000	30 per 10,000 (26 to 34)	RR 0.90 (0.79 to 1.02)	292153 (3 RCTs)	⊕⊕⊕⊖ Low ^{a,b}	For all age groups combined, screening mammography may have little or no effect on breast cancer mortality. The age of the trials and a confidence interval that includes a benefit reduced our certainty in the estimated effect by 1 level for indirectness and 1 level for imprecision (low certainty). While suboptimally randomised trials showed a benefit (RR 0.75; CI 0.67 to 0.83), our confidence in this estimate was further lowered (to very low) due to important risks of bias and inconsistency.
Deaths ascribed to any cancer, all women, 9 to 23 years of follow-up - Adequately randomised trials	288 per 10,000	288 per 10,000 (277 to 300)	RR 1.00 (0.96 to 1.04)	292954 (3 RCTs)	⊕⊕⊕⊖ Moderate ^a	For all age groups combined, screening mammography likely results in little to no difference in mortality from any cancer. This finding was consistent with that in the suboptimally randomised trials (RR 0.99; CI 0.93 to 1.06). We downgraded

GRADE Working Group grades of evidence

High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.

Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. This made available under a CC-BY-NC-ND 4.0 International license.

Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.

Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.

See interactive version of this table: https://gdt.gradeapro.org/presentations/#/isof/isof_question_revman_web_442941409808163915.

^a Age of trials; we downgraded one level for indirectness due to substantial changes in technology and treatment.

^b The confidence interval includes a benefit and we downgraded one level due to imprecision.

^c Outcome reported in only one adequately randomised trial. We downgraded one level due to imprecision.

Summary of findings 2

Summary of findings table - Screening with mammography compared to no screening with mammography for women not suspected of breast cancer (ages below 50 years)

Screening with mammography compared to no screening with mammography for women not suspected of breast cancer (ages below 50 years)

Patient or population: women not suspected of breast cancer (ages below 50 years)

Setting: population screening

Intervention: screening with mammography

Comparison: no screening with mammography

Outcomes	Anticipated absolute effects [*] (95% CI)		Relative effect (95% CI)	N° of participants (studies)	Certainty of the evidence (GRADE)	Comments
	Risk with no screening with mammography	Risk with screening with mammography				
Deaths ascribed to breast cancer, 13 years follow up, women below 50 years of age - Adequately randomised trials	28 per 10,000	24 per 10,000 (20 to 28)	RR 0.87 (0.73 to 1.03)	218697 (3 RCTs)	⊕⊕⊕⊕ Low ^{a,b}	Screening mammography may have little or no effect on breast cancer mortality in women below 50 years. The age of the trials and a confidence interval that includes a benefit reduced our certainty in the estimate by 1 level for indirectness and 1 level for imprecision. While suboptimally randomised trials showed a benefit (RR 0.80; CI 0.64 to 0.98), the certainty of this estimate was lowered further (to very low) due to important risks of bias and inconsistency.
Overall mortality, 13 years follow up, women below 50 years of age - Adequately randomised trials	188 per 10,000	184 per 10,000 (173 to 195)	RR 0.98 (0.92 to 1.04)	219324 (3 RCTs)	⊕⊕⊕⊕ Moderate ^a	Screening mammography likely does not reduce all-cause mortality in women below 50 years. This finding was consistent with that in the suboptimally randomised trials (RR 1.00; CI 0.92 to 1.10) and with findings in the two trials with results after 24 years of follow-up (RR 1.01; CI 0.99 to 1.04). We downgraded the certainty of the evidence by 1 level due to the age of the trials (Indirectness).

^{*}The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: confidence interval; RR: risk ratio

GRADE Working Group grades of evidence

High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.

Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.

Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.

See interactive version of this table: https://gdt.gradeapro.org/presentations/#/isof/isof_question_revman_web_442942357848719411.

^a Age of trials; substantial changes in technology and treatment.

^b Confidence interval includes a benefit.

Summary of findings 3

Summary of findings table - Screening with mammography compared to no screening with mammography for women not suspected of breast cancer (at least 50 years)

Screening with mammography compared to no screening with mammography for women not suspected of breast cancer (at least 50 years)

Patient or population: women not suspected of breast cancer (at least 50 years)

Setting: population screening

CI: confidence interval; OR: odds ratio

GRADE Working Group grades of evidence

High certainty: we are very confident in the effect estimate: the true effect is likely to be close to the estimate of the effect.

Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.

Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.

See interactive version of this table: https://gdt.gradeapro.org/presentations/#/isof/isof_question_revman_web_442942514527993973.

^a Suboptimal randomisation method (cluster-randomisation)

^b Age of trials; substantial changes in technology and treatment.

^c Only one trial included this age group and data is scarce.

Background

Breast cancer is an important cause of death among women worldwide with marked regional differences in disease burden (Arnold 2022). Early detection through screening with mammography has the potential to reduce mortality, but it also leads to overdiagnosis and overtreatment (IARC 2002). Since screening preferentially identifies slow-growing tumours (length bias) (Final reports 1977; Fox 1979), the harms of unnecessary treatment of overdiagnosed tumours could reduce or outweigh potential benefits.

The best way to reliably estimate the effectiveness of screening is with randomised trials at low risk of bias, as biases in the trials can easily erase or create the comparatively small effects of population based screening interventions (IARC 2002). Large trials, involving 650,000 women, have been carried out in North America and Europe (Canada 1980; Edinburgh 1978; Göteborg 1982; Malmö 1976; New York 1963; Stockholm 1981; Two-County 1977; UK age trial 1991). It should be noted that, as for most interventions, the trials do not assess effects in minority groups or subgroups with poor access to care or particular risk profiles.

Several systematic reviews and meta-analyses have been published (Berry 1998; Blamey 2000; Cox 1997; Demissie 1998; Elwood 1993; European Commission Initiative 2020; Glasziou 1992; Glasziou 1995; Glasziou 1997; Gøtzsche 2000; Gøtzsche 2011; Hendrick 1997; Humphrey 2002; IARC 2002; Kerlikowske 1995; Kerlikowske 1997; Larsson 1996; Larsson 1997; Nelson 2016; Nyström 1993; Nyström 1996; Nyström 1997; Nyström 2000; Nyström 2002; Olsen 2001a; Olsen 2001b; Smart 1995; Swed Cancer Soc 1996; UK review 2012; Wald 1993).

The large number of reviews reflects the controversies surrounding mammography screening and the uncertainties of its effects in women of various ages. There is wide variation in screening policies between different countries, with some countries abstaining from introducing screening partly because of the lack of a documented reduction in all-cause mortality (Isacsson 1985; Skrabanek 1993; Swift 1993). One area of concern is the potential for radiotherapy treatment of low-risk women, such as those who have their cancers identified at screening, to increase all-cause mortality because of adverse cardiovascular effects (EBCTCG 1995; EBCTCG 2000). Harms from radiotherapy has likely diminished in today's setting, but increased overdiagnosis with greater sensitivity of the screening test may mean more women are exposed. Overdiagnosis of breast cancer is acknowledged as the most important harm of breast screening (Barratt 2015), although uncertainty around its magnitude remains, as it does for its main benefit (UK review 2012). Overdiagnosis is the detection of cancers that would never have appeared in the lifetime of the individual in the absence of screening and is perhaps best known from prostate cancer screening.

In addition, there is concern that cause of death has not been ascribed in an unbiased fashion in some of the trials due to lack of blinded outcome assessment. Finally, carcinoma in situ is much more likely to be detected with screening mammography and although less than half of the cases will progress to become invasive (Nielsen 1987; Welch 1997), only 18% after 20 years of follow-up in the Canadian trials (To 2014), these women are often treated with surgery, drugs, and radiotherapy.

Since the trials were performed, major advances in earlier diagnosis of clinical cancers with increased breast cancer awareness (Rostgaard 2010) and in breast cancer treatment (Riemsma 2010) have happened. This has resulted in reductions in breast cancer mortality of 30% or more, most pronounced in younger women, below the age range invited for breast screening (Autier 2011a). Collectively, this means that the relevance of the results of the original trials have diminished in today's setting. This has led some prominent guideline groups to use modelling studies (Draft USPSTF recommendation 2023) as the basis for screening recommendations, which has raised concerns (Harris 2024; Woloshin 2023). As modelling studies come with substantial uncertainty, we do not include them in this update. We do not include observational studies either for the same reason, which is in agreement with other reviews (UK review 2012; European Commission Initiative 2020).

Meta-analyses of screening are often deficient (Walter 1999) and few of the meta-analyses listed above have taken account of the risk of bias in the individual trials or considered harms as well as benefits. We have identified important weaknesses in the trials (Gøtzsche 2000; Gøtzsche 2000a; Gøtzsche 2004; Gøtzsche 2011) and have now updated our Cochrane Review with additional data from two of the least biased trials, while no new trials contributed data. This update also include addition of Summary of Findings tables and a GRADE assessment of the certainty of the evidence for individual outcomes.

Description of the condition

medRxiv preprint doi: <https://doi.org/10.1101/2024.06.06.24308542>; this version posted June 6, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Breast cancer is the most common cancer among women worldwide ([World Cancer Data 2023](#)). It is a highly variable disease with some cases growing rapidly and aggressively, and some slowly or not at all. Like for most cancers, breast cancer incidence increase with age and the rapidity of growth slows. This has implications for the usefulness and the benefit to harm balance of screening. Breast cancer is also known to be able to return many years after treatment, sometimes after 20 years or more. This means it is difficult to say a breast cancer is 'cured', likely due to micro-metastases being present in the body after treatment. Breast cancer is thus regarded as a potentially systemic disease which affect treatment choices, although the exact time of metastasis is difficult to determine. Ideally, breast screening should detect cancers prior to metastasis to affect mortality and maximise chances of curative treatment.

Description of the intervention

Screening with mammography uses X-ray imaging to find breast cancer before symptoms are noticed. The X-ray screening test generally does not provide the diagnosis but may raise a suspicion. Those who are found to have suspicious lesions are subjected to further tests such as ultrasound, MRI scans, and biopsies. Those in which these follow-up tests have excluded a diagnosis of breast cancer are said to have experienced a false-positive screening mammogram. Screening mammography differs from diagnostic mammography in that those who receive screening mammograms do not have symptoms or a suspicion of breast cancer. Mammography screening programmes thus invite women without symptoms of breast cancer. While the screening test uses X-rays, the dose is quite low and presents a very small risk in itself ([IARC 2002](#)).

How the intervention might work

The idea with breast screening is to detect and treat breast cancer earlier, when a cure may be more likely and treatment possibly less aggressive. Breast screening is commonly offered annually, biennially, or triennially, varying between countries ([IARC 2002](#)). The most commonly screened age range is 50 to 69 years, but women in their 40s and 70s are sometimes targeted as well ([IARC 2002](#)). The interval between screening rounds means that rapidly growing cancers are less likely to be detected through screening and more likely to appear between screening rounds. This phenomenon is called 'length bias', as slower growing cancers has a greater length of time to allow screen detection ([Welch 2004](#)). Cancers detected between screening rounds are known as 'interval cancers'. Interval cancers are thus, on average, the more aggressive and fast growing ones ([Welch 2004](#)), and they cannot benefit from breast screening. The fact that breast screening is best at detecting cancers that grow slowly or not at all is the cause of its major harm: overdiagnosis. These women would have lived without symptoms from their cancer before they died from another cause. It means they unnecessarily experience the stress of a breast cancer diagnosis and the harms of breast cancer treatment ([Barratt 2015](#)). This is different from false positive results, where the suspicion of cancer is later dismissed through follow-up tests. False positive results affect far more women and result in important psychological harms ([Brodersen 2013](#)).

Earlier detection of breast cancer makes women live longer with the diagnosis, increasing the apparent survival time with the disease. However, survival time is a deceptive outcome, as earlier diagnosis invariably increases survival time, even if screening does not reduce mortality. This phenomenon is called 'lead time bias' ([Welch 2004](#)). Breast cancer mortality can also be a deceptive outcome, as cause of death is difficult to ascertain; as overdiagnosis leads to overtreatment, which increases deaths; and as a cancer diagnosis in itself increases cardiovascular mortality and risk of suicide ([Fang 2012](#)).

Why it is important to do this review

While earlier detection of cancer is well-documented to reduce incidence and mortality for some cancers, i.e. cervical ([Raffle 2003](#)) and colon cancer ([Jodal 2019](#)), this is not common. For example, large randomised trials of screening for ovarian cancer have shown that, although screening effectively brought the time of diagnosis forward and detected cancer at an earlier stage, this did not lead to reduced ovarian cancer mortality ([Menon 2021](#); [Prorok 2018](#)). For other cancers, it is the balance between a possible reduction in disease-specific mortality and important harms that questions the rationale for screening, e.g. prostate cancer screening with the prostate specific antigen (PSA) test. The fact that we cannot be certain that screening reduces disease-specific mortality or that a benefit outweighs the harms, is the reason that guideline groups such as the UK National Screening Committee require evidence from high-quality randomised trials to recommend it ([UKNSC Criteria](#)).

Mammography screening is being offered to billions of women world wide when they reach a certain age. It is resource intensive and the balance between its benefits and harms is contested. It is therefore important to know what the benefits and harms are. This is an update of a Cochrane review first published in 2001, and updated in 2009, 2011, and 2013. The previous versions questioned whether the data from the randomised trials supported the value of breast screening and identified important biases in key trials. Updated mortality results from two low risk of bias trials and new requirements for reporting in Cochrane reviews (GRADE assessments and Summary of Findings tables) necessitated this update.

Objectives

To study the effect of screening for breast cancer with mammography on mortality and morbidity.

medRxiv preprint doi: <https://doi.org/10.1101/2024.06.06.24308542>; this version posted June 6, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](#).

Methods

Criteria for considering studies for this review

Types of studies

Randomised clinical trials. We did not limit our inclusion of trials based on location, setting, definition of condition, demographic factors, the setting of the screening intervention (hospitals, private clinics, mobile units, etc.), or method of diagnosis (i.e. digital or print mammograms).

Trials using suboptimal randomisation methods such as cluster randomisation, were included but evaluated in separate subgroup analyses. In cases where substantial heterogeneity between trial results could be explained by use of optimal versus suboptimal randomisation methods, we based our conclusions on trials with optimal randomisation methods and chose not to present summary estimates including all trials.

We have discussed recent observational studies in this review as they have provided important contextual knowledge, e.g. in relation to evidence of overdiagnosis and other harms of screening in today's setting. However, such studies were not formally included or analysed in this review.

Types of participants

Women without clinically suspected or previously diagnosed breast cancer.

Types of interventions

The intervention was screening mammography with X-ray imaging. We included trials whether they used film or digital mammograms and did not exclude trials if they used technology such as computer-assisted detection. We did not include trials of tomosynthesis, magnetic resonance imaging (MRI), or ultrasound. Breast screening using X-ray in combination with ultrasound is evaluated in another review ([Glechner 2023](#)). We did not exclude trials based on the number or frequency of screening tests or based on age groups included. The control was no offer of screening mammograms, but we accepted clinical and self-breast examination in the control group.

Types of outcome measures

We included trials whether they reported our pre-specified outcomes or not. All our outcome measures of effects were dichotomous (binary data) and differences are presented as risk ratios (RR) with 95% confidence intervals. Absolute differences are also presented using a denominator that allows direct comparisons between benefits and harms, i.e. in our Summary of Findings tables. We report outcomes at 7, 13 and, when possible, 25 years of follow-up. Overdiagnosis was measured as the difference in incidence between the screening and control arm at the latest time of follow-up in those trials that did not offer mammography screening to the control group at the end of the intervention phase. This is the same definition as used in another review ([UK review 2012](#)).

Primary outcomes

Mortality from breast cancer
Mortality from any cancer
All-cause mortality
Use of surgical interventions
Use of adjuvant therapy
Harms of mammography

Secondary outcomes

None

Search methods for identification of studies

Electronic searches

For the 2023 update of our review, we searched the following databases up to 28 February 2023:

- PubMed ([Appendix 1](#)).
- The Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2023, Issue 2) ([Appendix 2](#)).
- The Cochrane Breast Cancer Group's Specialised Register. Details of the search strategies used by the CBCG for the identification of studies and the procedure used to code references are outlined in their

module (<http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/BREASTCA/frame.html>). Trials with the keywords 'mammography' and 'screening' were extracted for consideration.

medRxiv preprint doi: <https://doi.org/10.1101/2024.06.06.24308542>; this version posted June 6, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

- Clinicaltrials.gov (<http://clinicaltrials.gov/ct2/search>) (Appendix 4).

In the original version of the review, we used a very broad search strategy. We searched PubMed with (breast neoplasms[MeSH] OR "breast cancer" OR mammography[MeSH] OR mammograph*) AND (mass screening[MeSH] OR screen*). This search was supplemented with a search on author names in the author field (Alexander F*, Andersson I*, Baines C*, Bjurstam N*, Duffy S*, Fagerberg G*, Frisell J*, Miller AB, Moss S*, Nystrom L*, Shapiro S, Tabar L*). The latest search was done on 22 November 2012 and 29,222 records were imported into ProCite. Until the 2009 review, these records were searched for author names, cities and eponyms for the trials; thereafter, all new records were browsed. This very broad search strategy, combined with browsing the titles and reading the abstracts when a paper might be relevant for mammography screening, enabled us to assemble also observational studies of the benefits and harms of screening.

We searched the World Health Organization's International Clinical Trials Registry Platform (22 November 2012) with this strategy, for Recruitment Status ALL: (Condition: breast AND (cancer% OR carcinoma% OR neoplas% OR tumour% OR tumor%) AND Intervention: screen OR mass screen%) OR (Condition: breast AND (cancer% OR carcinoma% OR neoplas% OR tumour% OR tumor%) AND Intervention: mammograph%) OR (Condition: breast neoplasm AND Intervention: mammography).

Searching other resources

We scanned reference lists and included letters, abstracts, grey literature and unpublished data to retrieve as much relevant information as possible. There were no language restrictions.

Data collection and analysis

Selection of studies

In this updated review, we used Cochrane's Screen4Me workflow to help assess the search results. Screen4Me comprises three components: known assessments – a service that matches records in the search results to records that have already been screened in Cochrane Crowd and been labelled as an RCT or as Not an RCT; the RCT classifier – a machine learning model that distinguishes RCTs from non-RCTs, and if appropriate, Cochrane Crowd – Cochrane's citizen science platform where the Crowd help to identify and describe health evidence. For more information about Screen4Me and the evaluations that have been done, please go to the Screen4Me webpage on the Cochrane Information Specialist's portal: <https://community.cochrane.org/organizational-info/resources/resourcesgroups/information-specialists-portal>. In addition, more detailed information regarding evaluations of the Screen4Me components can be found in the following publications: [Noel-Storr 2020](#); [Noel-Storr 2021](#); [Marshall 2018](#); [Thomas 2020](#).

Two authors independently decided which trials to include based on the prestatd criteria using Covidence software. Disagreements were resolved by discussion ([Figure 1](#)).

Data extraction and management

Two authors independently extracted methodological and outcome data; disagreements were resolved by discussion. Extracted data included: number of women randomised; randomisation and blinding procedures; exclusions after randomisation; type of mammography; number of screenings and interval between screenings; attendance rate; introduction of screening in the control group; co-interventions; number of cancers identified; breast cancer mortality; cancer mortality; all-cause mortality; harms of mammography; and use of surgical interventions, chemotherapy, radiotherapy, tamoxifen and other adjuvant therapy.

Assessment of risk of bias in included studies

We assessed whether the randomisation was adequate and led to comparable groups, following standard criteria as closely as possible ([Higgins 2008](#)). These included sequence generation and allocation concealment. We also assessed blinding of outcome assessors; incomplete outcome data; selective reporting; and other biases. The risk of bias for each domain was assessed as 'high', 'moderate ' or 'low'. As trials of population screening look for small differences in absolute terms, they are sensitive to bias and we payed particular attention to the randomisation method and possible baseline imbalances. We divided the trials into those with adequate randomisation (individual, centralised randomisation) and those with suboptimal randomisation (cluster randomisation, randomisation by date of birth, or randomisation in other ways that would raise concern about baseline imbalances). According to the Cochrane Handbook ([Higgins 2008](#)), the primary analysis in a systematic review should be based on studies at low risk of bias. We therefore did not combine results from adequately randomised studies with other studies.

Measures of treatment effect

Risk ratios and 95% confidence intervals. All included outcomes were binary.

Unit of analysis issues

We based our conclusions on the individually randomised trials with adequate randomisation methods. Results from suboptimally randomised trials that used cluster randomisation are presented in separate subgroup analyses and did not form the basis for our conclusions. As the included trials were old, information required to adjust for clustering effects were not available. Given that we present the results from the cluster randomised trials for transparency and completeness, and as they did not influence our conclusions, an adjustment for clustering effects would not have changed them.

Dealing with missing data

This was assessed as part of our risk of bias assessment. We contacted the primary investigators to clarify uncertainties and to obtain additional data. We analysed available data only and did not impute missing data.

Assessment of heterogeneity

In case of indications of substantial statistical heterogeneity (non-overlapping confidence intervals or $I^2 > 70\%$) we explored possible causes in subgroup analyses. Possible methodological reasons for heterogeneity in terms of adequate versus suboptimal randomisation was also explored in subgroup analyses and using the Cochrane risk of bias tool. Any possible clinical heterogeneity was evaluated through the indirectness domain in our GRADE assessment.

Assessment of reporting biases

As trials of population screening tend to be very large, we consider it unlikely that trials were performed but not reported and we have not found indications that such trials exist. The size of the trials also means that small study effects are unlikely and we therefore did not use funnel plots to explore this. Incomplete data assessment and incomplete outcome reporting was considered as part of our risk of bias assessment.

Data synthesis

We performed intention-to-treat analyses, when possible, by including all randomised women. A fixed-effect model with the Mantel-Haenszel method was used, and 95% confidence intervals (CI) are presented. Absolute risk are calculated and presented in our Summary of Findings tables.

In the trials with suboptimal randomisation, we could not carry out a proper analysis for all-cause mortality as we did not have access to the necessary data to correct for baseline differences (see 'Risk of bias in included studies') but present the available data in the graphs for the sake of completeness. For breast cancer mortality, our estimates are not formally correct because we were unable to adjust for baseline differences since baseline characteristics were not reported for several of the suboptimally randomised trials. However, they turned out to be in close agreement with the estimates and CIs published by the trialists.

We report outcome data at approximately 7, 13, and 24 years, which were the most common follow-up periods in the trial reports and report effect estimates at multiple time points as not all trials presented data after very long follow-up and as some effects could be diluted over time. We present age groups under 50 years of age, 50 years and above; and 70 years and above, which is the age limits that has most often been used by the trialists and in screening programmes.

Subgroup analysis and investigation of heterogeneity

Apart from analyses by age groups and the division of the trials according to whether they were adequately or suboptimally randomised, we did not perform subgroup analyses.

Sensitivity analysis

We did not do any sensitivity analyses as we had already explored the possible impact of age and randomisation method on the robustness of results in subgroup analyses.

Summary of findings and assessment of the certainty of the evidence

We exported results of our meta-analyses to GRADEpro GDT, which presented these including absolute numbers for our calculated risk ratios. We selected effect measures from the least biased trials to be presented in the Summary of Findings table and presented a table for all age groups combined; for women aged <50 years; aged >50 years; and 70 years and above. We present Summary of Findings tables for various age groups separately as an expansion of breast screening is currently considered in various countries. However, not all outcomes could be assessed for all age groups and the most complete outcome set is reported for the combined assessment of the intervention for all age groups. We prioritised to present results at longest time of follow up, but as not all trials reported results for total mortality at 25 years, we present this outcome at 13 years of follow-up in the table. In GRADEpro GDT, we performed the GRADE assessment of the certainty of the evidence for each outcome. We assessed the domains: risk of bias; inconsistency; indirectness; imprecision; and publication bias. Data for all our outcomes were available for only one comparison (breast screening in all age groups combined versus no screening). For other comparisons, outcomes for which no data were available are not shown to avoid large empty tables for some age groups.

Results

medRxiv preprint doi: <https://doi.org/10.1101/2024.06.06.24308542>; this version posted June 6, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Description of studies

Our process of trial identification is depicted in [Figure 1](#) and [Figure 2](#). A description of the 8 included trials can be found here: [Canada 1980](#); [Canada 1980a](#); [Canada 1980b](#); [Edinburgh 1978](#); [Göteborg 1982](#); [Göteborg 1982a](#); [Göteborg 1982b](#); [Kopparberg 1977](#); [Malmö 1976](#); [Malmö II 1978](#); [New York 1963](#); [Östergötland 1978](#); [Stockholm 1981](#); [Two-County 1977](#); [UK age trial 1991](#). A description of the 3 excluded trial can be found here: [Berglund 2000](#); [Dales 1979](#); [Singapore 1994](#); and a description of the 2 trials awaiting classification can be found here: [AgeX Trial](#); [Murillo 2016](#).

Results of the search

In this updated review, after de-duplication, the search identified a total of 3,912 records. In assessing these, we used Cochrane's Screen4Me workflow to help identify potential reports of randomised trials. The results of the Screen4Me assessment process can be seen in [Figure 1](#). We then assessed the remaining 2,162 records left after Screen4Me. When 365 duplicates were removed, 1797 records were assessed for eligibility, of which 18 were retrieved in full text. We excluded 1 record because it did not address the relevant intervention and excluded 2 records because the study design did not fulfil our inclusion criteria. We did not identify any new, completed trials compared to our previous update, nor did we find any additional trials through other sources. The results of the searches are presented in the PRISMA flow diagram ([Figure 2](#)).

In total, we included 8 studies (8 from the previous review, with 15 new papers describing already included trials identified in the updated search).

The original PubMed search we performed in 2012 identified 29,222 records.

Included studies

We included eight trials ([Canada 1980](#); [Edinburgh 1978](#); [Göteborg 1982](#); [Malmö 1976](#); [New York 1963](#); [Stockholm 1981](#); [Two-County 1977](#); [UK age trial 1991](#)), which comprised slightly different subtrials. The Canadian trial was actually two trials, one covering the age group 40 to 49 years ([Canada 1980a](#)) and the other 50 to 59 years ([Canada 1980b](#)). The Edinburgh and Malmö trials continued to include women as they passed the lower age limit for entry to the trial, and the Two-County trial had different randomisation ratios in the two counties ([Kopparberg 1977](#); [Östergötland 1978](#)). Most trials covered the age range 45 to 64 years, but the UK Age trial invited women aged 39 to 41 years to participate. The Canadian trial was the only one in which the women were individually randomised after invitation and informed consent to participate; the others used a variety of procedures based on a prespecified segment of the female population that was randomised to invitation for screening or to a control group.

The number of screening invitations was in the range of four to nine for all trials except the Stockholm and Two-County trials, in which a large fraction were invited for only two or three screenings. In the Two-County trial, the mammographically screened women were encouraged to perform breast self-examinations once a month on a fixed date ([Rapport 1982](#)). This was Swedish policy generally but we do not know for certain whether this was also true for the Göteborg, Malmö and Stockholm trials. Clinical examinations of screened women were performed in New York and Edinburgh. In Canada, in the 40 to 49 year age group, screened women had an annual clinical breast examination whereas control women were examined at the first visit and were taught self-examination for use thereafter. In the 50 to 59 year age group, all women had their breasts clinically examined annually.

The women in the control group were not invited to screening at any point in time in the New York trial, whereas they were invited for screening after 10 to 13 years of follow up in the Edinburgh, Malmö and UK age trials. In the Canadian trial, most of the women in the control group were invited when the trial ended ([Baines 2005](#)). Some women were invited for screening while the trial was still ongoing in the Göteborg, Stockholm and Two-County trials (see 'Risk of bias in included studies').

In all trials, women in the control groups were offered usual care. This included mammography on indication, that is for suspected malignancy, with the probable exceptions of the New York trial and the first five years of the Two-County trial.

According to the information we identified, the technical quality of the mammograms and the observer variation were assessed only in the Canadian trial. There are data on diagnostic rates, however, that show that the sensitivity in the trials that followed the New York trial has not consistently improved ([Fletcher 1993](#); [IARC 2002](#)). Various combinations of one- and two-view mammography were used, i.e. one view mammography was used in the Two-County trial whereas two-view mammography was used in the Canadian trial (see 'Characteristics of included studies').

An additional trial in the UK is ongoing (<http://www.controlled-trials.com/ISRCTN33292440>). This is an age extension, cluster randomised trial, recruiting women aged 47-49 or 71-73 years old, and aiming for a sample size of 3 million women. It started in 2010 and has not yet reported any results.

A small trial from Colombia where only two women died from breast cancer at the time of reporting is awaiting classification ([Murillo 2016](#)).

medRxiv preprint doi: <https://doi.org/10.1101/2024.06.06.24308542>; this version posted June 6, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](#).

Excluded studies

We excluded two small trials of several interventions including mammography ([Berglund 2000](#); [Dales 1979](#)) and a trial involving 166,600 women where the only intervention was a prevalence screen and where exclusions after randomisation occurred only in the screened group; previous cancer at any site was an exclusion criterion and more than 1500 women were excluded from the screened group, 468 because they had already died ([Singapore 1994](#)).

Risk of bias in included studies

The trials have been conducted and reported over a long period of time, during which standards for reporting trials have improved. The New York trial, for example, was first reported in 1966 but crucial details on the randomisation method, exclusions and blinding were not published until 20 years later ([Aron 1986](#); [Shapiro 1985](#); [Shapiro 1988](#)). Our risk of bias assessment is depicted in our risk of bias graph ([Figure 3](#)) and our risk of bias summary ([Figure 4](#)), as well as in our forest plots. Data on use of radiotherapy and chemotherapy in the Kopparberg trial were published 14 years after the main results ([Tabar 1999](#)). Below, we discuss the trial methodology in detail, which is essential reading to understand the controversies surrounding the effects of screening and the often conflicting information presented. The trials are described consecutively by start date.

The New York trial ([New York 1963](#))

Population studied

The New York trial (also called the Health Insurance Plan (HIP) trial) invited women who were members of an insurance plan and aged 40 to 64 years from December 1963 to June 1966. It reported an individual randomisation within pairs matched by age, family size and employment group ([Shapiro 1985](#)). It is not clear whether the randomisation method was adequate; it was described as "alternation" by researchers who contacted one of the trial investigators ([Freedman 2004](#)). The entry date for a woman was the date she was scheduled for the examination ([Shapiro 1966](#)); the matched control was assigned the same date ([Shapiro 1985](#)). The matched pairs method should lead to intervention and control groups of exactly the same size. This is supported by the approximate numbers given in several publications, for example "The women were carefully chosen as 31,000 matched pairs" ([Strax 1973](#)). The largest published exact number of women invited is 31,092 ([Fink 1972](#)).

Comparability of groups

Postrandomisation exclusions of women with previous breast cancer occurred but this status "was most completely ascertained for screened women," whereas women in the control group "were identified through other sources as having had breast cancer diagnosed before their entry dates" ([Shapiro 1988](#)). Using information in the trial reports ([Fink 1972](#); [Shapiro 1985](#); [Shapiro 1994](#)), we calculated that 853 (31,092 minus 30,239) women were excluded from the screened group because of previous breast cancer compared with only 336 (31,092 minus 30,756) in the control group. Although it was reported that great care was taken to identify these women, the lead investigator noted that more than 20 years after the trial started some prior breast cancer cases among the controls were unknown to the investigators and those women should have been excluded ([Shapiro 1985a](#)). This creates a bias in favour of screening for all-cause mortality and likely also for breast cancer mortality though the authors have written, without providing data, that ascertainment of cases of previous breast cancer was "nearly perfect" in those women who died from breast cancer ([Shapiro 1988](#)).

It is difficult to evaluate whether there were other baseline differences between the groups. In one paper ([Shapiro 1972](#)) the text described all randomised women and referred to a table that showed baseline differences as percentages but did not provide the numbers upon which the percentages were based. Footnotes explained that some of the data were based on 10% and 20% samples. The table title referred to women entering the trial in 1964, and not all women as claimed in the text. Assuming that the table title is correct, the data presented in some cases were a 1964 subgroup of 10% and 20% samples. These resulting samples are therefore too small to study other possible baseline differences than those related to differential exclusion of women with previous breast cancer.

Assignment of cause of death

We found no data on the autopsy rate. Assignment of cause of death was unblinded for 72% of the women with breast cancer ([Shapiro 1988](#)). The differential exclusions and unblinded assessments make us question the reliability of the reported breast cancer mortality rates.

Likelihood of selection bias

We classified the trial as suboptimally randomised.

The Malmö trial ([Malmö 1976](#))

Population studied

This trial recruited women aged 45 to 69 years. Randomisation was carried out by computer within each birth year cohort (Andersson 1981), dividing a randomly arranged list in the middle (Andersson 1999a). The first publication reported that 21,242 women were randomised to the screening group and 21,240 to the control group (Andersson 1980, Andersson 1981a). It is made available under a [CC-BY-NC-ND 4.0 International license](#).

Comparability of groups

A later publication reported four more women in the control group (Andersson 1983) but the main publication (Andersson 1988) reported only 21,088 women in the study group and 21,195 in the control group. It did not account for the 199 or 203 missing women. The number of missing women was largest in the 45 to 50 years age group (137 from the intervention group and 26 or 27 from the control group), mainly because the 1929 birth year cohort was recruited by an independent research project that included mammography (Andersson 2001). The trialists recruited less than the planned 50% of this birth year cohort, but this does not explain why 26 or 27 women were missing from the control group. Exclusion of the 1929 birth year cohort from analysis changes the risk ratio for death from breast cancer by only 0.01 (Andersson 2001). For 17 of the 25 birth year cohorts, the size of the study and control groups were identical or differed by only one, as expected. The largest difference in the other eight cohorts, apart from the 1929 one, was 25 fewer women than expected in the study group for the 1921 cohort (Nyström 2002). Thus, the authors of a meta-analysis of the Swedish trials did not report on all randomised women in Malmö (Nyström 2002).

The date of entry into the trial was defined differently for the two groups. For the mammography group it was the date of invitation (Andersson 1988), and the midpoint of these dates for each birth year cohort defined the date of entry for women in the control group (Andersson 2000). Enrolment began in October 1976 (Andersson 2000) and ended in September 1978 (Andersson 1988). It is not clear whether screening of the control group began in December 1990 (Nyström 2000) or in October 1992 (Nyström 2002). Most women in the control group were never screened (Nyström 2002). We calculated the interval between when screening started in the study group and in the control group (the intervention contrast) to be 19 years (Nyström 2002). In the meta-analyses of the Swedish trials, breast cancer cases diagnosed before randomisation were explicitly excluded, further reducing the screened group by 393 and the control group by 412 (Nyström 1993); in total 86 more women were excluded from the screened group than the control group. Baseline data on age were not significantly different in the screened group and the control group (Gøtzsche 2000a).

Assignment of cause of death

The autopsy rate for breast cancer cases as presented in the main publication for this trial (Andersson 1988) was high at 76%, but it was halved from 1985 to 1997 (Andersson 2000). Cause-of-death assessments were blinded up to 1988 (Andersson 2000).

Likelihood of selection bias

We classified the trial as adequately randomised.

The Malmö II trial (Malmö II 1978)

Population studied

This was an extension of the Malmö trial, called MMST II. Women who reached the age of 45 years were enrolled between September 1978 and November 1990; screening of the control group began in September 1991 (Nyström 2000). The long enrolment period gives an average estimated intervention contrast of eight years. Although the entry criterion for age was stated to be 45 years, the trialists included 6780 women aged 40 to 44 (Nyström 2002).

Comparability of groups

The MMST II trial has been published only in brief (Andersson 1997). We therefore cannot check whether there were differential postrandomisation exclusions. If the same procedure as in the Malmö trial had been followed, the sizes of the study and control group cohorts should not differ by more than one. However, the group size differed more for seven of the 13 birth year cohorts (Nyström 2002). The reported numbers in the individual cohorts do not add up to the reported totals, but to 28 fewer in the study group and 28 more in the control group. Because of an administrative error, the entire 1934 birth year cohort was invited for screening (Andersson 1999b). If this cohort is excluded, there is still a gross imbalance with 5724 women in the study group and only 5289 in the control group, for those aged 45 to 49 years ($P = 0.00004$, Poisson analysis). In total, there were 9581 and 8212 women in the analyses, respectively (Nyström 2002).

This trial was neither included nor mentioned in the 1993 meta-analysis of the Swedish trials (Nyström 1993). The lead investigator informed us that it was not conducted according to a formal protocol (Andersson 1999b), whereas the most recent meta-analysis reported that the trial was conducted with the same protocol as the older part of the trial (Nyström 2002). When the breast cancer mortality rate in the screening group is plotted against the control group rate for eight trials, with data from younger women, the Malmö II trial is a clear outlier (Berry 1998).

Assignment of cause of death

An official registry was used for cause-of-death assessments.

Likelihood of selection bias

We classified the trial as suboptimally randomised.

The Two-County trial (Kopparberg 1977; Two-County 1977; Östergötland 1978)

medRxiv preprint doi: <https://doi.org/10.1101/2024.06.06.24308542>; this version posted June 6, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

This trial recruited women 40 years of age and over in Kopparberg and Östergötland; the two subtrials were age-matched and cluster randomised (21 and 24 clusters, respectively). The selection of clusters was stratified to ensure an even distribution between the two groups with respect to residency (urban or rural), socioeconomic factors and size (Kopparberg 1977; Tabar 1979; Östergötland 1978). The randomisation process and the definition of the date of entry have been inconsistently described; and some women were only 38 years of age, below the inclusion criterion (Nyström 2002). According to the first publications, random allocation of the women in each community block took place three to four weeks before screening started (Fagerberg 1985); all women from a given block entered the trial at the same time and this date was the date of randomisation (Tabar 1985). However, it has also been described that a public notary allocated the clusters in Östergötland by tossing a coin (Nyström 2000) while witnesses were present (Fagerberg, personal communication, 1999). We have been unable to find any detailed description of the randomisation in Kopparberg but found a recent description for the whole trial: "Randomisation was by traditional mechanical methods and took place under the supervision of the trial statistician" (Duffy 2003). Thus it is not clear whether the randomisation was carried out on one occasion or whether it took place over several years.

Women were invited to their first screening from October 1977 to January 1980 in Kopparberg (Tabar 1981). The cohorts in Östergötland were defined between May 1978 and March 1981. It is not clear how many women were randomised and reported numbers vary considerably, both for numbers randomised (Table 1) and for numbers of breast cancer deaths, despite similar follow up (Gøtzsche 2004). Documentation of baseline comparability was called for in 1988 (Andersson 1988a) but it appears not to have been published. Since the randomisation was stratified after socioeconomic factors (Tabar 1991), baseline data potentially affecting mortality should exist.

Comparability of groups

The randomisation procedure seems to have led to non-comparable groups. First, breast cancer mortality in the control group was almost twice as high in Kopparberg compared to Östergötland (0.0021 versus 0.0012, $P = 0.02$). This was not apparent from the tabulated data (Tabar 1985). The published graphs are also potentially misleading; although adjacent mortality curves look much the same the two y-axes are differently scaled (Tabar 1995). Second, in Kopparberg more women in the control group were diagnosed with breast cancer before entry to the trial than in the study group. How the diagnostic information was obtained was not described (Tabar 1989) and the number of women excluded for this reason was not stated, but can be calculated by comparing two tables (Tabar 1985; Tabar 1989). More women were excluded from the control group than from the study group ($P = 0.03$); most of the imbalance occurred in the age group 60 to 69 years ($P = 0.007$). In Östergötland, numbers of exclusions were very similar, 1.40% versus 1.39%. Third, age-matching was reported (Tabar 1979; Tabar 1981; Tabar 1985a) but study group women were on average five months older (Nixon 2000), which is a small bias against screening.

We were unable to ascertain when systematic screening of the control group started. The available information is conflicting and the range of the discrepancies amounts to three years for both counties (Arnesson 1995; Duffy 2003; Nyström 1993; ; Nyström 2000; Nyström 2002; Rapport 1982; Tabar 1979; Tabar 1985; Tabar 1992). It seems most likely that screening of the control group in Kopparberg started in 1982, in accordance with the trial protocol (Rapport 1982) and a doctoral thesis (Nyström 2000). In this case, the impression conveyed in the main publication for the trial that screening was offered to the control group after publication of the results in April 1985 is incorrect (Tabar 1985; Tabar 1992). In the protocol, a five-year intervention period was planned but with a stopping rule based on statistical significance testing every six months (Rapport 1982). The trial publications did not mention the repeated looks at the data (Tabar 1985). We estimated an intervention contrast of five years for Kopparberg and eight years for Östergötland. A valid comparison of benefits and harms of screening should be confined to the period prior to screening of the control group.

No information is available from the primary author of this trial (Atterstam 1999; Prorok 2000; Tabar 2000a). We have not received information from Nyström either on the missing account of the randomisation process in Kopparberg, or from the Swedish National Board of Health (Socialstyrelsen), which funded the trial.

Assignment of cause of death

The autopsy rate was 36% (Projektgruppen 1985). According to an investigator involved with the trial (Crewdson 2002), other Swedish trialists (Nyström 2002), and an IARC report (IARC 2002), cause-of-death assessments were not blind. This has been disputed by the lead investigator of the trial (Tabar 2002). In a meta-analysis of the Swedish trials, a blinded independent endpoint committee reassessed the death classifications (Nyström 1993).

Likelihood of selection bias

We classified the trial as suboptimally randomised and likely to be biased.

The Edinburgh trial (Edinburgh 1978)

Population studied

This trial used cluster randomisation with about 87 clusters (the number varies in different reports); the age group was 45 to 64 years. Coded general practices were stratified by size and allocated by manual application of random numbers. In one district, at least three of the 15 practices initially randomised to the screening group later

changed allocation status, and at least four others were added (Alexander 1989). Two of these practices were unintentionally told the wrong group, and three changed allocation group because of "statistical considerations" (Roberts 1984). One practice was included in the follow-up even though it was a control screening practice that did not participate in the randomisation (Roberts 1990). The trialists have conducted replicate analyses with these women removed (Alexander 2000) but as far as we know the data have not been published.

Comparability of groups

Doubts about the randomisation process were raised by the trialists (Alexander 1989), supported by baseline differences: 26% of the women in the control group and 53% in the study group belonged to the highest socioeconomic level (Alexander 1994), and mammographic screening was associated with an unlikely 26% reduction in cardiovascular mortality (Alexander 1989). Entry dates were defined differently. In most practices the entry date was the date the invitation letter was issued; for women in hospital it was the date their names appeared on a list sent to their general practitioner. The entry date for five practices was not defined. In the control group, the entry date was the date the physician's practice was indexed. Before entry, the general practitioners in the screening practices had to decide whether each woman would be suitable for invitation to screening. Physicians in the control practices decided whether each woman would be eligible to receive a leaflet about breast self-examination (Roberts 1984). The eligibility criteria were thus broader for the control group and the entry dates seem to be earlier. Practices were enrolled one at a time over a period of 2.5 years, from 1979 to 1981 (Alexander 1989). Women turning 45 years of age and women moving into the city were enrolled on an ongoing basis (Roberts 1984). Recruitment of the control group began in the 10th year of follow up (Alexander 1994). The exclusion procedures were different in the study and control groups (Chamberlain 1981; Roberts 1984) and 338 versus 177 women were excluded because of prior breast cancer (Alexander 1994).

Likelihood of selection bias

This trial was not adequately randomised and was so biased that it cannot provide reliable data. We have therefore shown its results in a separate graph, for completeness only.

The Canadian trial (Canada 1980; Canada 1980a; Canada 1980b)

Population studied

Women aged 40 to 59 years were individually randomised after invitation and giving informed consent. Their names were entered successively on allocation lists, where the intervention was prespecified on each line. An independent review of ways in which the randomisation could have been subverted uncovered no evidence of this (Bailar 1997). Enrolment took place from January 1980 to March 1985 (Canada 1980a).

Comparability of groups

Fifty-nine women in the age group 40 to 49 years and 54 in the age group 50 to 59 years were excluded after randomisation (Miller 2000; Miller 2002); none were excluded because of previous breast cancer. The comparison groups were nearly identical in size (25,214 versus 25,216 aged 40 to 49 years; and 19,711 versus 19,694 aged 50 to 59 years), and were similar at baseline for age and nine other factors of potential prognostic importance (Baines 1994; Canada 1980; Canada 1980a; Canada 1980b; Miller 2000; Miller 2002). There were more small node-positive cancers at baseline in the screened group than in the control group among women aged 40 to 49 years, but this is a post-hoc subgroup finding which is probably a result of the intervention (Baines 1995; Baines 1997; Canada 1980). Several women with positive nodes were probably unrecognised in the control group (Miller 1997a). This is supported by the fact that 47% of women with node-negative cancer in the usual care group died of breast cancer compared with 28% in the mammography group (Miller 1997). Exclusion of the deaths caused by these cancers did not change the result (Baines 1995; Baines 1997; Canada 1980).

Assignment of cause of death

The autopsy rate was low, 6% (Baines 2001). Cause-of-death assessments were blinded for women with diagnosed breast cancer and for other possible breast cancer deaths, for follow up after seven years. For follow up after 13 years, death certificates were used in a minority of cases as some hospitals refused to release clinical records (Miller 2000; Miller 2002).

Likelihood of selection bias

We classified the trial as adequately randomised.

The Stockholm trial (Stockholm 1981)

Population studied

In this trial, women were invited for screening if they were aged 40 to 64 years in 1981 (born 1917 to 1941) and were born on days 1 to 10 in a month, or if they were aged 40 to 64 years in 1982 (born 1918 to 1942) and were born on days 21 to 30 in a month (Frisell 1986). Similarly, there were two groups of controls but since they were all born on days 11 to 20 in a month, most women served as controls twice (those born in 1918 to 1941). Invitations were sent successively by ascending order of birth date (Frisell 1989). The date of entry was the date of invitation (Frisell 1991). Enrolment of the first cohort began in March 1981 and ended in April 1982; enrolment of the second cohort began in April 1982 and ended in May 1983 (Frisell 2000a).

Comparability of groups

Since the control women born in 1918 to 1941 served as controls for both subtrials (Frisell 1989a; Frisell 2000b) they should have two entry dates, approximately one year apart, but this was not described. According to the matching there should have been a similar number of women in the screened and control groups in each subtrial, but we found an imbalance in the second subtrial (Frisell 1991) with 508 more women belonging to the screened group than to the control group (Frisell 1991). Furthermore, in the time period where 19,507 women born from 1918 to 1942 were invited to screening, only 929 women, all born in 1942, were included in the control group (Nyström 2002).

The reported numbers of women in the various subgroups are inconsistent, as are the numbers reported to us in personal communications (Frisell 2000a; Frisell 2000b). Because of the problems related to timing and the overlap of the two control groups, results from the two subtrials were not independent, and the estimates cannot be pooled without correction for dependence. It is not clear how these difficulties were handled in the trialists' analysis (Frisell 1991) or in the Swedish meta-analyses (Nyström 1993; Nyström 2000; Nyström 2002).

The first trial report did not describe any women excluded after randomisation; only breast cancer cases identified during the intervention period were followed up to ascertain breast cancer deaths (Frisell 1991). Exclusions occurred in later publications but no numbers were given (Frisell 1997; Nyström 1993; Nyström 2000) and the numbers we have received in personal communications have been inconsistent (Frisell 2000a; Frisell 2000b).

Of those attending the first screening, 25% had had a mammogram in the two previous years (Frisell 1989a). Information on screening of the control group varied. A meta-analysis noted that a few women were screened after three years and most after four years (Nyström 1993), a doctoral thesis stated that the controls were invited for screening from October 1985 (Nyström 2000), and the trialists noted that they were invited during 1986 (Frisell 1989a; Frisell 1991). We estimated an intervention contrast of four years. A valid comparison of benefits and harms of screening should be restricted to this period (Frisell 1991).

Assignment of cause of death

It is not stated whether cause-of-death assessments were blinded for this initial period. The autopsy rate was 22% (Nyström 2000).

Likelihood of selection bias

We classified the trial as suboptimally randomised.

The Göteborg trial (Göteborg 1982)

Population studied

This trial included women aged 39 to 59 years. Birth year cohorts were randomised by the city municipality's computer department with the ratio between study group and control group adjusted according to the capacity of the screening unit (Bjurstam 2000; Nyström 2002). The randomisation was by cluster based on date of birth in the 1923 to 1935 cohorts, and by individual birth date for the 1936 to 1944 cohorts (Bjurstam 1997).

Comparability of groups

We found baseline data only on age, and only for those aged 39 to 49 years. Since the allocation ratios were irregular due to limited screening capacity (Bjurstam 2016), we could not assess the comparability of groups and adequacy of randomisation, but the randomisation process is described as by day-of-birth-cluster up to November 1983, after which individual randomisation was used (Bjurstam 2016). The randomisation ratios were most extreme for the oldest and the youngest birth-year cohorts randomised in clusters; for 1923, there were 2.0 times as many women in the control group as in the study group, whereas for 1935 there were only 1.1 times as many. Since breast cancer mortality increases with age, this bias favoured screening and can be adjusted for only by comparing the results within each birth-year cohort before they are pooled (Bjurstam 2003).

This was the only trial to show a difference in total mortality at 13 years of follow-up (RR 0.89, CI 0.83 to 0.95) (Analysis 1.10). As the trial was much underpowered to show such a difference, this result lends support to our assessment that the randomisation was suboptimal and led to baseline differences for prognostic factors important for survival. Furthermore, fewer breast cancers were identified in the screening arm than in the control arm when the control arm had been screened once at the end of the trial period (incidence rate ratio for women 39 to 59: 0.90). This can be calculated from data presented in a table in (Bjurstam 2016). For breast screening to reduce disease specific mortality, the requisite advancement of time of diagnosis means there must be more cancers detected in the screening arm than the control arm. The difference was driven by women aged 39 to 49 (incidence rate ratio: 0.82) whereas the incidence was similar between groups in women aged 50 to 59 years (incidence rate ratio: 0.99). As the disease specific mortality difference in the trial was driven by the younger age group as well (RR 0.60 vs 0.82 (ns)) (Bjurstam 2016), the apparent benefit of breast screening in this trial could be explained by baseline differences.

Entry dates were not defined but the birth year cohorts were randomised one at a time, beginning with the 1923 cohort in December 1982 and ending in April 1984 with the 1944 cohort. A similar proportion of women were excluded from the study and control groups, 254 (1.2%) and 357 (1.2%), because of previous breast cancer (Bjurstam 2003). Information on screening of the control group varied, ranging from three to seven years after randomisation (Bjurstam 1997; Bjurstam 2003; Nyström 1993, figure; Nyström 2000). We estimated an intervention contrast of five years. A valid comparison of benefits and harms of screening should be confined to this period.

Assignment of cause of death

The autopsy rate was 31% (Nyström 2000). Cause-of-death assessments were blinded.

Likelihood of selection bias
medRxiv preprint doi: <https://doi.org/10.1101/2024.06.06.24308542>; this version posted June 6, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. We classified the trial as suboptimally randomised. It is made available under a [CC-BY-NC-ND 4.0 International license](#).

The UK age trial (UK age trial 1991)

Population studied

This trial included women aged 39 to 41 years who were randomised individually between 1991 and 1997 to an intervention group or a control group, in a ratio of 1:2. Women in the control group received no information about the trial. The trial was undertaken in 23 breast-screening units in England, Wales, and Scotland. Women were identified from lists of patients from general practitioners held on local Health Authority databases and randomisation was carried out stratified by practice. Prior to this, the general practitioners could remove women with previous breast cancer and others deemed inappropriate to invite for screening. From 1992 onwards the allocations were carried out on the Health Authority computer system with specifically written software. Before this, for women in three early centres, random numbers generated from the coordinating centre computer were applied to the lists.

Comparability of groups

We found baseline data only on age; the mean age was 40.38 and 40.39 years, respectively.

Thirty and 51 women (0.05%) were excluded from analysis for similar reasons in the two groups. The intervention contrast was 10 years. A valid comparison of benefits and harms of screening should be confined to this period.

Assignment of cause of death

There was no information on autopsy rate; information on cause of death was obtained from the central register of the National Health Service.

Likelihood of selection bias

We classified the trial as adequately randomised.

Sources of data used for the meta-analyses

Deaths ascribed to breast cancer: Alexander 1999; Andersson 1988; Bjurstram 1997; Bjurstram 2003; Duffy 2020a; Frisell 1997; Habbema 1986; Miller 1992a; Miller 1992b; Miller 2000; Miller 2002; Miller 2014; Moss 2006; Moss 2015; Nyström 1993; Nyström 1993a; Nyström 2002; Roberts 1990; Shapiro 1977; Shapiro 1982; Tabar 1988; Tabar 1995.

Mortality among breast cancer patients: Tabar 1988.

Deaths ascribed to cancer, all patients: Andersson 1988; Aron 1986; Duffy 2020a; Miller 2000; Miller 2002; Shapiro 1988; Tabar 1988.

All-cause mortality: Andersson 1988; Aron 1986; Bjurstram 1997; Duffy 2020a; Miller 1992a; Miller 1992b; Miller 2000; Miller 2002; Moss 2006; Nyström 2000; Nyström 2002; Projektgruppen 1985; Roberts 1990; Shapiro 1977; Tabar 1989.

Mastectomies and lumpectomies: Andersson 1988; Frisell 1986; Frisell 1989a; Miller 1993; Shapiro 1972; Tabar 1999.

Radiotherapy: Andersson 1988; Benjamin 1996; Shapiro 1972; Tabar 1999.

Chemotherapy and hormone therapy: Andersson 1988; Tabar 1999.

Number of cancers: Andersson 1988; Baines 2016; Bjurstram 1997; Frisell 1989a; Miller 1993; Moss 2005; Tabar 1991.

Allocation

We classified three trials as adequately randomised (Canada, Malmö and UK age trial) and four as suboptimally randomised (Göteborg, New York, Stockholm, Two-County), as was also the extension of the Malmö trial, MMST II. One trial (Edinburgh) was not adequately randomised and cannot provide reliable data.

Blinding

We classified three trials as having low risk of bias for cause of death assessment (Canada, Malmö and UK age trial) and four trials as having high risk of bias due to lack of blinded cause of death assessment (Göteborg, New York, Stockholm, and Two-County).

Incomplete outcome data

We classified four trials as having low risk of bias due to incomplete reporting (Canada, Malmö, Göteborg and UK age trial) and three as having high risk (New York, Stockholm, Two-County).

Selective reporting

We classified four trials as having low risk of bias due to selective reporting (Canada, Malmö, Göteborg and UK age trial) and three as having high risk (New York, Stockholm, Two-County).

medRxiv preprint doi: <https://doi.org/10.1101/2024.06.06.24308542>; this version posted June 6, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](#).

We classified three trials as having low risk of bias due to other reasons (Canada, Malmö, and UK age trial) and four as having high risk (New York, Stockholm, Göteborg, and Two-County).

Effects of interventions

Eight trials provided data. We classified three trials as adequately randomised (Canada, Malmö and UK age trial) and four as suboptimally randomised (Göteborg, New York, Stockholm, Two-County), as was also the extension of the Malmö trial, MMST II. One trial (Edinburgh) was assessed as being too unreliable to provide reliable data due to substantial baseline imbalances and it is accordingly excluded from other key reviews (UK review 2012); we have therefore only shown its results for completeness, in a separate graph (Analysis 1.22). As the short-term results from the UK Age trial were obtained after a mean follow up of 10.7 years, we included them in the results both after 7 and after 13 years (Analysis 1.1; Analysis 1.2). The adequately randomised trials provided 40% of the breast cancer deaths after 13 years (Analysis 1.2). The effects of the intervention for various age groups and times of follow-up, as well as our GRADE assessments for primary and secondary outcomes, are summarized in our Summary of Findings tables here: [Summary of findings table 1](#); [Summary of findings table 2](#); [Summary of findings table 3](#); [Summary of findings table 4](#).

Deaths ascribed to breast cancer

We judged assignment of breast cancer mortality to be unreliable and biased in favour of screening (see above and 'Discussion'), but included this outcome because it was the main focus in all trials.

The three adequately randomised trials did not find an effect of screening on deaths ascribed to breast cancer, risk ratio (RR) 0.93 (95% CI 0.79 to 1.09) after 7 years; RR 0.90 (95% CI 0.79 to 1.02) after 13 years; and RR 0.95 (95% CI 0.86 to 1.04) after 22 years (data available only for the Canadian and UK age trials) (Analysis 1.1; Analysis 1.2; Analysis 1.7). The four suboptimally randomised trials found a beneficial effect: RR 0.71 (95% CI 0.61 to 0.83) after 7 years and RR 0.75 (95% CI 0.67 to 0.83) after 13 years (Analysis 1.1; Analysis 1.2).

The adequately randomised trials did not find an effect of screening on deaths ascribed to breast cancer in the youngest age group (under 50 years of age at randomisation except for Malmö for which the limit was 55 years): RR 0.94 (95% CI 0.78 to 1.14) after 7 years and RR 0.87 (95% CI 0.73 to 1.03) after 13 years (Analysis 1.3; Analysis 1.5). The suboptimally randomised trials found an RR of 0.81 (95% CI 0.63 to 1.05) after 7 years and RR of 0.80 (95% CI 0.64 to 0.98) after 13 years (Analysis 1.3; Analysis 1.5). For women aged >50 years, the estimates for the adequately randomised trials were RR 0.88 (95% CI 0.64 to 1.20) and RR 0.94 (95% CI 0.77 to 1.15), respectively; for suboptimally randomised trials they were RR 0.67 (95% CI 0.56 to 0.81) and RR 0.70 (95% CI 0.62 to 0.80), respectively (Analysis 1.4; Analysis 1.6).

Only the Two-County trial included women aged 70 years and above and reported results. It was not possible to provide reliable estimates of effect for this age group.

Deaths ascribed to any cancer

The adequately randomised trials did not find an effect of screening on deaths ascribed to any cancer, including breast cancer; RR 1.00, 95% CI 0.96 to 1.04; the follow up was 10.5 years for Canada, 9 years for Malmö and 23 years for the UK age trial (Analysis 1.8). The suboptimally randomised trials did not provide reliable estimates of total cancer mortality (see above); the estimate for the two suboptimally randomised trials that provided data (New York and Two-County trials) was RR 0.99 (95% CI 0.93 to 1.06) (Analysis 1.8).

All-cause mortality

All-cause mortality was not reduced; RR 0.98, 95% CI 0.94 to 1.03 after 7 years; RR 0.99, 95% CI 0.95 to 1.03 after 13 years; and RR 1.01, 95% CI 0.99 to 1.04 after 22 years (data only available for the Canadian and UK Age trials) (Analysis 1.9; Analysis 1.10; Analysis 1.15). The suboptimally randomised trials did not provide reliable estimates of the effects on all-cause mortality (see 'Risk of bias in included studies' and 'Discussion') and the reported effects were heterogeneous ($P = 0.03$ after 7 years; $P = 0.001$ after 13 years). For completeness, their mortality estimates are shown in the graphs but collectively, they did not show a difference either (Analysis 1.10). For women under age 50 years, see (Analysis 1.11; Analysis 1.13); for women over age 50 years, see (Analysis 1.12; Analysis 1.14).

Number of cancers (overdiagnosis)

More women were diagnosed with breast cancer in the screened group in the adequately randomised trials that did not systematically screen women in the control group after the intervention phase (RR 1.25, CI 1.18 to 1.34) (Analysis 1.23). Systematic screening offered to the control group at the end of the intervention phase means overdiagnosis cannot be reliably assessed in the remaining trials.

Surgery

More breast operations (mastectomies plus lumpectomies) were performed in the study groups than in the control groups: RR 1.31 (95% CI 1.22 to 1.42) for the adequately randomised trials; RR 1.42 (95% CI 1.26 to 1.61) for the suboptimally randomised trials before systematic screening in the control group started (data were available only for Kopparberg and Stockholm) (Analysis 1.16). The increased surgery rate could not be explained

by the excess of detected tumours at the first screen but seemed to persist, as the mean follow up was seven years for Canada and nine years for Malmö. For Stockholm, the reported data after five years had been transformed according to the smaller size of the control group (Frisch 1989a). We also detected a number of errors in the original report (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

The number of mastectomies (excluding partial mastectomies, quadrantectomies and lumpectomies) was also increased: RR 1.20 (95% CI 1.08 to 1.32) for the adequately randomised trials; RR 1.21 (95% CI 1.06 to 1.38) for the suboptimally randomised trials (Analysis 1.17).

Other adjuvant therapy

We found little information on other adjuvant therapy. It differed substantially for two of the Swedish trials even though they were carried out at the same time. Chemotherapy was given to only 7% of the breast cancer patients in Malmö but to 31% in Kopparberg before the control group was screened (Analysis 1.19). Conversely, hormone therapy was given to 17% in Malmö, and to 2% in Kopparberg (Analysis 1.20). Information exists from Kopparberg on therapeutic adjuvant therapy given over the years but has not been published (Tabar 1999).

Radiotherapy

More women received radiotherapy in the study groups: RR 1.24 (95% CI 1.04 to 1.49) for Malmö after nine years; and RR 1.40 (95% CI 1.17 to 1.69) for Kopparberg before the control group screen (Analysis 1.18).

Harms

We found no comparative data on psychological morbidity. Duration of sick leave and mobility of the shoulder were recorded in the Two-County trial (Rapport 1982) but have not been reported.

Discussion

Summary of main results

The decision to embark on the screening programmes was made mainly because of the positive results in the New York and Two-County trials (Forrest report 1986). Policy makers and many scientists believed that the benefit of screening was well documented. However, information essential to judging the reliability of the trials was often unpublished or published only in Swedish, in theses, letters, conference reports, reviews, or in journals that are not widely read and with titles and abstracts that did not indicate that important data were described. Furthermore, the harms of screening received very little attention.

Breast cancer mortality

The main focus in the screening trials was breast cancer mortality, as very large trials are needed to assess the effect on all-cause mortality. We cannot assume, however, that a beneficial effect on breast cancer mortality can be translated into improved overall survival. First, screening may increase mortality because of overdiagnosis and the increased use of radiotherapy. A meta-analysis predicted that overall, radiotherapy is beneficial for women at high risk of local recurrence. However, it is harmful for women at particularly low risk such as those who have their cancers found by screening and those who are overdiagnosed. This is primarily because of damage to the coronary arteries and development of heart failure resulting from at least some types of radiotherapy (EBCTCG 2000) and because radiotherapy causes lung cancer. A meta-analysis of radiotherapy showed that there was a 27% excess mortality from heart disease and a 78% excess mortality from lung cancer (EBCTCG 2005a). This excess mortality becomes important when many healthy women are overdiagnosed, even if radiotherapy has been improved and harms reduced since the trials.

Second, assessment of cause of death is susceptible to bias. The authors of the Two-County trial assessed cause of death openly and reported a 24% reduction in breast cancer mortality for Östergötland (Tabar 2000), whereas a meta-analysis of the Swedish trials based on an official cause of death register reported only a 10% reduction for Östergötland (Nyström 2002). The trial authors reported 10 fewer deaths from breast cancer in the study group despite slightly longer follow up, and 23 more deaths in the control group. They have not provided a plausible explanation of this large discrepancy (Duffy 2002; Tabar 2002). In 2009, "a complete audit of breast cancer cases and deaths" in the Two-County trial was published, but it is not convincing (Holmberg 2009). There was no blinding; it was not an independent audit; there was no attempt at producing a new data set based on the clinical records (which were only retrieved "where necessary"); and the Two-County trialists were directly involved with interpretations and resolving disagreements.

The bias seems to favour screening even when cause of death is determined blindly. In the New York trial, differential misclassification might be responsible for about half of the reported breast cancer mortality benefit. A similar number of dubious cases were selected for blinded review from each group, but a much smaller proportion of the screened group were finally classified as having died from breast cancer (Gøtzsche 2004). Furthermore, although the mammographic equipment was standard at the time, its performance was poor. Only 15% of 299 cancers in the study group were detected solely by mammography, and mammography did not identify a single case of minimal breast cancer (< 1 cm) (Thomas 1977). The New York trial reported a 35% reduction in breast cancer mortality after seven years, but we consider it unlikely that it was a true effect.

In conjunction with the first meta-analysis of the Swedish trials, causes of death were reclassified blindly in some patients (Nyström 1993). Breast cancer was considered the underlying cause of death in 419 of the screened group and 409 of the control group according to Statistics Sweden, and in 418 and 425 cases according to the committee (Nyström 1993). The fact that all 17 reclassifications favoured the screened group suggests differential

misclassification. This bias is difficult to avoid (Gøtzsche 2001). Early cancers are treated by lumpectomy and radiotherapy, and radiotherapy reduces the rates of local recurrence by about two-thirds (EBCTCG 2000). This might increase the likelihood that deaths among screen-detected breast cancer cases will be misclassified as deaths from other causes (EBCTCG 1995), and that the many deaths in the control group will be misclassified as breast cancer deaths. In fact, for the Swedish trials it was stated that "most patients with locally advanced disease will die due to cancer" and that breast cancer as the underlying cause of death includes women with locally advanced breast cancer, whereas women who have been treated successfully should not be classified as having breast cancer deaths if another specified disease could be the cause of death (Nyström 2000). The use of an official cause of death register as in more recent meta-analyses (Nyström 2002) cannot solve these problems.

Postrandomisation exclusion of women who already had breast cancer at the time of entry to the trial is another possible source of bias. The exclusions were sometimes made many years after the trial started, or even after it had ended. In the Two-County trial, only women who were considered to have died from breast cancer were excluded (Nixon 2000), a highly bias-prone process because those assessing cause of death were not blinded for screening status. Furthermore, the process seemed not to have been adequately monitored as it was not possible to identify prior breast cancers in Östergötland, by cluster (Nixon 2000). It should therefore not be possible to do analyses that respect the clustering with those women excluded, although such analyses have been reported (Tabar 1989; Tabar 1990; Tabar 1991; Tabar 1995). A study that used the same registers as those used by the trialists found that a large number of breast cancer cases and deaths seemed to be missing in reports on the Two-County trial (Zahl 2006). Another study found that the large reduction in breast cancer mortality agreed poorly with the cancer stages that were reported (Zahl 2001).

The largest effects on breast cancer mortality were reported in trials that had long intervals between screenings (Two-County trial), invited a large fraction of the women to only two or three screenings (Two-County and Stockholm trials), started systematic screening of the control group after three to five years (Two-County, Göteborg and Stockholm trials), had only one-view mammography rather than two views (Two-County trial), and that had poor equipment for mammography (New York trial); and the cancers found with mammography were considerably smaller in the Canadian trial than in the Two-County trial (Narod 1997). This suggests that differences in reported effects are related to the risk of bias in the trials rather than to the quality of the mammograms or the screening programmes. The sensitivity of mammographic readings in the trials that followed the New York trial has not consistently improved (Fletcher 1993; IARC 2002) and meta-analyses have failed to find an association between mammographic quality and breast cancer mortality (Glasziou 1995; Kerlikowske 1995). A meta-analysis found that the effect of screening was largest in those trials that found fewest node-positive cancers in the screened group relative to the control group (Gøtzsche 2011). However, the regression line was in the wrong place. A screening effectiveness of zero (same proportion of node-positive cancers in the screened group as in the control group) predicted a 16% reduction in breast cancer mortality after 13 years (95% CI 9% to 23% reduction). This can only occur if there is bias, and there was bias for both variables, assessment of cause of death and of the number of node-positive cancers.

Several of the trials had clinical examination or regular self-examination of the breasts as part of their design (see 'Description of studies') but this is not likely to have had a major influence on the effect estimates. The effect of clinical examination is uncertain, and large randomised trials did not find an effect of self-examination (Kösters 2003).

Cancer mortality

The major difficulty in assessing cause of death might have occurred when the patients were diagnosed with more than one malignant disease (Miller 2001). The importance of autopsy is illustrated by the fact that 21% of the women with breast cancer who died in the Malmö trial had two or three types of different cancers (Andersson 1988a; Janzon 1991). Patients with cachexia and no signs of recurrence of breast cancer would likely be assigned to another type of cancer.

Since cancer mortality is likely to be less subject to bias than breast cancer mortality, we calculated what the expected cancer mortality (including breast cancer mortality) would be if the reported reduction in breast cancer mortality of 29% after seven years for the suboptimally randomised trials (Analysis 1.1) were true. Weighting the four trials that provided data on number of cancer deaths (Analysis 1.8), the expected risk ratio was 0.95. However, all-cancer mortality in these trials was not reduced (RR 1.00, 95% CI 0.96 to 1.05), and this estimate was higher than what was expected ($P = 0.02$). This provides further evidence that assessment of cause of death was biased in favour of screening. Data from the Two-County trial (Tabar 1988) illustrates the misclassification directly (Analysis 1.21) (Gøtzsche 2004). Among women with a diagnosis of breast cancer, mortality for other cancers was higher in the screened group and mortality from all other causes also tended to be higher. The increase in mortality for causes other than breast cancer amounts to 38% of the reported decrease in breast cancer mortality in the Kopparberg part of the trial and 56% in the Östergötland part.

It has been shown that belief in the effectiveness of an intervention may influence the decision on which type of cancer caused the patient's death (Newschaffer 2000). Also, lethal complications of cancer treatments are often ascribed to other causes. The size of this misclassification is 37% for cancer generally and 9% for breast cancer (Brown 1993).

For our current update, we could include cancer deaths also from the UK Age trial. Screening still had no effect on cancer mortality, RR 1.00 (95% CI 0.96 to 1.04).

All-cause mortality

The trials were not powered to detect an effect on all-cause mortality, but it is an important outcome since the final results related to breast cancer mortality seem to be biased. The fact that trials in 2002 with 600,000 women did not have power to show an effect on all-cause mortality clearly indicates the comparatively small effect of the intervention, if any. The complex designs and insufficient reporting precluded us from providing reliable estimates for all-cause mortality in the trials with suboptimal randomisation. Furthermore, these trials had introduced early screening of the control group or had differentially excluded women after randomisation. Incidentally, however, all-cause mortality after 13 years was the same in adequately randomised trials and in suboptimally randomised trials (RR 0.99, 95% CI 0.95 to 1.03; and RR 0.99, 95% CI 0.97 to 1.01, respectively). There were many more deaths after 22 years, and RR was now 1.01 (95% CI 0.99 to 1.94) for the adequately randomised trials, which speaks against any mortality benefit of mammography screening.

While the Göteborg trial found a reduction in all-cause mortality (Bjurstam 2016), being the only trial to do so, it was substantially underpowered to show this, even if its estimated reduction in cause-specific mortality was correct. The reduction in all-cause mortality therefore supports that the trial was biased due to suboptimal randomisation and that its estimated effect on breast cancer mortality is unreliable.

In 2000, the estimate reported for the four Swedish trials was RR 1.00 (95% CI 0.98 to 1.02) after adjustment for imbalances in age (Nyström 2000). In 2002, the authors reported a 2% non-significant reduction in all-cause mortality (RR 0.98, 95% CI 0.96 to 1.00) and stated that they would have expected a 2.3% reduction (Nyström 2002). However, the calculation was incorrect and the expected reduction, given their results, was only 0.9% (Gøtzsche 2002a). The error has been acknowledged (Nyström 2002a; The Lancet Erratum 2002) but the published response to our criticism was also incorrect (Nyström 2002b). The reported decrease of 2% in total mortality corresponds to a 10% decrease in all-cancer mortality, which is not plausible (see 'Cancer mortality' above).

The Östergötland part of the Two-County trial contributed about half of the deaths in the 2002 report and had a risk ratio for all-cause mortality of 0.98 (Nyström 2002). The women were randomised to only 24 clusters. In the Edinburgh trial there were 87 clusters, but double as many women in the invited group belonged to the highest socioeconomic level compared to the control group (Alexander 1994). Socioeconomic factors are strong mortality predictors and could easily explain a 2% reduction in all-cause mortality, but such data remain unpublished and are also unavailable for the other Swedish trials. It has been reported that pretrial breast cancer incidence and breast cancer mortality were similar in the study group and in the control group in Östergötland (Nyström 2002), but the power of the test was very low (Gøtzsche 2002a). In contrast, another report found that breast cancer mortality was 15% lower in the invited groups in the Two-County trial and that correction for this difference changed the estimate of the effect from a 31% reduction to a 27% reduction in breast cancer mortality (Duffy 2003).

It is not clear why the unadjusted and age-adjusted estimates for all-cause mortality were the same with an RR of 0.98. The 2002 Swedish meta-analysis comprised 43,343 deaths whereas in the 2000 meta-analysis of 27,582 deaths the estimates were RR 1.06 (95% CI 1.04 to 1.08) (Gøtzsche 2000) and RR 1.00 (95% CI 0.98 to 1.02) (Nyström 2000), with non-overlapping confidence intervals. The Kopparberg part of the Two-County trial was not available for the 2002 meta-analysis, but this should not have made any difference since the RR for Kopparberg was 1.00 (95% CI 0.96 to 1.04) (Nyström 2000). The only other difference is that the extended data for the Malmö trial (MSST II) were included, but this trial contributed only 702 deaths (1.6%).

All-cause mortality has been reported to be lower in the Two-County trial when the analysis was confined to women with breast cancer (Tabar 2002a). Such subgroup analyses are very unreliable, as are similar analyses in historically controlled studies (Tabar 2001; Tabar 2003a), since many breast cancer cases in the screened groups will have an excellent prognosis because of overdiagnosis and length bias (Berry 2002).

Overdiagnosis and overtreatment

Overdiagnosis is an inevitable consequence of cancer screening and a critically important source of harm (IARC 2002). Screening primarily identifies slow-growing cancers and cell changes that are biologically benign (Doll 1981; Ernster 1996; Fox 1979). This is because slow-growing tumours have existed for longer than fast-growing tumours in the detectable range of tumour sizes and are therefore more likely to be detected at a screening session (length bias). Survival of women with screen-detected cancers is therefore very high, for example 97% in Malmö after 10 years (Janzon 1991). Even within the same stage, it is higher than for cancers detected clinically (Moody-Ayers 2000).

The level of overdiagnosis and overtreatment was about 25% in the trials that did not introduce early screening in the control group, and somewhat larger (33%) in the suboptimally randomised trials before the control group screen (Analysis 1.23). This is apart from the New York trial, which is unreliable since far more breast cancer cases were excluded from the screened group than from the control group (Shapiro 1977; Shapiro 1982; Shapiro 1989). The true increase in surgery is considerably larger, however. As the excess surgery in the trials is similar to the increase in diagnoses, reoperations have likely not been included, although many women are operated upon more than once. In New South Wales, for example, one third of women with carcinoma in situ had either mastectomy alone (19%) or after breast conserving surgery (17%) (Kriker 2000). The method of surgery has changed substantially since the trials were done and less invasive techniques are preferred today. The certainty of the estimates from the trials was downgraded for this reason (indirectness).

Large observational studies support that breast screening causes substantial overdiagnosis and overtreatment. Incidence increases of 40% to 60% since screening was implemented have been reported for Australia, Finland, New Zealand, Sweden, UK and USA (Barnes 2005; Baines 2003; Fletcher 2003; Gøtzsche 2002; Jørgensen 2004; Jørgensen 2005; Møller 2010; Pies 2002; Zahl 2008). It is made available under a CC-BY-NC-ND 4.0 International license. This version posted June 6, 2024. Copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license. In two additional studies, overdiagnosis was calculated as the percentage of all diagnoses, rather than the percentage of additional diagnoses; correcting for this gives an overdiagnosis of 45% in USA (Bleyer 2012) and 18-33% in Norway (Kalager 2012). The Norwegian estimate did not include carcinoma in situ and was also an underestimate for other reasons (Jørgensen 2012). A small study from Copenhagen claimed that it is possible to screen without overdiagnosis, but it showed the expected prevalence peak, had very little power and provided no statistical analyses in support of the claim (Olsen 2003). A study that included the whole of Denmark and also non-screened age groups found 33% overdiagnosis (Jørgensen 2009a). A systematic review that adjusted for decreases in incidence, if any, in older age groups no longer screened, and also for the trend in background incidence, found an overdiagnosis of 35% for invasive cancer and 52% when carcinoma in situ was included, in countries with organised screening programmes (Jørgensen 2009). Recently, based on long-term follow-up of the Canadian trials, overdiagnosis was estimated at 40% for the 40-49 years age group and 30% for the 50-59 year age group (Baines 2016).

Data from the UK show that when screening was extended to the age group 65-70 years in 2001, a sharp rise in invasive breast cancer incidence occurred in these women although they had been offered screening many times when they were younger and had already contributed to a massive increase in the incidence of DCIS and invasive cancers (Jørgensen 2011). This is difficult to explain unless we assume that many screen-detected cancers would have regressed spontaneously if left alone, which is supported by a study from Norway with a strong design (Zahl 2008), and by a similarly designed study from Sweden (Zahl 2011). A US study also suggested that some breast cancers regress, since the incidence declined much too rapidly after the use of hormone replacement therapy stopped (Chlebowski 2009). Another US study, of the breast cancer incidence and mortality rates during the period 1975 to 2000 when screening was introduced found that, in order to explain the observed trends, it was necessary to postulate that approximately 40% of the observed cancers had limited malignant potential and would have regressed if undetected (Fryback 2006).

Screening increased the number of mastectomies by 20%. Since screening advances the time of diagnosis, a policy change towards more lumpectomies could have led to an overestimate. However, the policy change has occurred slowly (Nattinger 2000) and even in the period 1993 to 1995, 52% of breast surgery in California was mastectomy (Malin 2002). In Stockholm, the increase in mastectomies was larger after five years of screening (25%) than after the first round (16%), and when screening was introduced in Southeast Netherlands, the rate of breast-conserving surgery increased by 71% while the rate of mastectomy increased by 84% (Gøtzsche 2002) despite the fact that this study did not include carcinoma in situ. The percentage of cases of carcinoma in situ treated by mastectomy declined from 71% in 1983 to 40% in 1993 in USA, but the estimated total numbers of mastectomies for this condition increased almost three-fold (Ernster 1997). In the UK, mastectomies increased by 36% for invasive cancer and by 422% for carcinoma in situ from 1990 to 2001 (Douek 2003). Carcinoma in situ is more often treated by mastectomy than invasive cancer (Patnick 2012).

Conversely, use of mammography in the control group would lead to an underestimate of overdiagnosis. In the trials from Malmö and Canada, 24% (Andersson 1988), 17% (Miller 1992b) and 26% (Baines 1994) of the women in the control group reported having received a mammogram during the trial; in the Two-County trial, it was 13% (Tabar 1985); in the Göteborg trial, 18% of women in the control group received a mammogram in a two-year period during the trial (Bjurstam 2003). In the Stockholm trial, 25% of those attending the first screening had had a mammogram in the two previous years (Frisell 1989a), and in the Göteborg trial, as many as 51% of the women in the age group 39-49 had ever received a mammogram (Bjurstam 1997). It is difficult to understand that this trial, with so much contamination reducing the observed benefit, reported a 45% reduction in breast cancer mortality.

The documented increase in mastectomies contrasts with assertions by trialists (Tabar 1989), policy makers (Statusrapport 1997; Swed Cancer Soc 1996; Westerholm 1988), websites supported by governmental institutions and advocacy groups (Jørgensen 2004), and invitational letters sent to women invited to screening (Jørgensen 2006; Gøtzsche 2009) that early detection spares patients more aggressive treatments, in particular mastectomy. This is likely because the focus is on an individual woman who is diagnosed earlier and not on the effects of breast screening at the population level. Publications that base their claims on numbers that include the control group screen (Tabar 2003) are also misleading, as are presentations of relative numbers rather than absolute numbers (Statusrapport 1997). The proportion of breast preserving operations is said to be increasing, but the trend for the number of mastectomies is not revealed. A small study from Florence, without a control group (Paci 2002), was also unreliable (Gøtzsche 2002b). The authors asserted that if screening increased the number of mastectomies, populations in which screening has been introduced should see a subsequent increase. Obviously, since the mastectomy rate has gone down steadily throughout many years, also in countries without screening, it is only to be expected that the authors found a decrease in the mastectomy rate when screening was introduced.

Denmark has a unique control group, as only 20% of the population was screened throughout 17 years. The large increase in mastectomies when screening was introduced has not been compensated later or by a corresponding decline in older age groups (Jørgensen 2011). A study from Norway has confirmed this (Suhrke 2011).

Quality assurance programmes could possibly reduce the surgical activity to some degree, but they could also increase it. In the UK, for example, the surgeons were blamed for not having treated even more women with

carcinoma in situ by mastectomy (BASO audit 2000), and the number of women treated by mastectomy almost doubled from 1998 to 2008 (Dixon 2009).

medRxiv preprint doi: <https://doi.org/10.1101/2024.06.06.24308542>; this version posted June 6, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license. (Gärtner 2009). Only half of the women with pain reported that it was mild (corresponding to 1-3 on a 10-point scale). The pain was equally common among those who had had breast-conserving surgery as among those with a mastectomy, and pain was more common when the women had had radiotherapy. Thus, half of all the overdiagnosed women will suffer from chronic pain, presumably for the rest of their lives.

False-positive diagnoses, psychological distress and painful mammograms

False-positive diagnoses can cause considerable and sustained psychological distress (Bülow 2000; Salz 2010), not only initially (Brodersen 2006) but for years after the women are declared free from cancer (Brodersen 2013). Many women experience anxiety, worry, despondency, sleeping problems, negative impact on sexuality and behaviour, and changes in their relationships with family, friends, and acquaintances as well as in existential values (Brodersen 2006; Brodersen 2007; Brodersen 2013; Salz 2010). In a large study, the severity of the psychological distress for women with false-positive findings was between that for healthy women and those with breast cancer even three years after they had been declared free from cancer (Brodersen 2013). Some women will feel more vulnerable about disease and see a doctor more often (Barton 2001).

In the Stockholm trial, one-third of women with false-positive findings were not declared cancer-free at six months (Lidbrink 1996). In the UK, women who had been declared cancer-free after additional testing or biopsies were twice as likely to suffer psychological consequences three years later than women who received a clear result after their last mammogram (Brett 2001). In the USA, three months after they had false-positive results, 47% of women who had highly suspicious readings reported that they had substantial anxiety related to the mammogram, 41% had worries about breast cancer, 26% reported that the worry affected their daily mood, and 17% that it affected their daily function (compared to 3% with a normal mammogram) (Lerman 1991). In Norway, 18 months after screening mammography 29% of women with false-positive results and 13% of women with negative results reported anxiety about breast cancer (Gram 1990).

The cumulative risk of a false-positive result after 10 mammograms ranges from about 20% to 60% (Barratt 2005; Castells 2006; Christiansen 2000; Elmore 1998; Hofvind 2004; Hubbard 2011; Johns 2010; Njor 2007). It is considerably higher in USA than elsewhere, e.g. the recall rate in women aged 50 to 54 years was 13% to 14% after the first mammogram, compared to 8% in the UK (Smith-Bindman 2003). The reported percentages are often too low because recalls due to poor technical quality of the mammogram are not included (Hofvind 2004; Johns 2010; Njor 2007), although these women may be just as affected by such recalls as by a real suspicion of cancer (Brodersen 2006). In USA, 19% would have had a biopsy after 10 mammograms (Elmore 1998).

Thus, it seems that screening inflicts important psychological distress on more than a quarter of the healthy population of women who attend a screening programme. The women are often not being informed about this risk (Gøtzsche 2009; Jørgensen 2004; Jørgensen 2006; Slaytor 1998; Werkö 1995) or the risk of receiving a diagnosis of carcinoma in situ (Gøtzsche 2009; Jørgensen 2004; Thornton 1997).

About half of the women report that it is painful to have a mammogram taken (Armstrong 2007; Miller 2002a; McNoe 1996), and half of the women who decline an invitation to the second round of screening note that the major reason was that their first mammogram was painful (Elwood 1998).

Overall completeness and applicability of evidence

There are now so many data on the outcomes of breast cancer treatment and mammography screening that the results can be directly applied to policy making. There have been substantial advances in treatment since the trials were performed. Anti-hormones and polychemotherapy are effective also when the cancer has metastasized (EBCTCG 2005), and the declines in breast cancer mortality we have seen in both screened and non-screened, otherwise comparable populations (Autier 2010) have occurred rather uniformly across prognostic groups (Blamey 2007). An updated meta-analysis of polychemotherapy showed that some regimens reduce breast cancer mortality by about one third, largely independently of tumour characteristics (EBCTCG 2012). This means that the effect of screening must be smaller today than when the trials were conducted in terms of the number of women who may avoid dying of breast cancer.

In order to be effective, screening must lead to a reduction in the number of advanced cancers. In the USA, there has been a very small decrease in advanced cancers (Esserman 2009; Jørgensen 2011). A detailed analysis of a time period spanning 30 years showed that the incidence of early-stage breast cancer in USA went up from 112 to 234 cases per 100,000 women (a 109% increase) while the incidence of late-stage cancer decreased by 8%, from 102 to 94 cases per 100,000 women (Bleyer 2012). Moreover, the small decline in advanced cancers was confined to regional disease involving the lymph nodes; there was no reduction in disease with distant metastases. A systematic review of several countries (Australia, Italy, Norway, Switzerland, the Netherlands, UK and the USA) found that, on average, the rate of cancers larger than 20 mm was not affected by screening (Autier 2011). In Norway, screening did not decrease the incidence of cancers in stages III and IV, as the reductions were exactly the same in screened and non-screened areas (Kalager 2012).

In contrast to screening, increased breast cancer awareness seems to have been important. In Denmark, the average tumour size at diagnosis was 33 mm in 1978-79, but only 24 mm ten years later, in 1988-89 (Rostgaard 2010). This change occurred before screening started, and in contrast to screening, breast cancer awareness is unlikely to cause overdiagnosis. The difference of 9 mm is much greater than the average difference between the

screened and the control groups in the trials, which was only 5 mm (Gøtzsche 2012a), despite the fact that the small overdiagnosed tumours would tend to spuriously exaggerate the difference. In Canada, the size of clinically detected tumours decreased by 4 mm from 1987-2001 (Hirvela 2011). There are many poor observational studies claiming large effects of screening but they often use statistical models with unsupported assumptions or misleading comparisons (Gøtzsche 2010; Gøtzsche 2012). The better studies rely on unmodified data. As noted above, Denmark has a unique control group, as only 20% of the population was screened throughout 17 years. The annual decline in breast cancer mortality in the relevant age group and time-period was 1% in the screened areas and 2% in the non-screened areas. In women who were too young to benefit from screening the declines were larger, 5% and 6%, respectively (Jørgensen 2010). Also in the UK, Sweden and Norway, there was no visible effect of screening when relevant age groups were compared (Jørgensen 2010; Kalager 2010; Jørgensen 2011). The Norwegian study (Kalager 2010) was criticized because of short follow-up, but the follow-up was 6.6 years, which is when an effect was seen in the trials.

A study reported a 15% effect in the USA (Berry 2005), but the authors noted that the decline in breast cancer mortality coincided not only with widespread propagation of screening but also with increasing use of adjuvant therapy. They also noted that slight variations in modelling assumptions could result in marked changes in estimated effects, and the statistical models adjusted for an increase in breast cancer incidence, which was inappropriate, as much of this increase was overdiagnosis. Unlike the USA, women below age 50 years are rarely offered screening in Europe. The mean decline in breast cancer mortality between 1989 and 2005 in these women was 37%, whereas it was 21% in women aged 50-69 years (Autier 2010). The declines began before organised screening in many countries and fitted better with the introduction of tamoxifen, which explains the larger decline in women too young to have been offered screening who often have oestrogen-sensitive tumours (Jørgensen 2011). A comparison of three pairs of neighbouring European countries that had introduced screening 10-15 years apart showed no relation between screening start and the reductions in breast cancer mortality (Autier 2011a); in fact, the reduction in breast cancer mortality was about the same in the six European countries as in USA (Bleyer 2011). An Australian study found that most, if not all, of the reduction in breast cancer mortality could be attributed to adjuvant hormonal and chemotherapy (Burton 2011).

Screening advocates have claimed that screening explains why breast cancer mortality rates are lower in Sweden than in Denmark (Dean 2010), but this difference existed decades before screening. Further, the reductions in breast cancer mortality in the screening period were largest in Denmark, 49% versus 36% in Sweden in women under 50, although half of these women were invited in Sweden versus none in Denmark (Autier 2010). In those aged 50-69 years, the reduction was 26% in Denmark versus 16% in Sweden, although only 20% of Danish women were invited, versus all in Sweden where more than 80% participated (Autier 2010; IARC 2002). Despite having the longest running programme, the widest invited age range, and the shortest screening interval in Europe (IARC 2002), Sweden has experienced lower reductions in breast cancer mortality than the European median (Autier 2010).

These studies taken in combination cast doubt as to the effectiveness of screening today. And even if screening reduces breast cancer mortality, the evidence does not support an effect on all-cause mortality or on total cancer mortality. However, both the randomised and non-randomised studies provide evidence that screening causes substantial overdiagnosis and false-positive results are very common.

Quality of the evidence

For the adequately randomised trials, the certainty of the effect on breast cancer mortality was assessed as low. The certainty was downgraded 1 level due to the age of the trials and substantial changes in screening technology and improvements in treatment. The certainty was also downgraded due to imprecision, as the confidence interval included clinically relevant effects. The certainty of the effect estimates for most of the remaining outcomes was assessed as moderate, downgraded 1 level due to the age of the trials. As our conclusions are based on the subgroup of adequately randomised trials, we did not have to downgrade for risk of bias. Results of the suboptimally randomised trials were downgraded 1 level due to risk of bias and the certainty of the evidence for this subgroup is thus 'very low'. As heterogeneity was explained by dividing trials into subgroups according to adequate versus suboptimal randomisation, and as there was little or no heterogeneity within each subgroup, we did not downgrade the certainty of evidence for each subgroup due to inconsistency. We did not detect or have reason to suspect publication bias and thus did not downgrade for this domain. As effects were either not documented or comparatively small, we did not upgrade the certainty of the evidence due to large effects. As we included only randomised trials, confounding effects did not impact our assessment of the certainty of the evidence. We did not detect any dose-effect relationship and thus did not upgrade based on this domain.

Potential biases in the review process

We took great care to avoid introducing bias in the review process and to take account of the apparent biases in the randomised trials. Our most important judgement was that we found it necessary to divide trials into subgroups according to method of randomisation. Cluster-randomised trials and trials with unclear randomisation methods often had other potentially important risks of bias as well, compared to individually randomised trials with adequate randomisation methods. We found indications that suboptimal randomisation methods were associated with important baseline differences, such as fewer breast cancers being detected in the screening arm (Bjurstam 2016), which is contrary to expectations. The confidence interval between the most and the least

optimistic trial result for breast cancer mortality did not overlap and the estimated effect differed more than what would be expected without systematic differences between the trials (a 42% reduction versus no effect).

Separating trials according to randomisation method explained the heterogeneity (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Agreements and disagreements with other studies or reviews

Previous reviews have generally not heeded the methodological quality of the trials, but when the methods were assessed blindly, the researchers judged the Canadian trial to be of high quality and the Two-County trial to be of poor quality (Glasziou 1995).

Prompted by our first Cochrane review in 2001, the US Preventive Services Task Force performed an updated systematic review (Humphrey 2002). It excluded the Edinburgh trial and reported a 16% reduction in breast cancer mortality for all ages. The authors noted that, "the mortality benefit of mammography screening is small enough that biases in the trials could erase or create it" and were concerned whether, across all age groups, the magnitude of benefit is sufficient to outweigh the harms. The Task Force gave mammography screening a grade B recommendation (US Task Force 2002). The Task Force reported a 15% reduction in breast cancer mortality for those aged 39 to 49 years in 2009 and larger effects in older age groups (Nelson 2009). A comprehensive IARC report (IARC 2002) was not a systematic review and paid little attention to the varying quality of the trials; it even included a non-randomised study in its meta-analysis. A 2012 UK review was not a systematic review either (UK review 2012). It used data from the Cochrane review for the benefit, but lumped the adequately randomised trials with the suboptimally randomised trials and did not take account of the improvements in treatment and breast cancer awareness. The report focussed on breast cancer mortality, and ignored all cause mortality, which biased its findings in favour of breast screening. It acknowledged that previous estimations of the benefits and harms of mammography screening had been overoptimistic and acknowledged uncertainties around estimations of the magnitude of benefit. It also acknowledged and estimated overdiagnosis as a major harm of breast screening, but did not use the Cochrane review estimate but a smaller one that was diluted because of screening in the control group (Welch 2006).

The meta-analyses of the Swedish trials are not systematic reviews as they do not include all relevant trials. There is a high risk of bias in cluster randomised trials with few clusters (Puffer 2003) and numbers of randomised women were inconsistently reported (Table 1). In Stockholm, for example, the number of randomised women decreased by 4.5% in the screening group but increased by 3.6% in the control group (Gøtzsche 2000) in the Swedish 1993 review (Nyström 1993) compared to the trial report (Frisell 1997). In the 2000 and 2002 reviews (Nyström 2000; Nyström 2002), numbers have increased by 1.6% in both groups but should have been the same as in the 1993 report since all women were identified through their unique identification number (Nyström 2002), which has been used in Sweden for several decades; exclusions of women with previous breast cancer was completed with the 1993 review; and all three reviews were based on the exact age at randomisation, and the age range was the same. The varying numbers therefore indicate that the randomisation was not respected. The estimates in the Swedish reviews were adjusted for differences in age, but since the distribution of age would be expected to differ over socioeconomic strata, such adjustment would be expected to lead to other imbalances (Gøtzsche 2000). Furthermore, simulation studies have shown that adjustments quite often increase bias rather than reduce it (Deeks 2003). The most recent review of the Swedish trials reported a 15% reduction in breast cancer mortality with the follow-up model (Nyström 2002); another estimate of 21% was based on an 'evaluation model', which is flawed, as it ignores breast cancer deaths among women in the control group whose breast cancer diagnosis was made after the first screening round of the control group (Berry 1998).

Authors' conclusions

Implications for practice

The most reliable trials did not support that breast screening reduces breast cancer mortality for the included age groups while trials that provided very low certainty evidence indicated a benefit. Breast cancer mortality has declined over the past decades, with the greatest reductions in women below the age group commonly invited to screening (Autier 2010), likely due to improved treatments and increased breast cancer awareness. As breast cancer mortality is an unreliable outcome that is biased in favour of screening, it is noteworthy that screening did not reduce total cancer mortality or total mortality, neither in the adequately randomised trials, nor in the suboptimally randomised trials. Overdiagnosis has human costs; increases the use of mastectomies; and increases mortality. Women, clinicians and policy makers should consider the trade-offs and the uncertainties of these data carefully when they decide whether or not to attend or to offer breast screening programmes.

Implications for research

We do not see any need for more mammography screening trials of the type we have reviewed. Research is needed to identify means of separating screen-detected cancers likely to result in death from cancers and cell changes identified by screening that do not need treatment. Several such trials are currently ongoing.

Acknowledgements

For this 2023 update, we would like to acknowledge and thank the following people for their help in assessing the search results for this review via Cochrane's Screen4Me workflow:

medRxiv preprint doi: <https://doi.org/10.1101/2024.06.06.24308542>; this version posted June 6, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Sideris, Anna Noel-Storr, Lai Ogunmoda, Shalimar Mohammed, Adria Bermudez-Gallaguet, William Garrett, Ivan Perez-Neri, Simon-Peter Gom, Amin Sharifan, Hadi Keshavarz, Vibor Milunović, Emerald Sy, Cheryl Sumner, Victor Ghosh, Anna Brocke, Amina Berour, Dr Manmohan Singh Shergillz, Yineli Villalobos Parra , Issa Hanna.

The following people conducted the editorial process for this article:

- Sign-off Editors (final editorial decision): Annabel Goodwin and Nicholas Wilcken, Co-ordinating Editors, Cochrane Breast Cancer; Peter Tugwell, Cochrane Editorial Board
- Managing Editor (selected peer reviewers, provided editorial guidance to authors, edited the article): Liz Bickerdike, Cochrane Central Editorial Service
- Editorial Assistant (conducted editorial policy checks, collated peer-reviewer comments and supported editorial team): Leticia Rodrigues, Cochrane Central Editorial Service
- Copy Editor (copy editing and production): [NAME, AFFILIATION];
- Peer-reviewers (provided comments and recommended an editorial decision): Nuala Livingstone and Rachel Richardson, Cochrane Evidence Production and Methods Directorate (methods), Afroditi Kanellopoulou, Cochrane Evidence Production and Methods Directorate (statistics), Jo Platt, Central Editorial Information Specialist (search), and Cecilia Fabrizio, DrPH (consumer). Two additional peer reviewers provided clinical peer review but chose not to be publicly acknowledged.

We thank Freda Alexander, Ingvar Andersson, Cornelia Baines, Niels Bjurstam, Gunnar Fagerberg, Jan Frisell, Anthony B Miller and Sam Shapiro for comments on their trials, Friederike M Perl for pointing out an inconsistency in one of the trials, Mike Clarke for advice, Ole Olsen who was an author on the 2001 version of this review and wrote the draft section on methodological quality of the trials for that version, Kay Dickersin for comments on the 2006 update of the review, and Margrethe Nielsen who was an author on the 2006 and 2009 updates.

Data and analyses

Comparison 1					
Screening with mammography versus no screening					
Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size	
1.1 Deaths ascribed to breast cancer, 7 years follow up	11		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only	
1.1.1 Adequately randomised trials	4	292958	Risk Ratio (M-H, Fixed, 95% CI)	0.93 [0.79, 1.09]	
1.1.2 Suboptimally randomised trials	7	323369	Risk Ratio (M-H, Fixed, 95% CI)	0.71 [0.61, 0.83]	
1.2 Deaths ascribed to breast cancer, 13 years follow up	9		Odds Ratio (M-H, Fixed, 95% CI)	Subtotals only	
1.2.1 Adequately randomised trials	4	292153	Odds Ratio (M-H, Fixed, 95% CI)	0.90 [0.79, 1.02]	
1.2.2 Suboptimally randomised trials	5	306937	Odds Ratio (M-H, Fixed, 95% CI)	0.75 [0.67, 0.83]	
1.3 Deaths ascribed to breast cancer, 7 years follow up, women below 50 years of age (Malmö 55)	9		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only	
1.3.1 Adequately	3	227333	Risk Ratio (M-H, Fixed,	0.94 [0.78, 1.14]	

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size	
randomised (which was not certified by peer review) It is made available under a CC-BY-NC-ND 4.0 International license.					medRxiv preprint doi: https://doi.org/10.1101/2024.06.06.24308572 ; this version posted June 6, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
1.3.2 Suboptimally randomised trials	6	129035	Risk Ratio (M-H, Fixed, 95% CI)	0.81 [0.63, 1.05]	
1.4 Deaths ascribed to breast cancer, 7 years follow up, women at least 50 years of age (Malmö 55)	7		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only	
1.4.1 Adequately randomised trials	2	65625	Risk Ratio (M-H, Fixed, 95% CI)	0.88 [0.64, 1.20]	
1.4.2 Suboptimally randomised trials	5	195419	Risk Ratio (M-H, Fixed, 95% CI)	0.67 [0.56, 0.81]	
1.5 Deaths ascribed to breast cancer, 13 years follow up, women below 50 years of age	8		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only	
1.5.1 Adequately randomised trials	3	218697	Risk Ratio (M-H, Fixed, 95% CI)	0.87 [0.73, 1.03]	
1.5.2 New Subgroup	5	110814	Risk Ratio (M-H, Fixed, 95% CI)	0.80 [0.64, 0.98]	
1.6 Deaths ascribed to breast cancer, 13 years follow up, women at least 50 years of age	7		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only	
1.6.1 Adequately randomised trials	2	74261	Risk Ratio (M-H, Fixed, 95% CI)	0.94 [0.77, 1.15]	
1.6.2 Suboptimally randomised trials	5	194613	Risk Ratio (M-H, Fixed, 95% CI)	0.70 [0.62, 0.80]	
1.7 Deaths ascribed to breast cancer, 24 years of follow-up	2	250671	Risk Ratio (M-H, Fixed, 95% CI)	0.95 [0.86, 1.04]	
1.8 Deaths ascribed to any cancer, all women	7		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only	
1.8.1 Adequately randomised trials	4	292954	Risk Ratio (M-H, Fixed, 95% CI)	1.00 [0.96, 1.04]	
1.8.2 Suboptimally randomised trials (unreliable estimates)	3	195871	Risk Ratio (M-H, Fixed, 95% CI)	0.99 [0.93, 1.06]	
1.9 Overall mortality, 7 years follow up	11		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only	

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1.9.1 Adequately randomised trials	4	292958	Risk Ratio (M-H, Fixed, 95% CI)	0.99 [0.94, 1.03]
1.9.2 Suboptimally randomised trials (unreliable estimates)	7	324977	Risk Ratio (M-H, Fixed, 95% CI)	0.99 [0.96, 1.02]
1.10 Overall mortality, 13 years follow up	8		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
1.10.1 Adequately randomised trials	4	292958	Risk Ratio (M-H, Fixed, 95% CI)	0.99 [0.95, 1.03]
1.10.2 Suboptimally randomised trials (unreliable estimates)	4	244868	Risk Ratio (M-H, Fixed, 95% CI)	0.99 [0.97, 1.01]
1.11 Overall mortality, 7 years follow up, women below 50 years of age	7		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
1.11.1 Adequately randomised trials	2	211270	Risk Ratio (M-H, Fixed, 95% CI)	0.97 [0.90, 1.04]
1.11.2 Suboptimally randomised trials (unreliable estimates)	5	99656	Risk Ratio (M-H, Fixed, 95% CI)	1.07 [0.98, 1.16]
1.12 Overall mortality, 7 years follow up, women at least 50 years of age	5		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
1.12.1 Adequately randomised trials	1	39405	Risk Ratio (M-H, Fixed, 95% CI)	1.01 [0.85, 1.20]
1.12.2 Suboptimally randomised trials (unreliable estimates)	4	161519	Risk Ratio (M-H, Fixed, 95% CI)	0.97 [0.94, 1.00]
1.13 Overall mortality, 13 years follow up, women below 50 years of age	6		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
1.13.1 Adequately randomised trials	3	219324	Risk Ratio (M-H, Fixed, 95% CI)	0.98 [0.92, 1.04]
1.13.2 Suboptimally randomised trials (unreliable estimates)	3	61344	Risk Ratio (M-H, Fixed, 95% CI)	1.00 [0.92, 1.10]
1.14 Overall mortality, 13 years follow up, women at	4		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only

medRxiv preprint doi: <https://doi.org/10.1101/2024.06.06.24308542>; this version posted June 6, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1.14.1 Adequately randomised trials	2	73634	Risk Ratio (M-H, Fixed, 95% CI)	1.00 [0.95, 1.04]
1.14.2 Suboptimally randomised trials (unreliable estimates)	2	98261	Risk Ratio (M-H, Fixed, 95% CI)	0.99 [0.97, 1.02]
1.15 Overall mortality, 24 years follow-up	2		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
1.15.1 Adequately randomised trials	2	250671	Risk Ratio (M-H, Fixed, 95% CI)	1.01 [0.99, 1.04]
1.16 Number of mastectomies and lumpectomies	5	250479	Risk Ratio (M-H, Fixed, 95% CI)	1.35 [1.26, 1.44]
1.16.1 Adequately randomised trials	3	132321	Risk Ratio (M-H, Fixed, 95% CI)	1.31 [1.22, 1.42]
1.16.2 Suboptimally randomised trials	2	118158	Risk Ratio (M-H, Fixed, 95% CI)	1.42 [1.26, 1.61]
1.17 Number of mastectomies	5	250479	Risk Ratio (M-H, Fixed, 95% CI)	1.20 [1.11, 1.30]
1.17.1 Adequately randomised trials	3	132321	Risk Ratio (M-H, Fixed, 95% CI)	1.20 [1.08, 1.32]
1.17.2 Suboptimally randomised trials	2	118158	Risk Ratio (M-H, Fixed, 95% CI)	1.21 [1.06, 1.38]
1.18 Number treated with radiotherapy	2	100383	Risk Ratio (M-H, Fixed, 95% CI)	1.32 [1.16, 1.50]
1.18.1 Adequately randomised trials	1	42486	Risk Ratio (M-H, Fixed, 95% CI)	1.24 [1.04, 1.49]
1.18.2 Suboptimally randomised trials	1	57897	Risk Ratio (M-H, Fixed, 95% CI)	1.40 [1.17, 1.69]
1.19 Number treated with chemotherapy	2	100383	Risk Ratio (M-H, Fixed, 95% CI)	0.96 [0.78, 1.19]
1.19.1 Adequately randomised trials	1	42486	Risk Ratio (M-H, Fixed, 95% CI)	0.63 [0.39, 1.04]
1.19.2 Suboptimally randomised trials	1	57897	Risk Ratio (M-H, Fixed, 95% CI)	1.06 [0.84, 1.34]
1.20 Number treated with hormone therapy	2	100383	Risk Ratio (M-H, Fixed, 95% CI)	0.73 [0.55, 0.96]
1.20.1 Adequately randomised trials	1	42486	Risk Ratio (M-H, Fixed, 95% CI)	0.81 [0.60, 1.08]
1.20.2 Suboptimally	1	57897	Risk Ratio (M-H, Fixed,	0.30 [0.12, 0.72]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size	
<p>randomised preprint doi: https://doi.org/10.1101/2024.06.06.24308542; this version posted June 6, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.</p>					
1.21 Mortality among breast cancer patients in the Two-County study, 7 years follow up	2		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only	
1.21.1 Mortality from cancers other than breast cancer	2	2063	Risk Ratio (M-H, Fixed, 95% CI)	2.42 [1.00, 5.85]	
1.21.2 Mortality from causes other than breast cancer	2	2063	Risk Ratio (M-H, Fixed, 95% CI)	1.37 [0.93, 2.04]	
1.22 Results for biased trial	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected	
1.22.1 Deaths ascribed to breast cancer, 7 years follow up	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected	
1.22.2 Deaths ascribed to breast cancer, 13 years follow up	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected	
1.22.3 Deaths ascribed to breast cancer, 7 years follow up, younger women (below 50 years of age)	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected	
1.22.4 Deaths ascribed to breast cancer, 7 years follow up, elderly women (at least 50 years of age)	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected	
1.22.5 Deaths ascribed to breast cancer, 13 years follow up, younger women (below 50 years of age)	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected	
1.22.6 Deaths ascribed to breast cancer, 13 years follow up, elderly women (at least 50 years of age)	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected	
1.22.7 Overall mortality, 7 years follow up	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected	
1.22.8 Number treated with radiotherapy	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected	
1.23 Number of cancers	7	512246	Risk Ratio (M-H, Fixed, 95% CI)	1.29 [1.23, 1.35]	

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size	
1.23.1 Randomised trials (after 7-9 years)	4	219267	Risk Ratio (M-H, Fixed, 95% CI)	1.25 [1.18, 1.34]	
1.23.2 Suboptimally randomised trials (before control group screen)	3	219267	Risk Ratio (M-H, Fixed, 95% CI)	1.33 [1.24, 1.44]	

What's new

Date	Event	Description
14 August 2023	New citation required but conclusions have not changed	To be decided after editorial and peer review
28 February 2023	New search has been performed	Two of the three studies with adequate randomisation have been updated with many more deaths.

History

Protocol first published: Issue 1, 2000

Review first published: Issue 4, 2001

Date	Event	Description
22 November 2012	New search has been performed	Performed search for new studies on 22 November 2012. No new studies included
22 November 2012	New citation required but conclusions have not changed	This review update includes an accumulation of changes in the discussion section
17 November 2010	Amended	Corrected labels for Figure 1.21.
5 August 2009	New citation required but conclusions have not changed	new citation = no change to conclusions
3 March 2009	New search has been performed	Data from a new trial, UK age trial, added.
12 July 2006	New citation required and conclusions have changed	Substantive amendment

Contributions of authors

PCG wrote the draft protocol. Two authors extracted the main data independently and contributed to the review. PCG is guarantor.

Declarations of interest

PGC and KJJ has declared that they have no conflict of interest. PGC and Ole Olsen were asked by the Danish National Board of Health in 1999 to review the randomised trials.

Sources of support

Internal sources

- Cochrane Denmark, Denmark
Facilities for 2023 update

External sources

- Danish Institute for Health Technology Assessment, Denmark
Financial support for the first version of this review

Differences between protocol and review

medRxiv preprint doi: <https://doi.org/10.1101/2024.06.06.24308542>; this version posted June 6, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. A new outcome was added when we discovered that breast cancer mortality is an unreliable outcome. We have clarified that our outcome 'number of cancers' is an expression of the risk of overdiagnosis. It is made available under a CC-BY-NC-ND 4.0 International license.

Characteristics of studies

Characteristics of included studies [ordered by study ID]

Canada 1980		
Study characteristics		
Methods	Individual randomisation in blocks of 2 or 4, stratified by centre and 5-year age group (see also text). Cause of death was assessed blinded and independently by two specialists for women with diagnosed breast cancer and for other possible breast cancer deaths.	
Participants	Women aged 40-59 years. Number randomised: see below.	
Interventions	Two-view mammography: cranio-caudal and mediolateral (later medio-lateral oblique except in two centres). 4-5 cycles of screening with yearly interval.	
Outcomes	Total mortality. Breast cancer mortality. Surgical interventions.	
Notes	Attendance rate: 100% in first round. This study was supported by the Canadian Breast Cancer Research Alliance, Canadian Breast Cancer Research Initiative, Canadian Cancer Society, Health and Welfare Canada, National Cancer Institute of Canada, Alberta Heritage Fund for Cancer Research, Manitoba Health Services Commission, Medical Research Council of Canada, le Ministère de la Santé et des Services Sociaux du Québec, Nova Scotia Department of Health, and Ontario Ministry of Health.	
Risk of bias		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer-generated block randomization with two block sizes (equalled out the allocations only after every 48 entries; Baines, personal information, June 2011).
Allocation concealment (selection bias)	Low risk	Adequate, see text.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Not possible for a screening trial and not relevant.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Cause of death was assessed blinded.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Very few women excluded after randomisation (see text) and none because of previous breast cancer.
Selective reporting (reporting bias)	Low risk	This trial has been meticulously reported and documented.
Other bias	Low risk	None detected

Canada 1980a		
Study characteristics		
Methods	See Canada 1980.	
Participants	Women aged 40-49 years. 50,472 randomised. 59 were excluded from analyses, distributed equally between the two groups.	
Interventions	See Canada 1980. Screened women had an annual clinical examination while control women were examined at the first visit and were taught self-examination at that visit and were reminded annually by mail.	
Outcomes	See Canada 1980.	
Notes	Attendance rate: 100% in first round, 89% in second, decreasing to 86% in fifth round. Mammography in control group: 26%, most only once during the trial.	
Risk of bias		
Bias	Authors' judgement	Support for judgement

Random sequence generation (selection bias)	Low risk	See Canada 1980.
Allocation concealment (selection bias)	Low risk	See Canada 1980.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	See Canada 1980.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	See Canada 1980.
Incomplete outcome data (attrition bias) All outcomes	Low risk	See Canada 1980.
Selective reporting (reporting bias)	Low risk	See Canada 1980.
Other bias	Low risk	See Canada 1980.

Canada 1980b

Study characteristics		
Methods	See Canada 1980.	
Participants	Women aged 50-59 years.	
	39,459 randomised.	
	54 were excluded from analyses, distributed equally between the two groups.	
Interventions	See Canada 1980.	
	All women had their breasts examined annually.	
Outcomes	See Canada 1980.	
Notes	Attendance rate: 100% in first round, 90% in second, decreasing to 87% in fifth round.	
	Mammography in control group: 17%.	
Risk of bias		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	See Canada 1980.
Allocation concealment (selection bias)	Low risk	See Canada 1980.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	See Canada 1980.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	See Canada 1980.
Incomplete outcome data (attrition bias) All outcomes	Low risk	See Canada 1980.
Selective reporting (reporting bias)	Low risk	See Canada 1980.
Other bias	Low risk	See Canada 1980.

Edinburgh 1978

Study characteristics		
Methods	Stratified cluster randomisation; general practices were clusters; stratification was by size of practice. About 87 clusters (numbers vary in different reports, see text). Blinding of outcome assessment not stated.	
Participants	Women aged 45-64 years. Number of women and practices randomised inconsistently reported (see text). Very biased exclusions occurred: exclusion procedures different in study and control group, 177 previous breast cancer cases excluded from control group and 338 from study group.	
Interventions	Two-view mammography at first screen: cranio-caudal and oblique (except in one practice); only oblique in later rounds. Screened group: mammography and physical examination year 1, 3, 5 and 7; physical examination year 2, 4 and 6. Control group: usual care.	
Outcomes	Total mortality. Breast cancer mortality. Radiotherapy.	
Notes	Attendance rate: Circa 60% in first round; 44% in seventh round. Mammography in control group: unknown. This study was undertaken by the Cancer Screening Evaluation Unit, which receives support from the UK Department of Health.	
Risk of bias		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	No information, but some clusters later changed allocation status.

medRxiv preprint doi: <https://doi.org/10.1101/2024.06.06.24308542>; this version posted June 6, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Allocation concealment (selection bias)	High risk	The randomisation failed to an important degree to create comparable groups.
Blinding of participants and personnel (performance bias) (All outcomes)	Low risk	Not possible for a screening trial and not relevant.
Blinding of outcome assessment (detection bias) (All outcomes)	High risk	Not stated.
Incomplete outcome data (attrition bias) (All outcomes)	High risk	Not relevant, as randomisation failed to create comparable groups.
Selective reporting (reporting bias)	Unclear risk	Not relevant, as randomisation failed to create comparable groups.
Other bias	High risk	Not relevant, as randomisation failed to create comparable groups.

Göteborg 1982

Study characteristics

Methods	See Göteborg 1982a and 1982b.
Participants	Women aged 39-59 years. Number of women randomised: 21,904 to screening, 30,318 to control (see also text). 254 women (1.2%) excluded from the screening group and 357 (1.2%) from the control group due to a history of breast carcinoma prior to randomisation.
Interventions	See Göteborg 1982a and 1982b.
Outcomes	Total mortality. Breast cancer mortality.
Notes	Mammography in control group: 18% during last two years. The Swedish Cancer Society supported this study.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	Day of birth used. Randomisation ratios varied, not clear whether this was taken into account in the analysis.
Allocation concealment (selection bias)	High risk	Day of birth.
Blinding of participants and personnel (performance bias) (All outcomes)	Low risk	Not possible for a screening trial and not relevant.
Blinding of outcome assessment (detection bias) (All outcomes)	Low risk	Blinding of outcome assessment.
Incomplete outcome data (attrition bias) (All outcomes)	Low risk	Women with previous breast cancer were excluded after randomisation.
Selective reporting (reporting bias)	Low risk	We found no evidence for this.
Other bias	High risk	The whole control group was invited to screening when the trial ended, which renders follow-up data unreliable.

Göteborg 1982a

Study characteristics

Methods	Individual randomisation within year of birth cohort - by day of birth in the cohorts 1923-1935 and by computer software for the cohorts 1936-1944 - randomisation ratio varied by cohort, on average approximately 1:1.2 (see also text). Blinding of outcome assessment.
Participants	Women aged 39-49 years. Number of women randomised: 11,792 to screening, 14,321 to control (see also text). 68 women (0.6%) excluded from the screening group and 104 (0.7%) from the control group due to a history of breast carcinoma prior to randomisation.
Interventions	Two-view mammography at first screen, single at later rounds - single read at first three rounds; double read thereafter. 5 cycles with an interval of 18 months. Control group: usual care.
Outcomes	Total mortality. Breast cancer mortality.
Notes	Attendance rate: 85%, 78%, 79%, 77%, 75% in rounds 1-5. 66% at first screen in control group. Mammography in control group: 19% during last two years; 51% ever. Early systematic screening of control group.

Risk of bias

Bias	Authors' judgement	Support for judgement
------	--------------------	-----------------------

Random sequence generation (selection bias)	Unclear risk	See Göteborg 1982.
Allocation concealment (selection bias)	Unclear risk	See Göteborg 1982.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	See Göteborg 1982.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	See Göteborg 1982.
Incomplete outcome data (attrition bias) All outcomes	Low risk	See Göteborg 1982.
Selective reporting (reporting bias)	Low risk	See Göteborg 1982.
Other bias	High risk	See Göteborg 1982.

Göteborg 1982b

Study characteristics

Methods	Individual randomisation by computer software - randomisation ratio varied by cohort, on average approximately 1:1.6. Blinding of outcome assessment.
Participants	Women aged 50-59 years. Number of women randomised not stated explicitly, but can be calculated by comparing two trial reports (see Göteborg 1992 above for total numbers).
Interventions	Two-view mammography at first screen, single at later rounds - single read at first three rounds; double read thereafter. 4 cycles with an interval of 18 months. Control group: usual care.
Outcomes	Total mortality. Breast cancer mortality.
Notes	Attendance rate: 83% at first screen. 78% at first screen in control group. Early systematic screening of control group.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	See Göteborg 1982.
Allocation concealment (selection bias)	Unclear risk	See Göteborg 1982.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	See Göteborg 1982.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	See Göteborg 1982.
Incomplete outcome data (attrition bias) All outcomes	Low risk	See Göteborg 1982.
Selective reporting (reporting bias)	Low risk	See Göteborg 1982.
Other bias	High risk	See Göteborg 1982.

Kopparberg 1977

Study characteristics

Methods	Stratified cluster randomisation; seven blocks each contained 3 units (in three blocks the units were parishes and in four municipalities); randomisation ratio 2:1 (see also text). Blinding of outcome assessment not stated.
Participants	Women aged 40 years and above. 21 units randomised: 47,389 women in screening areas and 22,658 in control areas (33,641 vs. 16,359 in age group 40-69 years; 39,051 versus 18,846 in age group 40-74 years). No parishes or municipalities excluded. Exclusion criteria for patients unclear but probably biased (see text).
Interventions	One-view mammography, mediolateral oblique; additional views on suspicion. Number of screenings: two cycles prestatd, but more may have occurred (see text). Interval between screens were 2 years for women aged 40-49 years; 3 years for women aged 50 years and above.
Outcomes	Total mortality. Breast cancer mortality. Surgical interventions.

	Chemotherapy. Radiotherapy.	
medRxiv preprint doi: https://doi.org/10.1101/2024.08.08.24388942 ; this version posted June 8, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.	Attendance rate: 91-94% for women younger than 60 years; 50-80% for women above 60 years. Unclear when screening started in control group (see text).	
Notes	Early systematic screening of control group. Mammography in control group: 13%. Supported by a grant from the Kopparberg City Council.	
Risk of bias		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	See Two-County 1977.
Allocation concealment (selection bias)	High risk	See Two-County 1977.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	See Two-County 1977.
Blinding of outcome assessment (detection bias) All outcomes	High risk	See Two-County 1977.
Incomplete outcome data (attrition bias) All outcomes	High risk	See Two-County 1977.
Selective reporting (reporting bias)	High risk	See Two-County 1977.
Other bias	High risk	See Two-County 1977.

Malmö 1976

Study characteristics		
Methods	Individual randomisation; within each birth cohort a computer list was randomised and the first half invited for screening. Blinding of outcome assessment: deaths among breast cancer cases assessed blinded and independently by a pathologist and an oncologist; discrepancies resolved by an internist.	
Participants	Women aged 45-69 years. 21,242 randomised into screened group; 21,240 or 21,244 into control group (see text). Biased exclusions seem to have occurred: 154 women excluded from control group, 49 from study group (see text).	
Interventions	One-view or two-view mammography; two-view in 1st and 2nd round; one-view or two-view in later rounds depending on parenchymal pattern. 5-6 cycles according to protocol; 8 cycles in 1988; more during 1988-1992. Interval between screens: 18-24 months. Control group: usual care.	
Outcomes	Total mortality. Breast cancer mortality. Surgical interventions. Chemotherapy. Radiotherapy.	
Notes	Attendance rate: Circa 70%; 74% in first round ranging from 64% in oldest age group to 79% in youngest. Mammography in control group: screening offered to age group 50-69 years in 1991; invited in 1992 and completed in 1993. 6% had more than 3 mammograms during study; 24% had one or more; 35% among women aged 45-49 years at entry. This study was supported by the Swedish Cancer Society.	
Risk of bias		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer.
Allocation concealment (selection bias)	Low risk	Done by a computer on one occasion for the whole sample.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Not possible for a screening trial and not relevant.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Blinding of outcome assessment.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Very few women missing.
Selective reporting (reporting bias)	Low risk	This trial has been meticulously reported and documented.

Other bias	Low risk	None detected
------------	----------	---------------

medRxiv preprint doi: <https://doi.org/10.1101/2024.06.06.24308542>; this version posted June 6, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](#).

This is made available under a [CC-BY-NC-ND 4.0 International license](#).

Study characteristics		
Methods	See text of the review; extension of Malmö 1976.	
Participants		
Interventions		
Outcomes		
Notes		
Risk of bias		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	See text of the review; extension of Malmö 1976, not done according to a formal protocol, inclusion criteria violated, group sizes differed although they should have been the same, and gross and unexplained imbalance in numbers in the two groups.
Allocation concealment (selection bias)	High risk	See 'Random sequence generation.'
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Not possible for a screening trial and not relevant.
Blinding of outcome assessment (detection bias) All outcomes	High risk	See 'Random sequence generation.'
Incomplete outcome data (attrition bias) All outcomes	High risk	See 'Random sequence generation.'
Selective reporting (reporting bias)	High risk	See 'Random sequence generation.'
Other bias	High risk	See 'Random sequence generation.'

New York 1963

Study characteristics		
Methods	Individual randomisation within matched pairs; pairs derived from a computer list sorted by age, family size and employment group. A blinded review was carried out in a subsample of death certificates where cause of death was breast cancer. The panel much more often stated breast cancer as cause of death in the control group.	
Participants	Women aged 40-64 years. Probably 31,092 pairs of women were randomised into screening and control group. Very biased exclusions occurred: probably 336 previous breast cancer cases were excluded from the control group and 853 from study group (see text).	
Interventions	Two view mammography: cephalocaudal and lateral. 4 cycles (three were planned according to the first publications). Screened group: annual physical examinations. Control group: usual care.	
Outcomes	Total mortality. Breast cancer mortality. Surgical interventions. Radiotherapy.	
Notes	Attendance rate: 65% in total population, circa 58%, 50% and 40% participated in 2, 3 and 4 screens, respectively. Mammography in control group: not described. Organised through the Health Insurance Plan of Greater New York	
Risk of bias		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	Confusing information and the exact number of randomised women not stated.
Allocation concealment (selection bias)	Unclear risk	Unclear.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Not possible for a screening trial and not relevant.
Blinding of outcome assessment (detection bias) All outcomes	High risk	A blinded review was carried out in a subsample of death certificates where cause of death was breast cancer. The panel much more often stated breast cancer as cause of death in the control group.
Incomplete outcome data (attrition bias)	High risk	Confusing information and the exact number of randomised women not stated.

All outcomes		
Selective reporting (reporting bias)	High risk	Confusing information and the exact number of randomised women not stated.
Other bias	High risk	Some women who have been screened for the disease could have been excluded, which they all were in the screened group.

Stockholm 1981

Study characteristics		
Methods	Individual randomisation by day of birth; 1-10 and 21-31 in study group and 11-20 in control group (see also text). Blinding of outcome assessment: not stated.	
Participants	Women aged 40-64 years. Number of women randomised inconsistently reported (see text). Exclusions after randomisation unclear (see text).	
Interventions	Single oblique mammography; recalled for conventional three-view if malignancies suspected. 2 cycles (number not predetermined - screening introduced in control group because of results from Kopparberg). Interval between screens: Circa 2 years; 2.5 years to complete first round and 2.1 to complete second round. Control group: usual care.	
Outcomes	Total mortality. Breast cancer mortality. Surgical interventions.	
Notes	Attendance rate: circa 80%. Mammography in control group: 8% during one year; 25% in study group during two years previous to screening. Early systematic screening of control group. Likely publicly funded.	
Risk of bias		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	Day of birth.
Allocation concealment (selection bias)	High risk	Day of birth.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Not possible for a screening trial and not relevant.
Blinding of outcome assessment (detection bias) All outcomes	High risk	Blinding of outcome assessment not stated.
Incomplete outcome data (attrition bias) All outcomes	High risk	Reported numbers are inconsistent.
Selective reporting (reporting bias)	High risk	Reported numbers are inconsistent.
Other bias	High risk	Reported numbers are inconsistent.

Two-County 1977

Study characteristics		
Methods	Stratified cluster randomisation (see Kopparberg 1977 and Östergötland 1978 for details). Blinding of cause of death assessments in some later updates for use in Swedish meta-analyses.	
Participants	Women aged 40-74 years. (See Kopparberg 1977 and Östergötland 1978 for details).	
Interventions	See Kopparberg 1977 and Östergötland 1978. Screened women were encouraged to perform self-examination of the breasts every month. Control women: usual care.	
Outcomes	See Kopparberg 1977 and Östergötland 1978.	
Notes	See Kopparberg 1977 and Östergötland 1978. Funded by the Swedish National Board of Health and Welfare.	
Risk of bias		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No information.
Allocation concealment (selection bias)	High risk	See text, information inconsistent and incomplete.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Not possible for a screening trial and not relevant.

Blinding of outcome assessment (detection bias) All outcomes (which was not certified by peer review) All outcomes	High risk High risk High risk	Blinding of outcome assessment not stated. Numbers of women, cancers and deaths vary in the reports of the trial.
Selective reporting (reporting bias)	High risk	Numbers of women, cancers and deaths vary in the reports of the trial.
Other bias	High risk	Numbers of women, cancers and deaths vary in the reports of the trial, see also main text.

UK age trial 1991

Study characteristics		
Methods	Individual randomisation by computer; randomisation ratio 1:2. Information on cause of death was obtained from the central register of the National Health Service.	
Participants	Women aged 39-41 years. 53,914 randomised into screened group; 107,007 into control group. 30 and 51 excluded after randomisation.	
Interventions	Two-view mammography at first screen, and by single mediolateral oblique view thereafter, with recall for full assessment if an abnormality was suspected. 7 annual screens planned. Control group: usual care.	
Outcomes	Total mortality. Breast cancer mortality.	
Notes	Number of cancers in latest report given per 1000 women-years. Participation rate: ca 66% at prevalence screen, below 50% at 8th screen. Funding through the National Institute for Health Research Health Technology Assessment programme.	
Risk of bias		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer.
Allocation concealment (selection bias)	Low risk	Individual randomisation by computer.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Not possible for a screening trial and not relevant.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Information on cause of death was obtained from the central register of the National Health Service.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Very few women excluded after randomisation.
Selective reporting (reporting bias)	Low risk	We found no evidence for this
Other bias	Low risk	We found no evidence for this

Östergötland 1978

Study characteristics	
Methods	Stratified cluster randomisation; 12 blocks (consisting of 164 parishes in total) were each split into 2 units of roughly equal size and socio-economic composition; randomisation ratio 1:1 (see also text). Blinding of outcome assessment not stated.
Participants	Women aged 40 years and above. 24 units with 92,934 women randomised into 47,001 in screening parishes and 45,933 in control parishes (39,034 versus 37,936 in age group 40-74 years). No parishes or municipalities excluded. Women with a previous history of breast cancer were excluded after randomisation; exclusions seem unbiased (see text).
Interventions	One-view mammography, mediolateral oblique; women who reported a lump were examined clinically and by complete mammography. 2 screens for women above 70 years, 3 for women originally in age group 40-69 years. Interval between screens: 2-2.5 years.
Outcomes	Total mortality. Breast cancer mortality.
Notes	Attendance rate: ca. 90% in first round, 80% in second, very age dependent. Mammography in control group: 13%. Early systematic screening of control group.

Funded by the Swedish National Board of Health and Welfare.		
Risk of bias		
Random sequence generation (selection bias)	High risk	See Two-County 1977.
Allocation concealment (selection bias)	High risk	See Two-County 1977.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	See Two-County 1977.
Blinding of outcome assessment (detection bias) All outcomes	High risk	See Two-County 1977.
Incomplete outcome data (attrition bias) All outcomes	High risk	See Two-County 1977.
Selective reporting (reporting bias)	High risk	See Two-County 1977.
Other bias	High risk	See Two-County 1977.

Characteristics of excluded studies [ordered by study ID]

Study	Reason for exclusion
Berglund 2000	Multiple risk factor intervention study, with several interventions, including mammography, not a randomised trial but alternating allocation of birth year cohorts with resulting age differences at baseline between the two groups; 50 women died from cancer of 8,712 participants, no data on breast cancer.
Dales 1979	Multiple risk factor intervention trial, with several interventions, regular mammography was only one of the interventions and only about 1000 women were invited for mammography.
Singapore 1994	Singapore Breast Screening Project. Randomised 166,600 women aged 50-64 years, but the only intervention was the prevalence screen, and exclusions after randomisation occurred only in the screened group. Previous cancer at any site was an exclusion criterion; more than 1500 women were excluded from the screened group, 468 because they were already dead.

Characteristics of studies awaiting classification [ordered by study ID]

AgeX Trial	
Methods	Cluster randomisation
Participants	Women without breast cancer aged 47 to 49 years and 71 to 73 years
Interventions	Mammography screening
Outcomes	Breast cancer mortality (primary); all-cause mortality; breast cancer incidence.
Notes	Information collected from study protocol available at https://www.ceu.ox.ac.uk/research/agex-trial/history-of-the-agex-trial .

Murillo 2016	
Methods	Cluster randomised trial
Participants	7,436 women
Interventions	Clinicians in 13 clinics instructed in clinical breast examination and referral to mammography versus 13 clinics continuing 'usual care'
Outcomes	Breast cancer incidence rates and use of surgery, by stage
Notes	

Appendices

Appendix 1. PubMed search strategy

#1 (breast neoplasms[MeSH Terms] OR "breast cancer" OR mammography[MeSH Terms] OR mammograph*)

#2 (mass screening[MeSH Terms] OR screen*)

#3 #1 AND #2

#4 (((randomized controlled trial [pt] OR "controlled clinical trial"[Publication Type] OR "randomized"[Title/Abstract] OR "placebo"[Title/Abstract]) OR ("clinical trials as topic" [mesh terms]) OR (randomly [tiab] OR trial [ti])) NOT (animals [mh] NOT humans [mh]))

#5 #3 AND #4

#6 ("2012/11/01"[Date - Publication] : "2023/02/28"[Date - Publication])

#7 #5 AND #6

medRxiv preprint doi: <https://doi.org/10.1101/2024.06.06.24285543>; this version posted June 6, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](#).

#1 MeSH descriptor: [Breast Neoplasms] explode all trees

#2 (early breast cancer* or early breast neoplas* or early breast carcinoma* or early breast tumour* or early breast tumor*)

#3 MeSH descriptor: [Mammography] explode all trees

#4 Mammograph*

#5 #1 OR #2 OR #3 OR #4

#6 MeSH descriptor: [Mass Screening] explode all trees

#7 screen*

#8 #6 OR #7

#9 #5 AND #8 with Publication Year from 2012 to present, in Trials

Appendix 3. World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) Search Strategy

Basic search:

Breast cancer AND mammograph*

Advanced search:

1. Condition: breast AND (cancer* OR carcinoma* OR neoplas* OR tumour* OR tumor*)

Intervention: mammograph*

Recruitment Status: All

2. Condition: breast AND (cancer* OR carcinoma* OR neoplas* OR tumour* OR tumor*)

Intervention: screen*

Recruitment Status: All

Appendix 4. Clinicaltrials.gov Search Strategy

Basic search:

Condition or disease: Breast cancer

Other terms: mammography

Status: All studies

Advanced search:

1. Condition: breast cancer OR breast neoplasm

Intervention/treatment: mammography

2. Condition: breast cancer OR breast neoplasm

Intervention/treatment: screening

References

References to studies included in this review

Canada 1980 {published and unpublished data}

To T, Wall C, Baines CJ, Miller AB. Is carcinoma in situ a precursor lesion of invasive breast cancer? International Journal of Cancer 2014;135:1646-52.

Miller AB, Wall C, Baines CJ, Sun P, To T, Narod SA. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ 2014;348:g366.

Bailar JC 3rd, MacMahon B. Randomization in the Canadian National Breast Screening Study: a review for evidence of subversion. Canadian Medical Association Journal 1997;156(2):193-9.

Baines CJ, Christen A, Simard A, Wall C, Dean D, Duncan L et al. The National Breast Screening Study: pre-recruitment sources of awareness in participants. Canadian Journal of Public Health 1989;80(3):221-5.

Baines CJ, McFarlane DV, Miller AB. Sensitivity and specificity of first screen mammography in 15 NBSS centres. Canadian Association of Radiologists Journal 1988;39(4):273-6.

Baines CJ, McFarlane DV, Miller AB. The role of the reference radiologist. Estimating the impact of the reviewer for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Baines CJ, McFarlane DV, Wall C. Audit procedures in the National Breast Screening Study: mammography interpretation. Canadian Association of Radiologists Journal 1986;37(4):256-60.

Baines CJ, Miller AB, Bassett AA. Physical examination. Its role as a single screening modality in the Canadian National Breast Screening Study. Cancer 1989;63(9):1816-22.

Baines CJ, Miller AB, Kopans DB, Moskowitz M, Sanders DE, Sickles EA et al. Canadian National Breast Screening Study: assessment of technical quality by external review. AJR. American Journal of Roentgenology 1990;155(4):743-7.

Baines CJ, Miller AB, Wall C, McFarlane DV, Simor IS, Jong R et al. Sensitivity and specificity of first screen mammography in the Canadian National Breast Screening Study: a preliminary report from five centers. Radiology 1986;160(2):295-8.

Baines CJ, Miller AB. Mammography versus clinical examination of the breasts. Journal of the National Cancer Institute. Monographs 1997;22:125-9.

Baines CJ, To T, Miller AB. Revised estimates of overdiagnosis from the Canadian National Breast Screening Study. Preventive Medicine 2016;90:66-71.

Baines CJ, To T, Wall C. Women's attitudes to screening after participation in the National Breast Screening Study. A questionnaire survey. Cancer 1990;65(7):1663-9.

Baines CJ, To T. Changes in breast self-examination behavior achieved by 89,835 participants in the Canadian National Breast Screening Study. Cancer 1990;66(3):570-6.

Baines CJ, Vidmar M, McKeown Eyssen G, Tibshirani R. Impact of menstrual phase on false-negative mammograms in the Canadian National Breast Screening Study. Cancer 1997;80(4):720-4.

Baines CJ, Wall C, Risch HA, Kuin JK, Fan IJ. Changes in breast self-examination behavior in a cohort of 8214 women in the Canadian National Breast Screening Study. Cancer 1986;57(6):1209-16.

Baines CJ. A different view on what is known about breast screening and the Canadian National Breast Screening Study. Cancer 1994;74(4):1207-11.

Baines CJ. Impediments to recruitment in the Canadian National Breast Screening Study: response and resolution. Controlled Clinical Trials 1984;5(2):129-40.

Baines CJ. NBSS: changes were made, suspicious changes were not [letter]. CMAJ 1997;157(3):248-50.

Baines CJ. Personal communication 18 Jan 2001.

Baines CJ. The Canadian National Breast Screening Study. Why? What next? And so what? Cancer 1995;76 Suppl(10):2107-12.

Baines CJ. The Canadian National Breast Screening Study: a perspective on criticisms. Annals of Internal Medicine 1994;120(4):326-34.

Baines CJ. The Canadian National Breast Screening Study: responses to controversy. Womens Health Issues 1992;2(4):206-11.

Basinski AS. The Canadian National Breast Screening Study: opportunity for a rethink. CMAJ 1992;147(10):1431-4.

Boyd NF, Byng JW, Jong RA, Fishell EK, Little LE, Miller AB et al. Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. Journal of the National Cancer Institute 1995;87(9):670-5.

Boyd NF, Jensen HM, Cooke G, Han HL. Relationship between mammographic and histological risk factors for breast cancer. Journal of the National Cancer Institute 1992;84(15):1170-9.

Boyd NF, Jong RA, Yaffe MJ, Trichter D, Lockwood G, Zylak CJ. A critical appraisal of the Canadian National Breast Cancer Screening Study. Radiology 1993;189(3):661-3.

Boyd NF, Lockwood GA, Martin LJ, Knight JA, Jong RA, Fishell E et al. Mammographic densities and risk of breast cancer among subjects with a family history of this disease. Journal of the National Cancer Institute 1999;91(16):1404-8.

Boyd NF, Wolfson C, Moskowitz M, Carlile T, Petitclerc M, Ferri HA et al. Observer variation in the interpretation of xeromammograms. Journal of the National Cancer Institute 1982;68(3):357-63.

Boyd NF. The review of randomization in the Canadian National Breast Screening Study. Is the debate over? CMAJ 1997;156(2):207-9.

Bryant H. The review of randomization in the Canadian National Breast Screening Study. What does the verdict mean for clinicians? CMAJ 1997;156(2):213-5.

Burhenne LJ, Burhenne HJ. The Canadian National Breast Screening Study: a Canadian critique. American Journal of Roentgenology 1993;161(4):761-3.

Busetti MC, Miller AB, To T, Rohan TE. Risk factors for breast cancer mortality among the National Breast Screening Study of Canada participants. Cancer Detection and Prevention 1996;20(2):122-9.

Cohen MM, Kaufert PA, MacWilliam L, Tate RB. Using an alternative data source to examine randomization in the Canadian National Breast Screening Study. Journal of Clinical Epidemiology 1996;49(9):1039-44.

Goel V, Cohen MM, Kaufert P, MacWilliam L. Assessing the extent of contamination in the Canadian National Breast Screening Study. American Journal of Preventive Medicine 1998;15(3):206-11.

Goldman B. When considering attacks against the National Breast Screening Study, consider the sources. CMAJ 1993;148(3):427-8.

Gray C. US resistance to Canadian mammogram study not only about data. CMAJ 1993;148(4):622-3.

- Haiart DC, Henderson J. A comparison of interpretation of screening mammograms by a radiographer, a doctor and a radiologist: results and implications. *The British Journal of Clinical Practice* 1991;45(1):43-5.
- Miller AB, Baines CJ, To T, Wall C, Wall C, Wall C. Effect of breast self-examination on the risk of death from breast cancer. *CMAJ* 1997;157(9):1205-12.
- Holowaty PH, Miller AB, Baines CJ, Risch H. Canadian National Breast Screening Study: first screen results as predictors of future breast cancer risk. *Cancer Epidemiology, Biomarkers & Prevention* 1993;2(1):11-9.
- Howe GR, Sherman GJ, Semenciw RM, Miller AB. Estimated benefits and risks of screening for breast cancer. *Canadian Medical Association Journal* 1981;124(4):399-403.
- Jain MG, Miller AB, Rohan TE, Rehm JT, Bondy SJ, Ashley MJ et al. Body mass index and mortality in women: follow-up of the Canadian National Breast Screening Study cohort. *International Journal of Obesity and Related Metabolic Disorders* 2005;29(7):792-7.
- Kopans DB, Feig SA. The Canadian National Breast Screening Study: a critical review. *American Journal of Roentgenology* 1993;161(4):755-60.
- Kopans DB, Halpern E, Hulka CA. Mammography screening for breast cancer. Reply to the commentaries. *Cancer* 1994;74(4):1212-6.
- Kopans DB, Halpern E, Hulka CA. Statistical power in breast cancer screening trials and mortality reduction among women 40-49 years of age with particular emphasis on the National Breast Screening Study of Canada. *Cancer* 1994;74(4):1196-203.
- Miller AB, Baines CJ, Sickles EA. Canadian National Breast Screening Study. *American Journal of Roentgenology* 1990;155:1133-4.
- Miller AB, Baines CJ, To T et al. The Canadian national breast screening study. In: Miller AB, Chamberlain J, Day NE et al, editors(s). *Cancer Screening*. Cambridge: Cambridge University Press, 1991:45-55.
- Miller AB, Baines CJ, To T, Wall C. Canadian national breast screening study [correction]. *CMAJ* 1993;148:718.
- Miller AB, Baines CJ, To T, Wall C. Screening mammography re-evaluated. *The Lancet* 2000;355:747.
- Miller AB, Baines CJ, Turnbull C. The role of the nurse-examiner in the National Breast Screening Study. *Canadian Journal of Public Health* 1991;82(3):162-7.
- Miller AB, Howe GR, Wall C. The National Study of Breast Cancer Screening Protocol for a Canadian Randomized Controlled trial of screening for breast cancer in women. *Clinical and Investigative Medicine* 1981;4(3-4):227-58.
- Miller AB. Canadian National Breast Screening Study: response [letter]. *CMAJ* 1993;149(10):1374-5.
- Miller AB. Mammography in mass screening [letter]. *European Journal of Cancer* 1980;16(5):737-9.
- Miller AB. More on breast cancer screening. *Cancer Forum* 1988;12:1-3.
- Miller AB. Re: "Author of Canadian breast cancer study retracts warnings" [letter]. *Journal of the National Cancer Institute* 1992;84(17):1365-70.
- Miller AB. Re: May we agree to disagree, or how do we develop guidelines for breast cancer screening in women? [letter]. *Journal of the National Cancer Institute* 1994;86(22):1729-31.
- Miller AB. Routine mammography and the National Breast Screening Study. *CMAJ* 1984;130(3):259-60, 273.
- Miller AB. The Canadian National Breast Screening Study: update on breast cancer mortality. In: NIH Consensus Development Conference on Breast Cancer Screening for Women ages 40-49. National Institutes of Health, 1997:51-3.
- Miller AB. The Canadian national breast screening study. In: Day NE, Miller AB, editors(s). *Screening for Breast Cancer*. Toronto: Hans Huber, 1988:51-8.
- Miller AB. The costs and benefits of breast cancer screening. *American Journal of Preventive Medicine* 1993;9(3):175-80.
- Narod SA. On being the right size: A reappraisal of mammography trials in Canada and Sweden. *The Lancet* 1997;349:1849.
- Simard A, Paquette L, Baillargeon J, Falardeau M. Perception of cancer detection and early treatment in a population participating in the National Breast Screening Study in Canada. *Canadian Journal of Public Health* 1989;80(3):226-7.
- Taghipour S, Banjevic D, Miller AB, Montgomery N, Jardine AK, Harvey BJ. Parameter estimates for invasive breast cancer progression in the Canadian National Breast Screening Study. *British Journal of Cancer* 2013;108:542-8.

Canada 1980a {published and unpublished data}

- Kopans DB. Canadian National Breast Screening Study [letter]. *The Lancet* 1997;350(9080):810.
- Miller AB, Baines CJ, To T, Wall C. Canadian National Breast Screening Study: 1. Breast cancer detection and death rates among women aged 40 to 49 years. *Canadian Medical Association Journal* 1992;147(10):1459-76.
- Miller AB, To T, Baines CJ, Wall C. The Canadian National Breast Screening Study-1: breast cancer mortality after 11 to 16 years of follow-up. A randomized screening trial of mammography in women age 40 to 49 years. *Annals of Internal Medicine* 2002;137(5 Part 1):305-12.
- Miller AB, To T, Baines CJ, Wall C. The Canadian National Breast Screening Study: update on breast cancer mortality. *Journal of the National Cancer Institute. Monographs* 1997;NA(22):37-41.

Canada 1980b {published and unpublished data}

Miller AB, Baines CJ, To T, Wall C. Canadian National Breast Screening Study: 2. Breast cancer detection and death rates among women aged 50 to 59 years. *Canadian Medical Association Journal* 1992;147(10):1477-83. <https://doi.org/10.1101/2024.06.06.24308542>; this version posted June 6, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Miller AB, To T, Baines CJ, Wall C. Canadian National Breast Screening Study: 2. 13-year results of a randomized trial in women aged 50-59 years. *Journal of the National Cancer Institute* 2000;92:1490-9.

Edinburgh 1978 {published data only}

- Alexander F, Roberts MM, Lutz W, Hepburn W. Randomisation by cluster and the problem of social class bias. *Journal of Epidemiology and Community Health* 1989;43(1):29-36.
- Alexander FE, Anderson TJ, Brown HK, Forrest AP, Hepburn W, Kirkpatrick AE et al. 14 years of follow-up from the Edinburgh randomised trial of breast-cancer screening. *The Lancet* 1999;353(9168):1903-8.
- Alexander FE, Anderson TJ, Brown HK, Forrest AP, Hepburn W, Kirkpatrick AE et al. The Edinburgh randomised trial of breast cancer screening: results after 10 years of follow-up. *British Journal of Cancer* 1994;70(3):542-8.
- Alexander FE, Anderson TJ, Donnan PT, Prescott RJ. Edinburgh trial of screening for breast cancer [letter]. *The Lancet* 1990;335(8695):969-70.
- Alexander FE, Anderson TJ, Donnan PT, Prescott RJ. Edinburgh trial of screening for breast cancer [letter]. *The Lancet* 1990;335:1290-1.
- Alexander FE, Anderson TJ, Hubbard AL. Screening status in relation to biological and chronological characteristics of breast cancers: a cross sectional survey. *Journal of Medical Screening* 1997;4(3):152-7.
- Alexander FE, Brown HK, Prescott RJ. Improved classification of socio-economic status explains differences in all-cause mortality in the randomised trial of breast cancer screening. *Journal of Epidemiology and Biostatistics* 1998;3(2):219-24.
- Alexander FE, O'Brien F, Hepburn W, Miller M. Association between mortality among women and socioeconomic factors in general practices in Edinburgh: an application of small area statistics. *BMJ* 1987;295(6601):754-6.
- Alexander FE, Roberts MM, Huggins A, Muir BB. Use of risk factors to allocate schedules for breast cancer screening. *Journal of Epidemiology and Community Health* 1988;42(2):193-9.
- Alexander FE. The Edinburgh Randomized Trial of Breast Cancer Screening. *Journal of the National Cancer Institute. Monographs* 1997;22:31-5.
- Anderson TJ, Lamb J, Alexander F, Lutz W, Chetty U, Forrest AP et al. Comparative pathology of prevalent and incident cancers detected by breast screening. Edinburgh Breast Screening Project. *The Lancet* 1986;1(8480):519-23.
- Anderson TJ, Lamb J, Donnan P, Alexander FE, Huggins A, Muir BB et al. Comparative pathology of breast cancer in a randomised trial of screening. *British Journal of Cancer* 1991;64(1):108-13.
- Benjamin DJ. The efficacy of surgical treatment of breast cancer. *Medical Hypotheses* 1996;47(5):389-97.
- Chamberlain J, Atkinson AB, Cochrane AL. Trial of early detection of breast cancer: Description of method. *British Journal of Cancer* 1981;44:618-27.
- Chamberlain J, Coleman D, Ellam R, Moss S. Progress report of the UK trial of early detection of breast cancer. In: Day NE, Miller AB, editors(s). *Progress report of the UK trial of early detection of breast cancer*. Toronto: Hans Huber, 1988:45-9.
- Chamberlain J, Coleman D, Ellman R, Moss S, Thomas B, Price J. Sensitivity and specificity of screening in the UK trial of early detection of breast cancer. In: Miller AB, Chamberlain J, Day NE et al, editors(s). *Cancer Screening*. Cambridge: Cambridge University Press, 1991:3-17.
- Chetty U, Wang CC, Forrest AP, Roberts MM. Benign breast disease and cancer. *The British Journal of Surgery* 1980;67(11):789-90.
- Dean C, Roberts MM, French K, Robinson S. Psychiatric morbidity after screening for breast cancer. *Journal of Epidemiology and Community Health* 1986;40(1):71-5.
- French K, Porter AM, Robinson SE, McCallum FM, Howie JG, Roberts MM. Attendance at a breast screening clinic: a problem of administration or attitudes. *BMJ* 1982;285(6342):617-20.
- Milne L. Mammography in the Edinburgh breast screening project. *Radiography* 1979;45(536):176-8.
- Nicholson S, Farndon JR. Edinburgh trial of screening for breast cancer [letter]. *The Lancet* 1990;335(8700):1290-1.
- Owen AW, Forrest AP, Anderson TJ, Samuel E, Young GB, Scott AM. Breast screening and surgical problems. *The British Journal of Surgery* 1977;64(10):725-8.
- Roberts MM, Alexander FE, Anderson TJ, Chetty U, Donnan PT, Forrest P et al. Edinburgh trial of screening for breast cancer: mortality at seven years. *The Lancet* 1990;335(8684):241-6.
- Roberts MM, Alexander FE, Anderson TJ, Forrest AP, Hepburn W, Huggins A et al. The Edinburgh randomised trial of screening for breast cancer: description of method. *British Journal of Cancer* 1984;50(1):1-6.
- Screening for breast cancer. Report from Edinburgh Breast Screening Clinic. *BMJ* 1978;2(6131):175-8.
- UK Trial of Early Detection of Breast Cancer Group. 16-year mortality from breast cancer in the UK Trial of Early Detection of Breast Cancer. *The Lancet* 1999;353(9168):1909-14.
- UK Trial of Early Detection of Breast Cancer Group. First results on mortality reduction in the UK Trial of Early Detection of Breast Cancer. *The Lancet* 1988;2(8608):411-6.
- Wald NJ, Murphy P, Major P, Parkes C, Townsend J, Frost C. UKCCCR multicentre randomised controlled trial of one and two view mammography in breast cancer screening. *BMJ* 1995;311(7014):1189-93.

Göteborg 1982 {published data only}

- Bjurstam N, Björnelid L, Warwick J, Sala E, Duffy SW, Nyström L. The Gothenburg Breast Screening Trial (which Cancer 2003;97(12):1387-96view) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
- Bjurstam NG, Björnelid LM, Duffy SW. Updated results of the Gothenburg Trial of Mammographic Screening. *Cancer* 2016;122:1832-5.
- * Nyström L, Andersson I, Bjurstam N, Frisell J, Nordenskjöld B, Rutqvist LE. Long-term effects of mammography screening: updated overview of the Swedish randomised trials. *The Lancet* 2002;359(9310):909-19.

Göteborg 1982a {published data only}

- Bjurstam N, Björnelid L, Duffy SW, Smith TC, Cahlin E, Eriksson O et al. The Gothenburg Breast Cancer Screening Trial: preliminary results on breast cancer mortality for women aged 39-49. *Journal of the National Cancer Institute. Monographs* 1997;22:53-5.
- Bjurstam N, Björnelid L, Duffy SW, Smith TC, Cahlin E, Eriksson O et al. The Gothenburg breast screening trial: first results on mortality, incidence, and mode of detection for women ages 39-49 years at randomization. *Cancer* 1997;80(11):2091-9.
- Bjurstam N, Björnelid L, Duffy SW, Prevost TC. Author Reply. *Cancer* 1998;83(1):188-90.
- Bjurstam N, Björnelid L, Duffy SW. The Gothenburg breast screening trial: results from 11 years followup. In: NIH Consensus Development Conference on Breast Cancer Screening for Women Ages 40-49. National Institutes of Health. 1997:63-4.
- Miller AB, Baines CJ, To T. The Gothenburg breast screening trial: first results on mortality, incidence, and mode of detection for women ages 39-49 years at randomization [letter]. *Cancer* 1998;83(1):186-90.

Göteborg 1982b {published data only}

- * Nyström L, Rutqvist LE, Wall S, Lindgren A, Lindqvist M, Ryden S et al. Breast cancer screening with mammography: overview of Swedish randomised trials. *The Lancet* 1993;341(8851):973-8.

Kopparberg 1977 {published data only}

- Bergkvist L, Tabar L, Bergstrom R, Adami HO. Epidemiologic determinants of the mammographic parenchymal pattern. A population-based study within a mammographic screening program. *American Journal of Epidemiology* 1987;126(6):1075-81.
- Tabar L, Chen HH, Duffy SW, Krusemo UB. Primary and adjuvant therapy, prognostic factors and survival in 1053 breast cancers diagnosed in a trial of mammography screening. *Japanese Journal of Clinical Oncology* 1999;29(12):608-16.
- Tabar L, Duffy SW, Krusemo UB. Detection method, tumour size and node metastases in breast cancers diagnosed during a trial of breast cancer screening. *European Journal of Cancer & Clinical Oncology* 1987;23(7):959-62.
- Tabar L, Gad A, Holmberg L, Ljungqvist U. Significant reduction in advanced breast cancer. Results of the first seven years of mammography screening in Kopparberg, Sweden. *Diagnostic Imaging in Clinical Medicine* 1985;54(3-4):158-64.
- Tabar L, Gad A. Screening for breast cancer: the Swedish trial. *Radiology* 1981;138(1):219-22.

Malmö 1976 {published data only}

- Andersson I, Andren L, Hildell J, Linell F, Ljungqvist U, Pettersson H. Breast cancer screening with mammography: a population-based, randomized trial with mammography as the only screening mode. *Radiology* 1979;132(2):273-6.
- Andersson I, Aspegren K, Janzon L, Landberg T, Lindholm K, Linell F et al. Mammographic screening and mortality from breast cancer: the Malmö mammographic screening trial. *BMJ* 1988;297(6654):943-8.
- Andersson I, Hellstrom L, Bjurstam N, Lundgren B, Fagerberg G, Tabar L. Bröstcancerscreening med mammografi i Sverige. *Läkartidningen* 1983;80(25):2559-62.
- Andersson I, Janzon L, Pettersson H. Radiographic patterns of the mammary parenchyma: variation with age at examination and age at first birth. *Radiology* 1981;138(1):59-62.
- Andersson I, Janzon L, Sigfusson BF. Mammographic breast cancer screening - a randomized trial in Malmö, Sweden. *Maturitas* 1985;7(1):21-9.
- Andersson I, Janzon L. Reduced breast cancer mortality in women under age 50: updated results from the Malmö Mammographic Screening Program. *Journal of the National Cancer Institute. Monographs* 1997;22:63-7.
- Andersson I, Janzon L. Screening with mammography - a critical attitude is supported by new findings. *Läkartidningen* 1988;85(44):3666-9.
- Andersson I, Nyström L. Mammography screening [letter]. *Journal of the National Cancer Institute. Monographs* 1995;87(16):1263-4.
- Andersson I, Sigfusson BF. Screening for breast cancer in Malmö: a randomized trial. *Recent Results in Cancer Research* 1987;105:62-6.
- Andersson I. Breast cancer screening in Malmö. *Recent Results in Cancer Research* 1984;90:114-6.
- Andersson I. Detection bias in mammographic screening for breast carcinoma. *Recent Results in Cancer Research* 1984;90:164-5.

Andersson I. Mammographic screening for breast carcinoma [thesis]. University of Lund, 1980.

Andersson I. Personal communication 10 Oct 2000.

medRxiv preprint doi: <https://doi.org/10.1101/2024.06.06.2001542>; this version posted June 6, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Andersson I. Personal communication 21 June 1999.

Andersson I. Radiographic screening for breast carcinoma. I. Program and primary findings in 45-69 year old women. Acta Radiologica: Diagnosis 1981;22(2):185-94.

Andersson I. Radiographic screening for breast carcinoma. II. Prognostic considerations on the basis of a short-term follow-up. Acta Radiologica: Diagnosis 1981;22(3A):227-33.

Andersson I. Radiographic screening for breast carcinoma. III. Appearance of carcinoma and number of projections to be used at screening. Acta Radiologica: Diagnosis 1981;22(4):407-20.

Andersson I. Överskattning av besparingar genom screening med mammografi [letter]. Läkartidningen 1996;93(32-33):2725.

Garne JP, Aspegren K, Balldin G, Ranstam J. Increasing incidence of and declining mortality from breast carcinoma. Trends in Malmö, Sweden, 1961-1992. Cancer 1997;79(1):69-74.

Gullberg B, Andersson I, Janzon L, Ranstam J. Screening mammography [letter]. The Lancet 1991;337(8735):244.

Ikedal DM, Andersson I, Wattsgård C, Janzon L, Linell F. Interval carcinomas in the Malmö Mammographic Screening Trial: radiographic appearance and prognostic considerations. AJR. American Journal of Roentgenology 1992;159(2):287-94.

Janzon L, Andersson I. The Malmö mammographic screening trial. In: Miller AB, Chamberlain J, Day NE et al, editors(s). Cancer Screening. Cambridge: Cambridge University Press, 1991:37-44.

Ringberg A, Andersson I, Aspegren K, Linell F. Breast carcinoma in situ in 167 women-incidence, mode of presentation, therapy and follow-up. European Journal of Surgical Oncology 1991;17(5):466-76.

Malmö II 1978 {published data only}

- * Andersson I, Janzon L. Reduced breast cancer mortality in women under age 50: updated results from the Malmö Mammographic Screening Program. Journal of the National Cancer Institute. Monographs 1997;22:63-7.

New York 1963 {published data only}

Aron JL, Prorok PC. An analysis of the mortality effect in a breast cancer screening study. Journal of the National Cancer Institute. Monographs 1986;15:36-43.

Chu KC, Connor RJ. Analysis of the temporal patterns of benefits in the Health Insurance Plan of Greater New York trial by stage and age. American Journal of Epidemiology 1991;133(10):1039-49.

Chu KC, Smart CR, Tarone RE. Analysis of breast cancer mortality and stage distribution by age for the Health Insurance Plan clinical trial. Journal of the National Cancer Institute 1988;80(14):1125-32.

Connor RJ, Prorok PC, Weed DL. The case-control design and the assessment of the efficacy of cancer screening. Journal of Clinical Epidemiology 1991;44(11):1215-21.

Final reports of National Cancer Institute ad hoc working groups on mammography screening for breast cancer and a summary report of their joint findings and recommendations. DHEW Publication No. (NIH) 77 1400. US Department of Health, Education and Welfare, 1977.

Fink R, Shapiro S, Lewison J. The reluctant participant in a breast cancer screening program. Public Health Reports 1968;83(6):479-90.

Fink R, Shapiro S, Roester R. Impact of efforts to increase participation in repetitive screenings for early breast cancer detection. American Journal of Public Health 1972;62(3):328-36.

Fink R, Shapiro S. Significance of increased efforts to gain participation in screening for breast cancer. American Journal of Preventive Medicine 1990;6(1):34-41.

Friedman DR, Dubin N. Case-control evaluation of breast cancer screening efficacy. American Journal of Epidemiology 1991;133(10):974-84.

Habbema JD, van Oortmarssen GJ, van Putten DJ, Lubbe JT, van der Maas PJ. Age-specific reduction in breast cancer mortality by screening: an analysis of the results of the Health Insurance Plan of Greater New York study. American Journal of Epidemiology 1986;77(2):317-20.

Habbema JD, van Oortmarssen GJ, van Putten DJ. An analysis of survival differences between clinically and screen-detected cancer patients. Statistics in Medicine 1983;2(2):279-85.

Shapiro S, Goldberg JD, Hutchison GB. Lead time in breast cancer detection and implications for periodicity of screening. American Journal of Epidemiology 1974;100(5):357-66.

Shapiro S, Strax P, Venet L, Fink R. The search for risk factors in breast cancer. American Journal of Public Health and the Nation's Health 1968;58(5):820-35.

Shapiro S, Strax P, Venet L, Venet W. Changes in 5-year breast cancer mortality in a breast cancer screening program. Proceedings. National Cancer Conference 1972;7:663-78.

Shapiro S, Strax P, Venet L. Evaluation of periodic breast cancer screening with mammography. Methodology and early observations. JAMA 1966;195(9):731-8.

Shapiro S, Strax P, Venet L. Evaluation of periodic breast cancer screening with mammography: methodology and early observations. 1966 [classical article]. CA: A Cancer Journal for Clinicians 1990;40(2):111-25.

Shapiro S, Strax P, Venet L. Periodic breast cancer screening in reducing mortality from breast cancer. JAMA 1971;215(11):1777-85.

- Shapiro S, Venet W, Strax P, Venet L, Roeser R. Prospects for eliminating racial differences in breast cancer survival rates. *American Journal of Public Health* 1982;72(10):1142-5.
- Shapiro S, Venet W, Strax P, Venet L, Roeser R. Selection, follow-up, and analysis in the Health Insurance Plan Study. a randomized trial with breast cancer screening. *Journal of the National Cancer Institute*. Monographs 1985;67:65-74.
- Shapiro S, Venet W, Strax P, Venet L, Roeser R. Ten- to fourteen-year effect of screening on breast cancer mortality. *Journal of the National Cancer Institute* 1982;69(2):349-55.
- Shapiro S, Venet W, Strax P, Venet L. Current results of the breast cancer screening randomized trial: The health insurance plan (HIP) of greater New York study. In: Day NE, Miller AB, editors(s). *Screening for breast cancer*. Toronto: Hans Huber, 1988:3-15.
- Shapiro S, Venet W, Strax P, Venet L. Periodic screening for breast cancer: The health insurance plan project and its sequelae, 1963-1986. Baltimore: Johns Hopkins University Press, 1988.
- Shapiro S. Determining the efficacy of breast cancer screening. *Cancer* 1989;63(10):1873-80.
- Shapiro S. Evaluation of two contrasting types of screening programs. *Preventive Medicine* 1973;2(2):266-77.
- Shapiro S. Evidence on screening for breast cancer from a randomized trial. *Cancer* 1977;39(6 Suppl):2772-82.
- Shapiro S. Periodic screening for breast cancer: the HIP Randomized Controlled Trial. *Health Insurance Plan. Journal of the National Cancer Institute. Monographs* 1997;22:27-30.
- Shapiro S. Screening: assessment of current studies. *Cancer* 1994;74 Suppl(1):231-8.
- Shapiro S. The status of breast cancer screening: a quarter of a century of research. *World Journal of Surgery* 1989;13(1):9-18.
- Smart CR. Highlights of the evidence of benefit for women aged 40-49 years from the 14-year follow-up of the Breast Cancer Detection Demonstration Project. *Cancer* 1994;74(1 Suppl):296-300.
- Strax P, Venet L, Shapiro S, Gross S, Venet W. Breast cancer found on repetitive examination in mass screening. *Archives of Environmental Health* 1970;20(6):758-63.
- Strax P, Venet L, Shapiro S, Gross S. Mammography and clinical examination in mass screening for cancer of the breast. *Cancer* 1967;20(12):2184-8.
- Strax P, Venet L, Shapiro S. Mass screening in mammary cancer. *Cancer* 1969;23(4):875-8.
- Strax P, Venet L, Shapiro S. Value of mammography in reduction of mortality from breast cancer in mass screening. *The American Journal of Roentgenology, Radium Therapy, and Nuclear Medicine* 1973;117(3):686-9.
- Strax P. Advances in detection of early breast cancer. *Cancer Detection and Prevention* 1983;6(4-5):409-14.
- Strax P. Benefit of breast cancer screening on morbidity and mortality. In: Bostrom H et al, editors(s). *Health control in detection of cancer*. Stockholm: Almqvist and Wiksell, 1976:133-45.
- Strax P. Mass screening for control of breast cancer. *Cancer* 1984;53(3 Suppl):665-70.
- Strax P. Physical methods in breast cancer diagnosis. *Israel Journal of Medical Sciences* 1981;17(9-10):847-53.
- Thomas LB, Ackerman LV, McDivitt RW, Hanson TAS, Hankey BF, Prorok PC. Report of NCI ad hoc pathology working group to review the gross and microscopic findings of breast cancer cases in the HIP study. *Journal of the National Cancer Institute* 1977;59(2):496-541.

Östergötland 1978 {published data only}

- Arnesson LG, Fagerberg G, Grontoft O, Lundstrom B. Surgical biopsy of non-palpable mammary lesions. Technique and results. *Acta Chirurgica Scandinavica* 1986;152:97-101.
- Arnesson LG, Smeds S, Fagerberg G, Grontoft O. Follow-up of two treatment modalities for ductal cancer in situ of the breast. *The British Journal of Surgery* 1989;76(7):672-5.
- Arnesson LG, Smeds S, Fagerberg G. Recurrence-free survival in patients with small breast cancer. An analysis of cancers 10 mm or less detected clinically and by screening. *The European Journal of Surgery* 1994;160(5):271-6.
- Arnesson LG, Smeds S, Hatschek T, Nordenskjöld B, Fagerberg G. Hormone receptors, ploidy and proliferation rate in breast cancers up to 10 mm. *European Journal of Surgical Oncology* 1992;18(3):235-40.
- Arnesson LG, Vitak B, Manson JC, Fagerberg G, Smeds S. Diagnostic outcome of repeated mammography screening. *World Journal of Surgery* 1995;19(3):372-7.
- Fagerberg G, Baldetorp L, Grontoft O, Lundstrom B, Manson JC, Nordenskjöld B. Effects of repeated mammographic screening on breast cancer stage distribution. Results from a randomised study of 92 934 women in a Swedish county. *Acta Chirurgica Scandinavica* 1985;24(6):465-73.
- Fagerberg G. Experience from randomized controlled breast screening with mammography in Östergötland county, Sweden: a preliminary report. *Recent Results in Cancer Research* 1984;90:117.
- Hatschek T, Carstensen J, Fagerberg G, Stal O, Grontoft O, Nordenskjöld B. Influence of S-phase fraction on metastatic pattern and post-recurrence survival in a randomized mammography screening trial. *Breast Cancer Research and Treatment* 1989;14(3):321-7.
- Hatschek T, Fagerberg G, Stal O, Sullivan S, Carstensen J, Grontoft O et al. Cytometric characterization and clinical course of breast cancer diagnosed in a population-based screening program. *Cancer* 1989;64(5):1074-81.
- Hatschek T, Grontoft O, Fagerberg G, Stal O, Sullivan S, Carstensen J et al. Cytometric and histopathologic features of tumors detected in a randomized mammography screening program: correlation and relative prognostic influence. *Breast Cancer Research and Treatment* 1990;15(3):149-60.

Lundström B, Fagerberg G. Clinical problems in relation to breast cancer screening with mammography. A preliminary report. Acta Chirurgica Scandinavica. Supplementum 1984;519:61-3.

medRxiv preprint doi: <https://doi.org/10.1101/2020.08.05.20166044>; this version posted August 10, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Stockholm 1981 {published data only}

- Frisell J, Eklund G, Hellstrom L, Glas U, Somell A. The Stockholm breast cancer screening trial - 5-year results and stage at discovery. Breast Cancer Research and Treatment 1989;13(1):79-87.
- Frisell J, Eklund G, Hellstrom L, Lidbrink E, Rutqvist LE, Somell A. Randomized study of mammography screening - preliminary report on mortality in the Stockholm trial. Breast Cancer Research and Treatment 1991;18(1):49-56.
- Frisell J, Eklund G, Hellstrom L, Somell A. Analysis of interval breast carcinomas in a randomized screening trial in Stockholm. Breast Cancer Research and Treatment 1987;9(3):219-25.
- Frisell J, Eklund G, Nilsson R, Hellstrom L, Somell A. Additional value of fine-needle aspiration biopsy in a mammographic screening trial. The British Journal of Surgery 1989;76(8):840-3.
- Frisell J, Glas U, Hellstrom L, Somell A. Randomized mammographic screening for breast cancer in Stockholm. Design, first round results and comparisons. Breast Cancer Research and Treatment 1986;8(1):45-54.
- Frisell J, Lidbrink E, Hellstrom L, Rutqvist LE. Followup after 11 years - update of mortality results in the Stockholm mammographic screening trial. Breast Cancer Research and Treatment 1997;45(3):263-70.
- Frisell J, Lidbrink E. The Stockholm Mammographic Screening Trial: Risks and benefits in age group 40-49 years. Journal of the National Cancer Institute. Monographs 1997;22:49-51.
- Frisell J, von Rosen A, Wiege M, Nilsson B, Goldman S. Interval cancer and survival in a randomized breast cancer screening trial in Stockholm. Breast Cancer Research and Treatment 1992;24(1):11-6.
- Frisell J. Mammographic screening for breast cancer [thesis]. Stockholm: Södersjukhuset, 1989. [ISBN: 91-7900-659-0]
- Frisell J. Personal communication 13 Nov 2000.
- Frisell J. Personal communication 16 Nov 2000.
- Lidbrink E, Elfving J, Frisell J, Jonsson E. Neglected aspects of false positive findings of mammography in breast cancer screening: analysis of false positive cases from the Stockholm trial. BMJ 1996;312(7026):273-6.
- Lidbrink E, Frisell J, Brandberg Y, Rosendahl I, Rutqvist LE. Nonattendance in the Stockholm mammography screening trial: relative mortality and reasons for nonattendance. Breast Cancer Research and Treatment 1995;35(3):267-75.
- von Rosen A, Frisell J, Glas U, Hellstrom L, Nilsson R, Skoog L et al. Non-palpable invasive breast carcinomas from the Stockholm screening project. Acta Oncologica (Stockholm, Sweden) 1989;28(1):23-7.
- von Rosen A, Frisell J, Nilsson R, Wiege M, Auer G. Histopathologic and cytochemical characteristics of interval breast carcinomas from the Stockholm Mammography Screening Project. Acta Oncologica (Stockholm, Sweden) 1992;31(4):399-402.

Two-County 1977 {published data only}

- Chen HH, Tabar L, Fagerberg G, Duffy SW. Effect of breast cancer screening after age 65. Journal of Medical Screening 1995;2(1):10-4.
- Day NE, Williams DR, Khaw KT. Breast cancer screening programmes: the development of a monitoring and evaluation system. British Journal of Cancer 1989;59(6):954-8.
- Day NE. Surrogate measures in the design of breast screening trials. In: Miller AB, Chamberlain J, Day NE et al, editors(s). Cancer Screening. Cambridge: Cambridge University Press, 1991:391-403.
- Duffy S, Tabar L, Krusemo UB, Day N. Randomization by cluster in the Swedish two-county trial: recent results from Kopparberg and implications for interpretation [abstract]. Nordic Cancer Union 1989, Symposium in Stockholm 17-19 Aug 1989.
- Duffy SW, Chen HH, Tabar L, Fagerberg G, Paci E. Sojourn time, sensitivity and positive predictive value of mammography screening for breast cancer in women aged 40-49. International Journal of Epidemiology 1996;25(6):1139-45.
- Duffy SW, Day NE, Tabar L, Chen HH, Smith TC. Markov models of breast tumor progression: some age-specific results. Journal of the National Cancer Institute. Monographs 1997;22:93-7.
- Duffy SW, South MC, Day NE. Cluster randomization in large public health trials: the importance of antecedent data. Statistics in Medicine 1992;11(3):307-16.
- Duffy SW, Tabar L, Fagerberg G, Gad A, Grontoft O, South MC et al. Breast screening, prognostic factors and survival - results from the Swedish two county study. British Journal of Cancer 1991;64(6):1133-8.
- Duffy SW, Tabar L, Vitak B, Yen MF, Warwick J, Smith RA et al. The Swedish Two-County Trial of mammographic screening: cluster randomisation and end point evaluation. Annals of Oncology 2003;14(8):1196-8.
- Duffy SW, Tabar L, Vitak B, et al. The Swedish Two-County Trial of mammographic screening: cluster randomisation and end point evaluation. Annals of Oncology 2003;14(8):1196-8.
- Duffy SW, Tabar L. Screening for breast cancer [letter]. The Lancet 1995;346(8978):852.
- Fagerberg CJG, Tabar L. The results of periodic one-view mammography screening in a randomized, controlled trial in Sweden. In: Day NE, Miller AB, editors(s). Screening for breast cancer. Toronto: Hans

Huber, 1988:33-8.

- medRxiv preprint doi: <https://doi.org/10.1101/2024.02.06.24017119>; this version posted February 6, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
- Holmberg L, Adami HO, Lundstrom T, Persson I, Tabar L. [Mass screening mammography results in an increased need for surgical wards]. *Läkartidningen* 1986;80(22):2047-9.
- Holmberg L, Adami HO, Persson I, Lundstrom T, Tabar L. Demands on surgical inpatient services after mass mammographic screening. *BMJ* 1986;293(6550):779-82.
- Holmberg LH, Tabar L, Adami HO, Bergstrom R. Survival in breast cancer diagnosed between mammographic screening examinations. *The Lancet* 1986;2(8497):27-30.
- Miller AB, Chamberlain J, Day NE et al. Summary of the discussion on breast cancer screening. In: Miller AB, Chamberlain J, Day NE et al, editors(s). *Cancer screening*. Cambridge: Cambridge University Press, 1991:78-80.
- Nixon R, Prevost TC, Duffy SW, Tabar L, Vitak B, Chen HH. Some random-effects models for the analysis of matched-cluster randomised trials: application to the Swedish two-county trial of breast-cancer screening. *Journal of Epidemiology and Biostatistics* 2000;5(6):349-58.
- Nixon RM, Pharoah P, Tabar L et al. Mammographic screening in women with a family history of breast cancer: some results from the Swedish two-county trial. *Revue D'épidémiologie et de Santé Publique* 2000;48(4):325-31.
- Projektgruppen för WE-studien i Kopparbergs och Östergötlands län samt socialstyrelsens bearbetningsgrupp för WE-projektet. Reply on mammography [Replik om mammografi]. *Läkartidningen* 1985;82:2674.
- Prorok PC. Personal communication 2 Feb 2000.
- Rapport över mammografiscreening i Kopparbergs och Östergötlands läns landsting (WE-projektet) - Resultat efter första screeningsomgången. Unknown. Stockholm: Socialstyrelsen, 1982.
- Socialstyrelsens beredningsgrupp för WE-projektet. Minskad mortalitet i bröstcancer genom hälskontroll med mammografi. *Nordisk Medicin* 1985;100:175-8.
- Tabar L, Akerlund E, Gad A. Five-year experience with single-view mammography randomized controlled screening in Sweden. *Recent Results in Cancer Research* 1984;90:105-13.
- Tabar L, Chen HH, Fagerberg G, Duffy SW, Smith TC. Recent results from the Swedish Two-County Trial: the effects of age, histologic type, and mode of detection on the efficacy of breast cancer screening. *Journal of the National Cancer Institute. Monographs* 1997;22:43-7.
- Tabar L, Duffy SW, Burhenne LW. New Swedish breast cancer detection results for women aged 40-49. *Cancer* 1993;72 Suppl(4):1437-48.
- Tabar L, Duffy SW, Chen HH. Quantitative interpretation of age-specific mortality reductions from the Swedish Breast Cancer-Screening Trials [letter]. *Journal of the National Cancer Institute* 1996;88(1):52-5.
- Tabar L, Duffy SW, Day NE. Screening with mammography [letter]. *International Journal of Technology Assessment in Health Care* 1990;6(3):498-500.
- Tabar L, Duffy SW, Yen MF, Warwick J, Vitak B, Chen HH et al. All-cause mortality among breast cancer patients in a screening trial: support for breast cancer mortality as an end point. *Journal of Medical Screening* 2002;9(4):159-62.
- Tabar L, Duffy SW, Yen MF, et al. All-cause mortality among breast cancer patients in a screening trial: support for breast cancer mortality as an end point. *Journal of Medical Screening* 2002;9(4):159-62.
- Tabar L, Duffy SW. Criticisms of Swedish mammography trials were wrong [letter]. *BMJ* 1999;319:1367.
- Tabar L, Fagerberg G, Day NE, Holmberg L. What is the optimum interval between mammographic screening examinations? An analysis based on the latest results of the Swedish two-county breast cancer screening trial. *British Journal of Cancer* 1987;55(5):547-51.
- Tabar L, Fagerberg CJ, Gad A, Baldetorp L, Holmberg LH, Grontoft O et al. Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare. *The Lancet* 1985;1(8433):829-32.
- Tabar L, Fagerberg CJG, Day NE. The results of periodic one-view mammographic screening in Sweden. Part 2: Evaluation of the results. In: Day NE, Miller AB, editors(s). *Screening for breast cancer*. Toronto: Hans Huber, 1988:39-44.
- Tabar L, Fagerberg CJG, South MC, Day NE, Duffy SW. The Swedish Two-county Trial of mammographic screening for breast cancer: recent results on mortality and tumour characteristics. In: Miller AB, Chamberlain J, Day NE et al, editors(s). *Cancer screening*. Cambridge University Press: Cambridge University Press, 1991:23-36.
- Tabar L, Fagerberg G, Chen HH, Duffy SW, Gad A. Screening for breast cancer in women aged under 50: mode of detection, incidence, fatality, and histology. *Journal of Medical Screening* 1995;2(2):94-8.
- Tabar L, Fagerberg G, Chen HH, Duffy SW, Gad A. Tumour development, histology and grade of breast cancers: prognosis and progression. *International Journal of Cancer* 1996;66(4):413-9.
- Tabar L, Fagerberg G, Chen HH, Duffy SW, Smart CR, Gad A et al. Efficacy of breast cancer screening by age. New results from the Swedish Two-County Trial. *Cancer* 1995;75(10):2507-17.
- Tabar L, Fagerberg G, Day NE, Duffy SW, Kitchin RM. Breast cancer treatment and natural history: new insights from results of screening. *The Lancet* 1992;339(8790):412-4.
- Tabar L, Fagerberg G, Day NE, Duffy SW. The Swedish two-county trial of mammographic screening for breast cancer: recent results on mortality and tumor characteristics. *Pathologie-Biologie* 1992;39(9):846.
- Tabar L, Fagerberg G, Duffy SW, Day NE, Gad A, Grontoft O. Update of the Swedish two-county program of mammographic screening for breast cancer. *Radiologic Clinics of North America* 1992;30(1):187-210.
- Tabar L, Fagerberg G, Duffy SW, Day NE. Mammografi minskar dödligheten i bröstcancer signifikant. *Läkartidningen* 1990;87(1-2):36-9.

- Tabar L, Fagerberg G, Duffy SW, Day NE. The Swedish two county trial of mammographic screening for breast cancer: recent results and calculation of benefit. *Journal of Epidemiology and Community Health* 1999;43(2):107-14. doi.org/10.1101/2024.06.06.24308542; this version posted June 6, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
- Tabar L, Gad A, Akerlund L, Fors B, Fagerberg G, Badeloni L. Screening for breast cancer in Sweden. A randomised controlled trial. In: Logan WW, Muntz EP, editors(s). *Reduced dose mammography*. New York: Masson, 1979:407-14.
- Tabar L, Smith RA, Vitak B, et al. Mammographic screening: a key factor in the control of breast cancer. *Cancer Journal* (Sudbury, Mass.) 2003;9(1):15-27.
- Tabar L, Vitak B, Chen HH et al. The Swedish Two-County Trial twenty years later. Updated mortality results and new insights from long-term follow-up. *Radiologic Clinics of North America* 2000;38(4):625-51.
- Tabar L, Vitak B, Chen HH, Prevost TC, Duffy SW. Update of the Swedish Two-County Trial of breast cancer screening: histologic grade-specific and age-specific results. *Swiss Surgery* 1999;5(5):199-204.
- Tabar L, Vitak B, Yen MF, Chen HH, Smith RA, Duffy SW. Number needed to screen: lives saved over 20 years of follow-up in mammographic screening. *Journal of Medical Screening* 2004;11(3):126-9.
- Tabar L. Mammografins förmåga finna högriskfallen är nyckelfrågan [letter]. *Läkartidningen* 1996;93(38):3221.
- Tabar L. Personal communication 17 Jan 2000.
- Tabar L. SBU:s aktuella statistik inaktuell [letter]. *Läkartidningen* 1995;92(48):4540-1.
- Warwick J, Tabar L, Vitak B, Duffy SW. Time-dependent effects on survival in breast carcinoma: results of 20 years of follow-up from the Swedish Two-County Study. *Cancer* 2004;100(7):1331-6.
- Yen AM, Duffy SW, Chen TH, Chen LS, Chiu SY, Fann JC. Long-term incidence of breast cancer by trial arm in one county of the Swedish Two-County Trial of mammographic screening. *Cancer* 2012;118:5728-42.

UK age trial 1991 {published data only}

- Duffy S, Vulkan D, Cuckle H, Parmar D, Sheikh S, Smith R, et al. Annual mammographic screening to reduce breast cancer mortality in women from age 40 years: long-term follow-up of the UK Age RCT. *Health Technology Assessment* 2020;24:1-24.
- Duffy SW, Vulkan D, Cuckle H, Parmar D, Sheikh S, Smith RA, et al. Effect of mammographic screening from age 40 years on breast cancer mortality (UK Age trial): final results of a randomised, controlled trial. *Lancet Oncology* 2020;9:1165-72.
- Johns LE, Moss SM. False-positive results in the randomized controlled trial of mammographic screening from age 40 ("Age" trial). *Cancer Epidemiology Biomarkers and Prevention* 2010;19:2758-64.
- Johns LE, Moss SM. Randomized controlled trial of mammographic screening from age 40 ('Age' trial): patterns of screening attendance. *J Med Screen* 2010; 17(1):37-43.. *Journal of Medical Screening* 2010;17:37-43.
- Moss S, Thomas I, Evans A, Thomas B, Johns L. Randomised controlled trial of mammographic screening in women from age 40: results of screening in the first 10 years. *British Journal of Cancer* 2005;92:949-54.
- Moss S, Waller M, Anderson TJ, Cuckle H. Randomised controlled trial of mammographic screening in women from age 40: predicted mortality based on surrogate outcome measures. *British Journal of Cancer* 2005;92:955-60.
- Moss S. A trial to study the effect on breast cancer mortality of annual mammographic screening in women starting at age 40. Trial Steering Group. *Journal of Medical Screening* 1999;6(3):144-8.
- Moss SM, Cuckle H, Evans A, Johns L, Waller M, Bobrow L, for the Trial Management Group. Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial. *The Lancet* 2006;368:2053-60.
- Moss SM, Wale C, Smith R, Evans A, Cuckle H, Duffy SW. Effect of mammographic screening from age 40 years on breast cancer mortality in the UK Age trial at 17 years' follow-up: a randomised controlled trial. *Lancet Oncology* 2015;16:1123-32.

References to studies excluded from this review

Berglund 2000 {published data only}

- * Berglund G, Nilsson P, Eriksson K F, Nilsson J A, Hedblad B, Kristenson H, et al. Long-term outcome of the Malmo preventive project: mortality and cardiovascular morbidity. *Journal of Internal Medicine* 2000;247:19-29.

Dales 1979 {published data only}

- Dales LG, Friedman GD, Collen MF. Evaluating periodic multiphasic health checkups: a controlled trial. *Journal of Chronic Diseases* 1979;32:385-404.

Singapore 1994 {published data only}

- Ng EH, Ng FC, Tan PH, Low SC, Chiang G, Tan KP et al. Results of intermediate measures from a population-based, randomized trial of mammographic screening prevalence and detection of breast carcinoma among Asian women: the Singapore Breast Screening Project. *Cancer* 1998;82(8):1521-8.

References to studies awaiting assessment

AgeX Trial {published data only}

medRxiv preprint doi: <https://doi.org/10.1101/2024.06.06.24308542>; this version posted June 6, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Murillo R, Díaz S, Perry F, Poveda C, Píñeros M, Sánchez C, et al. Increased breast cancer screening and downstaging in Colombian women: A randomized trial of opportunistic breast-screening. *International Journal of Cancer* 2016;3:705-13.

Additional references

Alexander 1989

Alexander F, Roberts MM, Lutz W, Hepburn W. Randomisation by cluster and the problem of social class bias. *Journal of Epidemiology and Community Health* 1989;43(1):29-36.

Alexander 1994

Alexander FE, Anderson TJ, Brown HK, Forrest AP, Hepburn W, Kirkpatrick AE et al. The Edinburgh randomised trial of breast cancer screening: results after 10 years of follow-up. *British Journal of Cancer* 1994;70(3):542-8.

Alexander 1999

Alexander FE, Anderson TJ, Brown HK, Forrest AP, Hepburn W, Kirkpatrick AE et al. 14 years of follow-up from the Edinburgh randomised trial of breast-cancer screening. *The Lancet* 1999;353(9168):1903-8.

Alexander 2000

Alexander F. Personal communication 3 Oct 2000.

Andersson 1980

Andersson I. Mammographic screening for breast carcinoma [thesis]. University of Lund, 1980.

Andersson 1981

Andersson I. Radiographic screening for breast carcinoma. I. Program and primary findings in 45-69 year old women. *Acta Radiologica: Diagnosis* 1981;22(2):185-94.

Andersson 1981a

Andersson I. Radiographic screening for breast carcinoma. II. Prognostic considerations on the basis of a short-term follow-up. *Acta Radiologica: Diagnosis* 1981;22(3A):227-33.

Andersson 1983

Andersson I, Hellstrom L, Bjurstam N, Lundgren B, Fagerberg G, Tabar L. Bröstcancerscreening med mammografi i Sverige. *Läkartidningen* 1983;80(25):2559-62.

Andersson 1988

Andersson I, Aspegren K, Janzon L, Landberg T, Lindholm K, Linell F et al. Mammographic screening and mortality from breast cancer: the Malmo mammographic screening trial. *BMJ* 1988;297(6654):943-8.

Andersson 1988a

Andersson I, Janzon L. Mammografi för screening - kritisk inställning stöds av nya fynd [Screening with mammography - a critical attitude is supported by new findings]. *Läkartidningen* 1988;85(44):3666-9.

Andersson 1997

Andersson I, Janzon L. Reduced breast cancer mortality in women under age 50: updated results from the Malmo Mammographic Screening Program. *Journal of the National Cancer Institute* 1997;22:63-7.

Andersson 1999a

Andersson I. Personal communication 15 June 1999.

Andersson 1999b

Andersson I. Personal communication 21 June 1999.

Andersson 2000

Andersson I. Personal communication 10 Oct 2000.

Andersson 2001

Andersson I. Personal communication 12 Feb 2001.
medRxiv preprint doi: <https://doi.org/10.1101/2024.06.06.24308542>; this version posted June 6, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](#).

Armstrong 2007

Armstrong K, Moye E, Williams S, Berlin JA, Reynolds EE. Screening mammography in women 40 to 49 years of age: a systematic review for the American College of Physicians. *Annals of Internal Medicine* 2007;146:516-26.

Arnesson 1995

Arnesson LG, Vitak B, Manson JC, Fagerberg G, Smeds S. Diagnostic outcome of repeated mammography screening. *World Journal of Surgery* 1995;19(3):372-7.

Arnold 2022

Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, Vignat J, Gralow JR, Cardoso F, Siesling S, Soerjomataram I. Current and future burden of breast cancer: Global statistics for 2020 and 2040. *Breast* 2022;66:15-23. [DOI: [10.1016/j.breast.2022.08.010](https://doi.org/10.1016/j.breast.2022.08.010).]

Aron 1986

Aron J, Prorok PC. An analysis of the mortality effect in a breast cancer screening study. *International Journal of Epidemiology* 1986;15:36-43.

Atterstam 1999

Atterstam I. Nil [Ohederliga arbetsmetoder undergräver mammografiresultat]. *Svenska Dagbladet* 1999, 21. july;sect 1:6.

Autier 2010

Autier P, Boniol M, LaVecchia C, Vatten L, Gavin A, Hery C et al. Disparities in breast cancer mortality trends between 30 European countries: retrospective trend analysis of WHO mortality database. *BMJ* 2010;341:c3620.

Autier 2011

Autier P, Boniol M, Middleton R, Doré JF, Héry C, Zheng T et al. Advanced breast cancer incidence following population based mammographic screening. *Annals of Oncology* 2011;22(8):1726-35.

Autier 2011a

Autier P, Boniol M, Gavin A, Vatten LJ. Breast cancer mortality in neighbouring European countries with different levels of screening but similar access to treatment: trend analysis of WHO mortality database. *BMJ* 2011;343:d4411.

Bailar 1997

Bailar JC 3rd, MacMahon B. Randomization in the Canadian National Breast Screening Study: a review for evidence of subversion. *Canadian Medical Association Journal* 1997;156(2):193-9.

Baines 1994

Baines CJ. The Canadian National Breast Screening Study: a perspective on criticisms. *Annals of Internal Medicine* 1994;120(4):326-34.

Baines 1995

Baines CJ. The Canadian National Breast Screening Study. Why? What next? And so what? *Cancer* 1995;76 Suppl(10):2107-12.

Baines 1997

Baines CJ, Miller AB. Mammography versus clinical examination of the breasts. *Journal of the National Cancer Institute. Monographs* 1997;22:125-9.

Baines 2001

Baines CJ. Personal communication 18 Jan 2001.

Baines 2005

Baines CJ. Personal communication 30 Nov 2005.

Baines 2016

Baines CJ, To T, Miller AB. Revised estimates of overdiagnosis from the Canadian National Breast Screening Study. *Preventive Medicine* 2016;90:66-71. (which Study, *Preventive Medicine* 2016;90:66-71, this version posted June 6, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Barratt 1997

Barratt AL, Cockburn J, Redman S, Paul C, Perkins J. Mammographic screening: results from the 1996 National Breast Health Survey. *The Medical Journal of Australia* 1997;167:521-4.

Barratt 1999

Barratt A, Cockburn J, Furnival C, McBride A, Mallon L. Perceived sensitivity of mammographic screening: women's views on test accuracy and financial compensation for missed cancers. *Journal of Epidemiology and Community Health* 1999;53:716-20.

Barratt 2005

Barratt A, Howard K, Irwig L, Salkeld G, Houssami N. Model of outcomes of screening mammography: information to support informed choices. *BMJ* 2005;330:936-8.

Barratt 2015

Barratt A. Overdiagnosis in mammography screening: a 45 year journey from shadowy idea to acknowledged reality. *BMJ* 2015;350:h867. [DOI: [doi:10.1136/bmj.h867](https://doi.org/10.1136/bmj.h867)]

Barton 2001

Barton MB, Moore S, Polk S, Shtatland E, Elmore JG, Fletcher SW. Increased patient concern after false-positive mammograms: clinician documentation and subsequent ambulatory visits. *Journal of General Internal Medicine* 2001;16:150-6.

BASO audit 2000

NHS cancer screening programmes. BASO Breast Audit 1999/2000. www.cancerscreening.nhs.uk/breastscreen/publications.html (accessed Dec 12, 2001).

Baum 2000

Baum M, Tobias JS. Investment in treatment would be more effective (letter). *BMJ* 2000;321:1528.

Benjamin 1996

Benjamin DJ. The efficacy of surgical treatment of breast cancer. *Medical Hypotheses* 1996;47(5):389-97.

Berry 1998

Berry DA. Benefits and risks of screening mammography for women in their forties: a statistical appraisal. *Journal of the National Cancer Institute* 1998;90:1431-9.

Berry 2002

Berry DA. The Utility of Mammography for Women 40 to 50 Years of Age (Con). In: DeVita VT, Hellman S, Rosenberg SAE, editors(s). *Progress in Oncology*. Sudbury: Jones and Bartlett, 2002:346-72.

Berry 2005

Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M et al. Effect of screening and adjuvant therapy on mortality from breast cancer. *New England Journal of Medicine* 2005;353:1784-92.

Bjurstam 1997

Bjurstam N, Bjorneld L, Duffy SW, Smith TC, Cahlin E, Eriksson O et al. The Gothenburg breast screening trial: first results on mortality, incidence, and mode of detection for women ages 39-49 years at randomization. *Cancer* 1997;80(11):2091-9.

Bjurstam 2000

Bjurstam N. Personal communication 10 Oct 2000.

Bjurstam 2003

Bjurstam N, Björneld L, Warwick J, Sala E, Duffy SW, Nyström L. The Gothenburg Breast Screening Trial. *Cancer* 2003;97:2387-96.

Bjurstam 2016

Bjurstam NG, Björneld LM, Duffy SW. Updated results of the Gothenburg Trial of Mammographic Screening (which Cancer 2016;112(12):2248-55) [BMJ. 2016;352:g1884]. medRxiv preprint doi: <https://doi.org/10.1101/2024.06.06.24388542>; this version posted June 8, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Blamey 2000

Blamey RW, Wilson ARM, Patnick J. ABC of breast diseases: screening for breast cancer. BMJ 2000;321:689-93.

Blamey 2007

Blamey RW, Ellis IO, Pinder SE, Lee AHS, Macmillan RD, Morgan DAL, et al. Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990-1999. European Journal of Cancer 2007;43:1548-55.

Bleyer 2011

Bleyer A. US breast cancer mortality is consistent with European data. BMJ 2011;343:d5630.

Bleyer 2012

Bleyer A, Welch HG. Effect of three decades of screening mammography on breast-cancer incidence. New England Journal of Medicine 2012;367:1998-2005.

Brett 2001

Brett J, Austoker J. Women who are recalled for further investigation for breast screening: psychological consequences 3 years after recall and factors affecting re-attendance. Journal of Public Health Medicine 2001;23(4):292-300.

Brodersen 2006

Brodersen J. Measuring psychosocial consequences of false-positive screening results - breast cancer as an example (PhD thesis). Institute of Public Health, Faculty of Health Sciences, Department of General Practice, University of Copenhagen. (http://cms.ku.dk/sund-sites/ifsv-sites/ifsv-inst/ominstitutet/afdelinger/almen_medicin/medarbejdere/publicationdetail/?id=1109837) 2006.

Brodersen 2007

Brodersen J, Thorsen H, Kreiner S. Validation of a condition-specific measure for women having an abnormal screening mammography. Value in Health 2007;10:294-304.

Brodersen 2013

Brodersen J, Siersma V. Long-term psychosocial consequences of false-positive screening mammography – a cohort study with 3-year follow-up. Annals of Family Medicine 2013;11(2):106-15.

Brown 1993

Brown BW, Brauner C, Minnotte MC. Noncancer deaths in white adult cancer patients. Journal of the National Cancer Institute 1993;85(12):979-87.

Burton 2011

Burton RC, Bell RJ, Thiagarajah G, Stevenson C. Adjuvant therapy, not mammographic screening, accounts for most of the observed breast cancer specific mortality reductions in Australian women since the national screening program began in 1991. Breast Cancer Research and Treatment 2012;131(3):949-55.

Bülow 2000

Bülow B von. Psykologiske følger af screening for brystkræft blandt raske kvinder. Ugeskrift for Laeger 2000;162:1053-9.

Castells 2006

Castells X, Molins E, Macia F. Cumulative false positive recall rate and association with participant related factors in a population based breast cancer screening programme. Journal of Epidemiology and Community Health 2006;60:316-21.

Chamberlain 1981

Chamberlain J, Atkinson AB, Cochrane AL. Trial of early detection of breast cancer: Description of method. British Journal of Cancer 1981;44:618-27.

Chlebowski 2009

Chlebowski RT, Kuller LH, Prentice RL, Stefanick ML, Manson JE, Gass M, et al. Breast cancer after use of
medRxiv preprint doi: <https://doi.org/10.1101/2024.06.06.24308542>; this version posted June 6, 2024. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license.

Christiansen 2000

Christiansen CL, Wang F, Barton MB, Kreuter W, Elmore JG, Gelfand AE, Fletcher SW. Predicting the cumulative risk of false-positive mammograms. *Journal of the National Cancer Institute* 2000;92:1657-66.

Cox 1997

Cox B. Variation in the effectiveness of breast screening by year of follow-up. *Journal of the National Cancer Institute. Monographs* 1997;22:69-72.

Crowdson 2002

Crowdson J. Swedes doubt mammography trial: disparities found in landmark study. *Chicago Tribune* 2002;March 15:<http://www.chicagotribune.com/news/chi-0203150264mar15.story> (accessed 15 March, 2002).

Dean 2010

Dean P, Tabár L. Why does vehement opposition to screening come from Denmark, which has one of Europe's highest breast cancer mortality rates? *BMJ* 2010;http://www.bmj.com/content/340/bmj.c1241.full/reply#bmj_el_234798.

Deeks 2003

Deeks JJ, Dinnes J, D'Amico R, Sowden AJ, Sakarovich C, Song F, Petticrew M, Altman DG, International Stroke Trial Collaborative Group, European Carotid Surgery Trial Collaborative Group. Evaluating non-randomised intervention studies. *Health Technology Assessment (Winchester, England)* 2003;7(27):1-173.

Demissie 1998

Demissie K, Mills OF, Rhoads GG. Empirical comparison of the results of randomized controlled trials and case-control studies in evaluating the effectiveness of screening mammography. *Journal of Clinical Epidemiology* 1998;52:81-91.

Dixon 2009

Dixon JM. Breast screening has increased the number of mastectomies. *Breast Cancer Research* 2009;11(Suppl 3):S19.

Dixon-Woods 2001

Dixon-Woods M, Baum M, Kurinczuk JJ. Screening for breast cancer with mammography. *The Lancet* 2001;358:2167-8.

Doll 1981

Doll R, Peto R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. *Journal of the National Cancer Institute* 1981;66:1191-308.

Domenighetti 2003

Domenighetti G, D'Avanzo B, Egger M, Berrino F, Perneger T, Mosconi P et al. Women's perception of the benefits of mammography screening: population-based survey in four countries. *International Journal of Epidemiology* 2003;32:816-21.

Douek 2003

Douek M, Baum M. Mass breast screening: is there a hidden cost? *The British Journal of Surgery* 2003;90 Suppl 1:(Abstract Breast 14).

Draft USPSTF recommendation 2023

US Preventive Services Task Force. https://www.uspreventiveservicestaskforce.org/files/breast-cancer/Breast_Cancer_DRS_News_Bulletin.pdf.

Duffy 2002

Duffy SW, Tabár L, Smith RA. The mammographic screening trials: commentary on the recent work by Olsen and Gøtzsche (authors' reply). *Journal of Surgical Oncology* 2002;81:164-6.

Duffy 2003

Duffy SW, Tabar L, Vitak B, Yen MF, Warwick J, Smith RA et al. The Swedish Two-County Trial of mammographic screening: a randomised and controlled evaluation. *Lancet Oncology* 2003;14(8):1196-8. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

Duffy 2020a

Duffy SW, Vulkan D, Cuckle H, Parmar D, Sheikh S, Smith RA, et al. Effect of mammographic screening from age 40 years on breast cancer mortality (UK Age trial): final results of a randomised, controlled trial. *Lancet Oncology* 2020;9:1165-72.

EBCTCG 1995

Early Breast Cancer Trialists' Collaborative Group. Effects of radiotherapy and surgery in early breast cancer: An overview of the randomized trials. *The New England Journal of Medicine* 1995;333:1444-55.

EBCTCG 2000

Early Breast Cancer Trialists' Collaborative Group. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: An overview of the randomised trials. *The Lancet* 2000;355:1757-70.

EBCTCG 2005

Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. *Lancet* 2005;365:1687-717.

EBCTCG 2005a

Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. *Lancet* 2005;366:2087-106.

EBCTCG 2012

Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. *Lancet* 2012;379:432-44.

Elmore 1998

Elmore JG, Barton MB, Moceri VM, Polk S, Arena PJ, Fletcher SW. Ten-year risk of false positive screening mammograms and clinical breast examinations. *The New England Journal of Medicine* 1998;338(16):1089-96.

Elwood 1993

Elwood JM, Cox B, Richardson AK. The effectiveness of breast cancer screening by mammography in younger women. *The Online Journal of Current Clinical Trials* [electronic resource] 1993;Doc No 32.

Elwood 1998

Elwood M, McNoe B, Smith T, Bandaranayake M. Once is enough - why some women do not continue to participate in a breast screening programme. *The New Zealand Medical Journal* 1998;111:180-3.

Ernster 1996

Ernster VL, Barclay J, Kerlikowske K, Grady D, Henderson C. Incidence of and treatment for ductal carcinoma in situ of the breast. *JAMA* 1996;275(12):913-8.

Ernster 1997

Ernster VL, Barclay J. Increases in ductal carcinoma in situ (DCIS) of the breast in relation to mammography: a dilemma. *Journal of the National Cancer Institute. Monographs* 1997;NA(22):151-6.

Esserman 2009

Esserman L, Shieh Y, Thompson I. Rethinking Screening for Breast Cancer and Prostate Cancer. *JAMA* 2009;302:1685-92.

European Commission Initiative 2020

Schünemann HJ, Lerda D, Quinn C, Follmann M, Alonso-Coello P, Rossi PG, Lebeau A, Nyström L, Broeders M, Ioannidou-Mouzaka L, Duffy SW, Borisch B, Fitzpatrick P, Hofvind S, Castells X, Giordano L, Canelo-Aybar C, Altman DG, Mansel R, Sardanelli F, Pammelli E, Grøwingholt A, Szabo P, Kinsor Z, European Commission Initiative on Breast Cancer (ECIBC) Contributor Group. Breast Cancer Screening and Diagnosis: A Synopsis of the European Breast Guidelines. *Annals of Internal Medicine* 2020;172:46-56. [PMID: [31766052](#)]

Fagerberg 1985

Fagerberg G, Baldetorp L, Grøntoft O, Lundström B, Manson JC, Nordenskjöld B. Effects of repeated mammographic screening on breast cancer stage distribution. Results from a randomised study of 92 934 women in a Swedish county. *Acta Radiologica. Oncology* 1985;24(6):465-73.

Fang 2012

Fang F, Fall K, Mittleman MA, Sparén P, Ye W, Adami HO, Vadimarsdóttir U. Suicide and cardiovascular death after a cancer diagnosis. *New England Journal of Medicine* 2012;366:1310-18. [DOI: DOI: 10.1056/NEJMoa1110307]

Final reports 1977

Final reports of National Cancer Institute ad hoc working groups on mammography screening for breast cancer and a summary report of their joint findings and recommendations. DHEW Publication No. (NIH) 77 1400. US Department of Health, Education and Welfare, 1977.

Fink 1972

Fink R, Shapiro S, Roester R. Impact of efforts to increase participation in repetitive screenings for early breast cancer detection. *American Journal of Public Health* 1972;62(3):328-36.

Fletcher 1993

Fletcher SW, Black W, Harris R, Rimer BK, Shapiro S. Report of the International Workshop on Screening for Breast Cancer. *Journal of the National Cancer Institute* 1993;85(20):1644-56.

Fletcher 2003

Fletcher SW, Elmore JG. Clinical practice. Mammographic screening for breast cancer. *The New England Journal of Medicine* 2003;348:1672-80.

Forrest report 1986

Forrest P, editor. Breast Cancer Screening. Report to the Health Ministers of England, Wales, Scotland & Northern Ireland. Department of Health and Social Science 1986.

Fox 1979

Fox MS. On the diagnosis and treatment of breast cancer. *JAMA* 1979;241(5):489-94.

Freedman 2004

Freedman DA, Petitti DB, Robins JM. On the efficacy of screening for breast cancer. *International Journal of Epidemiology* 2004;33:43-55.

Frisell 1986

Frisell J, Glas U, Hellström L, Somell A. Randomized mammographic screening for breast cancer in Stockholm. Design, first round results and comparisons. *Breast Cancer Research and Treatment* 1986;8(1):45-54.

Frisell 1989

Frisell J, Eklund G, Hellström L, Glas U, Somell A. The Stockholm breast cancer screening trial - 5-year results and stage at discovery. *Breast Cancer Research and Treatment* 1989;13(1):79-87.

Frisell 1989a

Frisell J. Mammographic screening for breast cancer [thesis]. Stockholm: Södersjukhuset, 1989. [ISBN: 91-7900-659-0]

Frisell 1991

Frisell J, Eklund G, Hellström L, Lidbrink E, Rutqvist LE, Somell A. Randomized study of mammography screening - preliminary report on mortality in the Stockholm trial. *Breast Cancer Research and Treatment*

Frisell 1997 Preprint doi: <https://doi.org/10.1101/2024.06.06.24308542>; this version posted June 6, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Frisell J, Lidbrink E, Hellström L, Rutqvist L. Follow-up after 11 years' update of mortality results in the Stockholm mammographic screening trial. *Breast Cancer Research and Treatment* 1997;45(3):263-70.

Frisell 2000a

Frisell J. Personal communication 13 Nov 2000.

Frisell 2000b

Frisell J. Personal communication 16 Nov 2000.

Fryback 2006

Fryback DG, Stout NK, Rosenberg MA, Trentham-Dietz A, Kuruchittham V, Remington PL. The Wisconsin Breast Cancer Epidemiology Simulation Model. *Journal of the National Cancer Institute Monographs* 2006;36:37-47.

Glasziou 1992

Glasziou PP. Meta-analysis adjusting for compliance: the example of screening for breast cancer. *Journal of Clinical Epidemiology* 1992;45(11):1251-6.

Glasziou 1995

Glasziou PP, Woodward AJ, Mahon CM. Mammographic screening trials for women aged under 50. A quality assessment and meta-analysis. *The Medical Journal of Australia* 1995;162(12):625-9.

Glasziou 1997

Glasziou P, Irwig L. The quality and interpretation of mammographic screening trials for women ages 40-49. *Journal of the National Cancer Institute. Monographs* 1997;22:73-7.

Glechner 2023

Glechner A, Wagner G, Mitus JW, Teufer B, Klerings I, Böck N, Grillich L, Berzaczy D, Helbich TH, Gartlehner G. Mammography in combination with breast ultrasonography versus mammography for breast cancer screening in women at average risk. *Cochrane Database of Systematic Reviews* 2023;(3). [ART. NO.: : CD009632] [DOI: DOI: 10.1002/14651858.CD009632.pub3]

Gram 1990

Gram IT, Lund E, Slenker SE. Quality of life following a false positive mammogram. *British Journal of Cancer* 1990;62(6):1018-22.

Gärtner 2009

Gärtner R, Jensen MB, Nielsen J, Ewertz M, Kroman N, Kehlet H. Prevalence of and factors associated with persistent pain following breast cancer surgery. *JAMA* 2009;302:1985-92.

Gøtzsche 2000

Gøtzsche PC, Olsen O. Is screening for breast cancer with mammography justifiable? *The Lancet* 2000;355(9198):129-34.

Gøtzsche 2000a

Gøtzsche PC, Olsen O. Screening mammography re-evaluated [reply]. *The Lancet* 2000;355:752.

Gøtzsche 2001

Gøtzsche PC. Screening for breast cancer with mammography. *The Lancet* 2001;358:2167-8.

Gøtzsche 2002

Gøtzsche PC. Trends in breast-conserving surgery in the Southeast Netherlands: Comment on article by Ernst and colleagues *European Journal of Cancer* 2001, 37, 2435-2440. *European Journal of Cancer* 2002;38:1288.

Gøtzsche 2002a

Gøtzsche PC. Update on effects of screening mammography. *Lancet* 2002;360:338.

Gøtzsche 2002b

Gøtzsche PC. Misleading paper on mastectomy rates in a screening programme. BMJ (which has been corrected) 2002;325:736-41. doi:10.1136/bmj.325.7364.11.2002.060225.25 Aug 2002. It is made available under a [CC-BY-NC-ND 4.0 International license](#).

Gøtzsche 2004

Gøtzsche PC. On the benefits and harms of screening for breast cancer. International Journal of Epidemiology 2004;33:56-64.

Gøtzsche 2009

Gøtzsche P, Hartling OJ, Nielsen M, Brodersen J, Jørgensen KJ. Breast screening: the facts - or maybe not. BMJ 2009;338:446-8.

Gøtzsche 2010

Gøtzsche PC, Jørgensen KJ, Zahl PH. Breast screening: why estimates differ by a factor of 20-25. Journal of Medical Screening 2010;17:158-9.

Gøtzsche 2011

Gøtzsche PC. Relation between breast cancer mortality and screening effectiveness: systematic review of the mammography trials. Danish Medical Bulletin 2011;58:A4246.

Gøtzsche 2012

Gøtzsche PC. Mammography screening: truth, lies and controversy. London: Radcliffe, 2012.

Gøtzsche 2012a

Gøtzsche PC, Jørgensen KJ, Zahl P-H, Mæhlen J. Why mammography screening hasn't lived up to expectations from the randomised trials. Cancer Causes & Control 2012;23:15-21.

Gøtzsche 2015

Gøtzsche PC. Mammography screening is harmful and should be abandoned. Journal of the Royal Society of Medicine 2015;108:341-5.

Habbema 1986

Habbema JD, van Oortmarssen GJ, van Putten DJ, Lubbe JT, van der Maas PJ. Age-specific reduction in breast cancer mortality by screening: an analysis of the results of the Health Insurance Plan of Greater New York study. Journal of the National Cancer Institute 1986;77(2):317-20.

Harris 2024

Harris R. The New Proposed U.S. Preventive Services Task Force Recommendation on Breast Cancer Screening for Women in Their 40s: Should the Message Change? Annals of Internal Medicine 2024. [DOI: [10.7326/M23-2908](#)]

Hendrick 1997

Hendrick RE, Smith RA, Rutledge JH 3rd, Smart CR. Benefit of screening mammography in women aged 40-49: a new meta-analysis of randomized controlled trials. Journal of the National Cancer Institute. Monographs 1997;22:87-92.

Higgins 2008

Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. In: Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. Available from [www.cochrane-handbook.org](#). The Cochrane Collaboration, 2008.

Hofvind 2004

Hofvind S, Thoresen S, Tretli S. The cumulative risk of a false-positive recall in the Norwegian Breast Cancer Screening Program. Cancer 2004;101:1501-7.

Holmberg 2009

Holmberg L, Duffy SW, Yen AM, Tabar L, Vitak B, Nyström L et al. Differences in endpoints between the Swedish W-E (two county) trial of mammographic screening and the Swedish overview: methodological consequences. Journal of Medical Screening 2009;16:73-80.

Hubbard 2011

Hubbard RA, Kerlikowske K, Flowers CJ, Yankaskas BC, Zhu W, Miglioretti DL. Cumulative probability of false-positive mammography results after 10 years of screening mammography: a cohort study. *Annals of Internal Medicine* 2011;155:481-92. It is made available under a CC-BY-NC-ND 4.0 International license.

Humphrey 2002

Humphrey LL, Helfand M, Chan BK, Woolf SH. Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force. *Annals of Internal Medicine* 2002;137(5 Part 1):347-60.

IARC 2002

Vainio H, Bianchini F, eds. IARC Handbooks of Cancer Prevention. Volume 7. Breast Cancer Screening. Lyon: IARC Press, 2002. [ISBN 92-832-3007-8]

Isacsson 1985

Isacsson S-O, Larsson L-G, Janzon L. Är dokumentationen verkligen tillräcklig? Forcera inte fram screening utan debatt. *Läkartidningen* 1985;82(32-33):2672-3.

Janzon 1991

Janzon L, Andersson I. The Malmö mammographic screening trial. In: Miller AB, Chamberlain J, Day NE et al, editors(s). *Cancer Screening*. Cambridge: Cambridge University Press, 1991:37-44.

Jodal 2019

Jodal HC, Helsing LM, Anderson JC, Lytvyn L, Vandvik PO, Emilsson L. Colorectal cancer screening with faecal testing, sigmoidoscopy or colonoscopy: a systematic review and network meta-analysis. *BMJ Open* 2019;9:e032773. [DOI: doi: 10.1136/bmjopen-2019-032773]

Johns 2010

Johns LE, Moss SM. False-positive results in the randomized controlled trial of mammographic screening from age 40 ("Age" trial). *Cancer Epidemiology Biomarkers and Prevention* 2010;19:2758-64.

Jonsson 2005

Jonsson H, Johansson R, Lenner P. Increased incidence of invasive breast cancer after the introduction of service screening with mammography in Sweden. *International Journal of Cancer* 2005;117(5):842-7.

Jørgensen 2004

Jørgensen KJ, Gøtzsche PC. Presentation on websites of possible benefits and harms from screening for breast cancer: cross sectional study. *BMJ* 2004;328:148-51.

Jørgensen 2006

Jørgensen KJ, Gøtzsche PC. Content of invitations for publicly funded screening mammography. *BMJ* 2006;332:538-41.

Jørgensen 2009

Jørgensen KJ, Gøtzsche PC. Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends. *BMJ* 2009;339:b2587.

Jørgensen 2009a

Jørgensen KJ, Zahl P-H, Gøtzsche PC. Overdiagnosis in organised mammography screening in Denmark: a comparative study. *BMC Women's Health* 2009;9:36.

Jørgensen 2010

Jørgensen KJ, Zahl PH, Gøtzsche PC. Breast cancer mortality in organised mammography screening in Denmark. A comparative study. *BMJ* 2010;340:c1241.

Jørgensen 2011

Jørgensen KJ, Keen JD, Gøtzsche PC. Is mammographic screening justifiable considering its substantial overdiagnosis rate and minor effect on mortality? *Radiology* 2011;260:621-7.

Jørgensen 2012

Jørgensen KJ. Overdiagnosis of invasive breast cancer due to mammography screening. *Annals of Internal Medicine* 2012;157:219-20.

medRxiv preprint doi: <https://doi.org/10.1101/2024.06.06.24308542>; this version posted June 6, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](#).

Kalager 2010

Kalager M, Zelen M, Langmark F, Adami HO. Effect of Screening Mammography on Breast-Cancer Mortality in Norway. *New England Journal of Medicine* 2010;363:1203-10.

Kalager 2012

Kalager M, Adami HO, Bretthauer M, Tamimi RM. Overdiagnosis of invasive breast cancer due to mammography screening: results from the Norwegian screening program. *Annals of Internal Medicine* 2012;156:491-9.

Kerlikowske 1995

Kerlikowske K, Grady D, Rubin SM, Sandrock C, Ernster VL. Efficacy of screening mammography. A meta-analysis. *JAMA* 1995;273(2):149-54.

Kerlikowske 1997

Kerlikowske K. Efficacy of screening mammography among women aged 40 to 49 years and 50 to 69 years: comparison of relative and absolute benefit. *Journal of the National Cancer Institute. Monographs* 1997;22:79-86.

Kricker 2000

Kricker A, Smoothy V, Armstrong B. Ductal carcinoma in situ in NSW women in 1995 to 1997. National Breast & Ovarian Cancer Centre, 15 April 2000.

Kösters 2003

Kösters JP, Gøtzsche PC. Regular self-examination or clinical examination for early detection of breast cancer. *Cochrane Database of Systematic Reviews* 2003, Issue 2. Art. No: CD003373. [DOI: [10.1002/14651858.CD003373](https://doi.org/10.1002/14651858.CD003373)]

Larsson 1996

Larsson LG, Nystrom L, Wall S, Rutqvist L, Andersson I, Bjurstam N et al. The Swedish randomised mammography screening trials: analysis of their effect on the breast cancer related excess mortality. *Journal of Medical Screening* 1996;3(3):129-32.

Larsson 1997

Larsson LG, Andersson I, Bjurstam N, Fagerberg G, Frisell J, Tabar L et al. Updated overview of the Swedish Randomized Trials on Breast Cancer Screening with Mammography: age group 40-49 at randomization. *Journal of the National Cancer Institute. Monographs* 1997;22:57-61.

Lerman 1991

Lerman C, Trock B, Rimer BK, Boyce A, Jepson C, Engstrom PF. Psychological and behavioral implications of abnormal mammograms. *Annals of Internal Medicine* 1991;114(8):657-61.

Lidbrink 1996

Lidbrink E, Elfving J, Frisell J, Jonsson E. Neglected aspects of false positive findings of mammography in breast cancer screening: analysis of false positive cases from the Stockholm trial. *BMJ* 1996;312(7026):273-6.

Malin 2002

Malin JL, Kahn KL, Adams J, Kwan L, Laouri M, Ganz PA. Validity of cancer registry data for measuring the quality of breast cancer care. *Journal of the National Cancer Institute* 2002;94(11):835-44.

Marshall 2018

Marshall IJ, Noel-Storr A, Kuiper J, Thomas J, Wallace BC. Machine learning for identifying Randomized Controlled Trials: An evaluation and practitioner's guide. *Research Synthesis Methods* 2018;9(4):602-14.

McNoe 1996

McNoe B, Miller D, Elwood M. Women's experience of the Otago-Southland breast screening programme - a compilation of five studies. *Hugh Adam Cancer Epidemiology Unit for the Ministry of Health, New Zealand* 1996.

Menon 2021

Menon JJ, Gentry-Maharaj A, Burnell M, Singh N, Ryan A, Karpinskyj G, Carino G, Taylor J, Massingham SK, Reason M, Kaled JJ, Aboelenen M, Manchanda R, Arora H, Casey L, Durrani A, Gohh S, Gosselin M, Haidich A, Haidich T, Seif MW, Sharma A, Williamson R, Liu Y, Pallowfield L, McGuire AU, Campbell S, Skates SJ, Jacobs IJ, Parmar M. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. *Lancet* 2021;397:2182-93. [DOI: doi: 10.1016/S0140-6736(21)00731-5]

Miller 1992a

Miller AB, Baines CJ, To T, Wall C. Canadian National Breast Screening Study: 1. Breast cancer detection and death rates among women aged 40 to 49 years. *Canadian Medical Association Journal* 1992;147(10):1459-76.

Miller 1992b

Miller AB, Baines CJ, To T, Wall C. Canadian National Breast Screening Study: 2. Breast cancer detection and death rates among women aged 50 to 59 years. *Canadian Medical Association Journal* 1992;147(10):1477-88.

Miller 1993

Miller AB. The costs and benefits of breast cancer screening. *American Journal of Preventive Medicine* 1993;9(3):175-80.

Miller 1997

Miller AB, To T, Baines CJ, Wall C. The Canadian National Breast Screening Study: update on breast cancer mortality. *Journal of the National Cancer Institute. Monographs* 1997;NA(22):37-41.

Miller 1997a

Miller AB. The Canadian National Breast Screening Study: update on breast cancer mortality. In: NIH Consensus Development Conference on Breast cancer screening for women ages 40-49. 1997:51-3.

Miller 2000

Miller AB, To T, Baines CJ, Wall C. Canadian National Breast Screening Study-2: 13-year results of a randomized trial in women aged 50-59 years. *Journal of the National Cancer Institute* 2000;92:1490-9.

Miller 2001

Miller AB. Screening for breast cancer with mammography. *The Lancet* 2001;358:2164.

Miller 2002

Miller AB, To T, Baines CJ, Wall C. The Canadian National Breast Screening Study-1: breast cancer mortality after 11 to 16 years of follow-up. A randomized screening trial of mammography in women age 40 to 49 years. *Annals of Internal Medicine* 2002;137(5 Part 1):305-12.

Miller 2002a

Miller D, Martin I, Herbison P. Interventions for relieving the pain and discomfort of screening mammography. *Cochrane Database of Systematic Reviews* 2002, Issue 4. Art. No: CD002942. [DOI: 10.1002/14651858.CD002942]

Miller 2014

Miller AB, Wall C, Baines CJ, Sun P, To T, Narod SA. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. *BMJ* 2014;348:g366.

Moody-Ayers 2000

Moody-Ayers SY, Wells CK, Feinstein AR. "Benign" tumors and "early detection" in mammography-screened patients of a natural cohort with breast cancer. *Archives of Internal Medicine* 2000;160:1109-15.

Morrell 2010

Morrell S, Barratt A, Irwig L, Howard K, Biesheuvel C, Armstrong B. Estimates of overdiagnosis of invasive breast cancer associated with screening mammography. *Cancer Causes and Control* 2010;21:275-82.

Moss 2005

Moss S, Thomas I, Evans A, Thomas B, Johns L. Randomised controlled trial of mammographic screening in women from age 40: results of screening in the first 10 years. *British Journal of Cancer* 2005;92:949-54.
medRxiv preprint doi: <https://doi.org/10.1101/2024.06.06.24308542>; this version posted June 6, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](#).

Moss 2006

Moss SM, Cuckle H, Evans A, Johns L, Waller M, Bobrow L, for the Trial Management Group. Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial. *The Lancet* 2006;368:2053-60.

Moss 2015

Moss SM, Wale C, Smith R, Evans A, Cuckle H, Duffy SW. Effect of mammographic screening from age 40 years on breast cancer mortality in the UK Age trial at 17 years' follow-up: a randomised controlled trial. *Lancet Oncology* 2015;16:1123-32.

Narod 1997

Narod SA. On being the right size: A reappraisal of mammography trials in Canada and Sweden. *The Lancet* 1997;349:1849.

Narod 2011

Narod SA. Age of diagnosis, tumor size, and survival after breast cancer: implications for mammographic screening. *Breast Cancer Research and Treatment* 2011;128(1):259-66.

Nattinger 2000

Nattinger AB, Hoffmann RG, Kneusel RT, Schapira MM. Relation between appropriateness of primary therapy for early-stage breast carcinoma and increased use of breast-conserving surgery. *The Lancet* 2000;356(9236):1148-53.

NBCC 2002

National Breast Cancer Coalition. Positions, Facts and Analyses.
<http://www.stopbreastcancer.org/bin/index.htm> (accessed 7 July 2002).

Nelson 2009

Nelson H, Tyne K, Naik A, Bougatsos C, Chan BK, Humphrey L. Screening for breast cancer: an update for the U.S. Preventive Services Task Force. ;151:727-37. [DOI: <https://doi.org/10.7326/0003-4819-151-10-200911170-0000>]

Nelson 2016

Nelson HD, Cantor A, Humphrey L, Fu R, Pappas M, Daeges M, Griffin J S 2016 Jan Report No: 14-05201-EF-1 PMID: 26889531. Screening for Breast Cancer: A Systematic Review to Update the 2009 U.S. Preventive Services Task Force Recommendation.. Rockville (MD): Agency for Healthcare Research and Quality (US) 2016;Report No.: 14-05201-EF-1. [PMID: [26889531](#)]

New Reference 1

Newschaffer 2000

Newschaffer CJ, Otani K, McDonald MK, Penberthy LT. Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort. *Journal of the National Cancer Institute* 2000;92(8):613-21.

NHS leaflet 2001

Breast screening: an informed choice. www.cancerscreening.nhs.uk/breastscreen/publications/ia-02.html (accessed 2 Oct, 2002).

NHS leaflet 2010

NHS Breast Screening Programme leaflet. Department of Health
2010:<http://www.cancerscreening.nhs.uk/breastscreen/publications/ia-02.html>.

Nielsen 1987

Nielsen M, Thomsen JL, Primdahl S, Dyreborg U, Andersen JA. Breast cancer and atypia among young and middle-aged women: a study of 110 medicolegal autopsies. *British Journal of Cancer* 1987;56(6):814-9.

Nixon 2000

Nixon R, Prevost TC, Duffy SW, Tabar L, Vitak B, Chen HH. Some random-effects models for the analysis of matched clustered longitudinal data with application to the Swedish randomised trials of breast cancer screening. *Journal of Epidemiology and Biostatistics* 2000;5(6):349-58. <https://doi.org/10.1191/2024.06.06.24300342>; this version posted June 6, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Njor 2007

Njor SH, Olsen AH, Schwartz W, Vejborg I, Lynge E. Predicting the risk of a false-positive test for women following a mammography screening programme. *Journal of Medical Screening* 2007;14:94-7.

Noel-Storr 2020

Noel-Storr AH, Dooley G, Wisniewski S, Glanville J, Thomas J, Cox S, et al. Cochrane Centralised Search Service showed high sensitivity identifying randomised controlled trials: A retrospective analysis. *Journal of Clinical Epidemiology* 2020;127:142-50.

Noel-Storr 2021

Noel-Storr A, Dooley G, Elliott J, Steele E, Shemilt I, Mavergames C, et al. An evaluation of Cochrane Crowd found that crowdsourcing produced accurate results in identifying randomized trials. *Journal of Clinical Epidemiology* 2021;133:130-9.

Nyström 1993

Nyström L, Rutqvist LE, Wall S, Lindgren A, Lindqvist M, Ryden S et al. Breast cancer screening with mammography: overview of Swedish randomised trials. *The Lancet* 1993;341(8851):973-8.

Nyström 1993a

Nyström L, Larsson L-G. Breast cancer screening with mammography [reply]. *The Lancet* 1993;341:1531-2.

Nyström 1996

Nyström L, Larsson LG, Wall S, Rutqvist LE, Andersson I, Bjurstam N et al. An overview of the Swedish randomised mammography trials: total mortality pattern and the representivity of the study cohorts. *Journal of Medical Screening* 1996;3(2):85-7.

Nyström 1997

Nyström L, Wall S, Rutqvist LE, Andersson I, Bjurstam N, Fagerberg G et al. Update of the overview of the Swedish randomized trials on breast cancer screening with mammography. In: NIH Consensus Development Conference on Breast Cancer Screening for Women Ages 40-49. National Institutes of Health. 1997:65-9.

Nyström 2000

Nyström L. Assessment of population screening: the case of mammography [thesis]. Umeå: Umeå University Medical Dissertations, 2000.

Nyström 2002

Nyström L, Andersson I, Bjurstam N, Frisell J, Nordenskjöld B, Rutqvist LE. Long-term effects of mammography screening: updated overview of the Swedish randomised trials. *The Lancet* 2002;359(9310):909-19.

Nyström 2002a

Nyström L. Personal communication 31 July 2002.

Nyström 2002b

Nyström L, Andersson I, Bjurstam N, Frisell J, Rutqvist LE. Update on effects of screening mammography. *The Lancet* 2002;360:339-40.

Olsen 2001a

Olsen O, Gøtzsche PC. Cochrane review on screening for breast cancer with mammography. *The Lancet* 2001;358:1340-2.

Olsen 2001b

Olsen O, Gøtzsche PC. Systematic review of screening for breast cancer with mammography. <http://image.thelancet.com/extras/fullreport.pdf> 2001.

Olsen 2003

Olsen AH, Jensen A, Njor SH, Villadsen E, Schwartz W, Veiborg I et al. Breast cancer incidence after the start of mammography screening in Denmark. *British Journal of Cancer* 2003;88:362-5.
medRxiv preprint doi: <https://doi.org/10.1101/2024.06.06.24300542>; this version posted June 6, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Paci 2002

Paci E, Duffy SW, Giorgi D, Zappa M, Crocetti E, Vezzosi V, et al. Are breast cancer screening programmes increasing rates of mastectomy? Observational study. *BMJ* 2002;325:418.

Patnick 2012

Patnick J. NHS Breast Screening Programme: annual review 2011. NHS Breast Screening Programme 2012.

Projektgruppen 1985

Projektgruppen för WE-studien i Kopparbergs och Östergötlands län samt socialstyrelsens bearbetningsgrupp för WE-projektet. Reply on mammography [Replik om mammografi]. *Läkartidningen* 1985;82:2674.

Prorok 2000

Prorok PC. Personal communication 2 Febr 2000.

Prorok 2018

Prorok PC, Wright P, Riley TR, Kramer BS, Berg CD, Gohagan JK Rev Recent Clin Trials 2018, 13(4):257-273 PMID: 29629665. Overall and Multiphasic Findings of the Prostate, Lung, Colorectal and Ovarian (PLCO) Randomized Cancer Screening Trial. Reviews on Recent Clinical Trials 2018;13:257-73. [DOI: doi: 10.2174/1574887113666180409153059]

Puffer 2003

Puffer S, Torgerson D, Watson J. Evidence for risk of bias in cluster randomised trials: review of recent trials published in three general medical journals. *BMJ* 2003;327:785-9.

Raffle 2003

Raffle AE, Alden B, Quinn M, Babb PJ, Brett MT. Outcomes of screening to prevent cancer: analysis of cumulative incidence of cervical abnormality and modelling of cases and deaths prevented. *BMJ* 2003;326:901. [DOI: doi: 10.1136/bmj.326.7395.901]

Rapport 1982

Rapport över mammografiscreening i Kopparbergs och Östergötlands läns landsting (WE-projektet) - Resultat efter första screeningsomgången. Unknown. Stockholm: Socialstyrelsen, 1982.

Riemsma 2010

Riemsma R, Forbes CA, Kessels A, Lykopoulos K, Amonkar MM, Rea DW, Kleijnen J. Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer. *Breast Cancer Research and Treatment* 2010;123:9-24. [PMID: [20535542](#)]

Ries 2002

Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, et al. SEER Cancer Statistics Review, 1973-1999. http://seer.cancer.gov/csr/1973_1999/ 2002 (accessed 26 June, 2003).

Roberts 1984

Roberts MM, Alexander FE, Anderson TJ, Forrest AP, Hepburn W, Huggins A et al. The Edinburgh randomised trial of screening for breast cancer: description of method. *British Journal of Cancer* 1984;50(1):1-6.

Roberts 1990

Roberts MM, Alexander FE, Anderson TJ, Chetty U, Donnan PT, Forrest P et al. Edinburgh trial of screening for breast cancer: mortality at seven years. *The Lancet* 1990;335(8684):241-6.

Rostgaard 2010

Rostgaard K, Vaeth M, Rootzén H, Lynge E. Why did the breast cancer lymph node status distribution improve in Denmark in the pre-mammography screening period of 1978-1994? *Acta Oncologica* 2010;49:313-321.

Salz 2010

Salz T, Richman AR, Brewer NT. Meta-analyses of the effect of false-positive mammograms on generic and specific psychosocial outcomes. *Psychooncology* 2010;19:1026-34.

medRxiv preprint doi: <https://doi.org/10.1101/2024.06.06.24308542>; this version posted June 6, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](#).

Schwartz 2000

Schwartz LM, Woloshin S, Sox HC, Fischhoff B, Welch HG. US women's attitudes to false positive mammography results and detection of ductal carcinoma in situ: cross sectional survey. *BMJ* 2000;320:1635-40.

Shapiro 1966

Shapiro S, Strax P, Venet L. Evaluation of periodic breast cancer screening with mammography. Methodology and early observations. *JAMA* 1966;195(9):731-8.

Shapiro 1972

Shapiro S, Strax P, Venet L, Venet W. Changes in 5-year breast cancer mortality in a breast cancer screening program. *Journal of the National Cancer Institute* 1972;7:663-78.

Shapiro 1977

Shapiro S. Evidence on screening for breast cancer from a randomized trial. *Cancer* 1977;39 Suppl(6):2772-82.

Shapiro 1982

Shapiro S, Venet W, Strax P, Venet L, Roeser R. Ten- to fourteen-year effect of screening on breast cancer mortality. *Journal of the National Cancer Institute* 1982;69(2):349-55.

Shapiro 1985

Shapiro S, Venet W, Strax P, Venet L, Roeser R. Selection, follow-up, and analysis in the Health Insurance Plan Study: a randomized trial with breast cancer screening. *Journal of the National Cancer Institute. Monographs* 1985;67:65-74.

Shapiro 1985a

Shapiro S. Discussion II. *Journal of the National Cancer Institute. Monographs* 1985;67:75.

Shapiro 1988

Shapiro S, Venet W, Strax P, Venet L. Periodic screening for breast cancer: The health insurance plan project and its sequelae, 1963-1986. Baltimore: Johns Hopkins University Press, 1988.

Shapiro 1989

Shapiro S. The status of breast cancer screening: a quarter of a century of research. *World Journal of Surgery* 1989;13(1):9-18.

Shapiro 1994

Shapiro S. Screening: assessment of current studies. *Cancer* 1994;74 Suppl(1):231-8.

Skrabanek 1993

Skrabanek P. Breast cancer screening with mammography [letter]. *The Lancet* 1993;341:1531.

Slaytor 1998

Slaytor EK, Ward JE. How risks of breast cancer and benefits of screening are communicated to women: analysis of 58 pamphlets. *BMJ* 1998;317(7153):263-4.

Smart 1995

Smart CR, Hendrick RE, Rutledge JH 3rd, Smith RA. Benefit of mammography screening in women ages 40 to 49 years. Current evidence from randomized controlled trials. *Cancer* 1995;75(7):1619-26.

Smith-Bindman 2003

Smith-Bindman R, Chu PW, Miglioretti DL, Sickles EA, Blanks R, Ballard-Barbash R, et al. Comparison of screening mammography in the United States and the United kingdom. *JAMA* 2003;290:2129-37.

Socialstyrelsen 1985

Socialstyrelsens beredningsgrupp för WE-projektet. Minskad mortalitet i bröstcancer genom hälskontroll med mammografi. Nordisk Medicin 1985;100:175-8.

medRxiv preprint doi: <https://doi.org/10.1101/2024.06.06.24308542>; this version posted June 6, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](#).

statusrapport 1997

Unknown. Tidlig opsporing og behandling af brystkræft: statusrapport. København: Sundhedsstyrelsen, 1997.

Strax 1973

Strax P, Venet L, Shapiro S. Value of mammography in reduction of mortality from breast cancer in mass screening. The American Journal of Roentgenology, Radium Therapy, and Nuclear Medicine 1973;117(3):686-9.

Suhrke 2011

Suhrke P, Mæhlen J, Schlichting E, Jørgensen KJ, Gøtzsche PC, Zahl P-H. Effect of mammography screening on surgical treatment for breast cancer in Norway: comparative analysis of cancer registry data. BMJ 2011;343:d4692.

Swed Cancer Soc 1996

Swedish Cancer Society and the Swedish National Board of Health and Welfare. Breast-cancer screening with mammography in women aged 40-49 years. International Journal of Cancer 1996;68(6):693-9.

Swift 1993

Swift M. Screening mammography [letter]. The Lancet 1993;342:549-50.

Tabar 1979

Tabar L, Gad A, Akerlund E, Fors B, Fagerberg G, Baldetorp L. Screening for breast cancer in Sweden. A randomised controlled trial. In: Logan WW, Muntz EP, editors(s). Reduced dose mammography. New York: Masson, 1979:407-14.

Tabar 1981

Tabar L, Gad A. Screening for breast cancer: the Swedish trial. Radiology 1981;138(1):219-22.

Tabar 1985

Tabar L, Fagerberg CJ, Gad A, Baldetorp L, Holmberg LH, Grøntoft O et al. Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare. Lancet 1985;1(8433):829-32.

Tabar 1985a

Tabar L, Gad A, Holmberg L, Ljungquist U. Significant reduction in advanced breast cancer. Results of the first seven years of mammography screening in Kopparberg, Sweden. Diagnostic Imaging in Clinical Medicine 1985;54(3-4):158-64.

Tabar 1988

Tabar L, Fagerberg CJG, Day NE. The results of periodic one-view mammographic screening in Sweden. Part 2: Evaluation of the results. In: Day NE, Miller AB, editors(s). Screening for breast cancer. Toronto: Hans Huber, 1988:39-44.

Tabar 1989

Tabar L, Fagerberg G, Duffy SW, Day NE. The Swedish two county trial of mammographic screening for breast cancer: recent results and calculation of benefit. Journal of Epidemiology and Community Health 1989;43(2):107-14.

Tabar 1990

Tabar L, Duffy SW, Day NE. Screening with mammography [letter]. International Journal of Technology Assessment in Health Care 1990;6(3):498-500.

Tabar 1991

Tabar L, Fagerberg CJG, South MC, Day NE, Duffy SW. The Swedish Two-county Trial of mammographic screening for breast cancer: recent results on mortality and tumour characteristics. In: Miller AB, Chamberlain J, Day NE et al, editors(s). Cancer screening. Cambridge: Cambridge University Press, 1991:23-36.

Tabar 1992

medRxiv preprint doi: <https://doi.org/10.1101/2024.06.06.24308542>; this version posted June 8, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Tabar 1995

Tabar L, Fagerberg G, Chen HH, Duffy SW, Smart CR, Gad A et al. Efficacy of breast cancer screening by age. New results from the Swedish Two-County Trial. Cancer 1995;75(10):2507-17.

Tabar 1999

Tabar L, Chen HH, Duffy SW, Krusemo UB. Primary and adjuvant therapy, prognostic factors and survival in 1053 breast cancers diagnosed in a trial of mammography screening. Japanese Journal of Clinical Oncology 1999;29(12):608-16.

Tabar 2000

Tabar L, Vitak B, Chen HH et al. The Swedish Two-County Trial twenty years later. Updated mortality results and new insights from long-term follow-up. Radiologic Clinics of North America 2000;38(4):625-51.

Tabar 2000a

Tabar L. Personal communication 17 Jan 2000.

Tabar 2001

Tabar L, Vitak B, Chen HH, Yen MF, Duffy SW, Smith RA. Beyond randomized controlled trials: organized mammographic screening substantially reduces breast carcinoma mortality. Cancer 2001;91(9):1724-31.

Tabar 2002

Tabár L, Smith RA, Duffy SW. Update on effects of screening mammography. Lancet 2002;360:337.

Tabar 2002a

Tabar L, Duffy SW, Yen MF, Warwick J, Vitak B, Chen HH et al. All-cause mortality among breast cancer patients in a screening trial: support for breast cancer mortality as an end point. Journal of Medical Screening 2002;9(4):159-62.

Tabar 2003

Tabar L, Smith RA, Vitak B, Yen MF, Chen TH, Warwick J et al. Mammographic screening: a key factor in the control of breast cancer. Cancer Journal 2003;9(1):15-27.

Tabar 2003a

Tabar L, Yen MF, Vitak B, Chen HH, Smith RA, Duffy SW. Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening. Lancet 2003;361:1405-10.

The Lancet Erratum 2002

The Lancet Erratum. Department of error: update on screening mammography. The Lancet 2002.

Thomas 1977

Thomas LB, Ackerman LV, McDivitt RW, Hanson TAS, Hankey BF, Prorok PC. Report of NCI ad hoc pathology working group to review the gross and microscopic findings of breast cancer cases in the HIP study. Journal of the National Cancer Institute 1977;59(2):496-541.

Thomas 2020

Thomas J, McDonald S, Noel-Storr AH, Shemilt I, Elliott J, Mavergames C, et al. Machine learning reduced workload with minimal risk of missing studies: development and evaluation of a randomized controlled trial classifier for Cochrane Reviews. Journal of Clinical Epidemiology 2021;133:140-51.

Thornton 1997

Thornton H. The voice of the breast cancer patient - a lonely cry in the wilderness. European Journal of Cancer 1997;33(6):825-8.

To 2014

To T, Wall C, Baines CJ, Miller AB. Is carcinoma in situ a precursor lesion of invasive breast cancer? International Journal of Cancer 2014;135:1646-52.

medRxiv preprint doi: <https://doi.org/10.1101/2024.06.06.24308542>; this version posted June 6, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](#).

UK Review 2012

Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Lancet 2010;380:1778-86.

UKNSC Criteria

Criteria for a population screening programme. <https://www.gov.uk/government/publications/evidence-review-criteria-national-screening-programmes/criteria-for-appraising-the-viability-effectiveness-and-appropriateness-of-a-screening-programme>.

US Task Force 2002

US Preventive Services Task Force. Screening for breast cancer: recommendations and rationale. Annals of Internal Medicine 2002;137(5 Part 1):344-6.

Wald 1993

Wald NJ, Chamberlain J, Hackshaw A. Report of the European Society for Mastology Breast Cancer Screening Evaluation Committee (1993). Breast 1993;2:209-16.

Walter 1999

Walter SD, Jadad AR. Meta-analysis of screening data: a survey of the literature. Statistics in Medicine 1999;18(24):3409-24.

Welch 1997

Welch HG, Black WC. Using autopsy series to estimate the disease reservoir for ductal carcinoma in situ of the breast. Annals of Internal Medicine 1997;127:1023-8.

Welch 2004

Welch HG. Should I be tested for cancer?. University of California Press, 2004.

Welch 2006

Welch HG. How much overdiagnosis? BMJ 2006 Mar 10;<http://www.bmj.com/content/332/7543/689?tab=responses> (accessed 21 Dec 2012).

Werkö 1995

Werkö L. Mammografi, vinst och risk. Läkartidningen 1995;92:4540.

Westerholm 1988

Westerholm B. Stötande syn på medelålders kvinnors värde. Läkartidningen 1988;85(47):4056-7.

Woloshin 2023

Woloshin S, Jørgensen KJ, Hwang S, Welch HG. The New USPSTF Mammography Recommendations - A Dissenting View. New England Journal of Medicine 2023;389:1061-4. [PMID: [37721382](#)]

World Cancer Data 2023

World Cancer Research Fund International. Worldwide cancer data. <https://www.wcrf.org/cancer-trends/worldwide-cancer-data/2023> (accessed 9 Jan 2023).

Zahl 2001

Zahl P-H, Kopjar B, Mæhlen J. Norwegian breast cancer mortality rates and validity in Swedish mammography trials. Tidsskrift for den Norske Lægeforening 2001;121:1928-31.

Zahl 2004

Zahl PH, Strand BH, Maehlen J. Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening: prospective cohort study. BMJ 2004;328:921-4.

Zahl 2006

Zahl P-H, Gøtzsche PC, Andersen JM, Mæhlen J. Results of the Two-County trial of mammography screening are not compatible with contemporaneous official Swedish breast cancer statistics. Danish Medical

Zahl 2008 Preprint doi: <https://doi.org/10.1101/2024.06.06.24308542>; this version posted June 6, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Zahl PH, Mæhlen J, Welch H. The natural history of breast cancers detected by screening mammography. Archives of Internal Medicine 2008;168:2311-6.

Zahl 2011

Zahl PH, Gøtzsche PC, Mæhlen J. Natural history of breast cancers detected in the Swedish mammography screening programme: a cohort study. Lancet Oncology 2011;12(12):1118-24.

References to other published versions of this review

Gøtzsche 2006

Gøtzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database of Systematic Reviews 2006, Issue 4. Art. No: CD001877. [DOI: [10.1002/14651858.CD001877](https://doi.org/10.1002/14651858.CD001877)]

Gøtzsche 2009a

Gøtzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database of Systematic Reviews 2009, Issue 4. Art. No: CD001877. [DOI: [10.1002/14651858.CD001877](https://doi.org/10.1002/14651858.CD001877)]

Gøtzsche 2013

Gøtzsche PC, Jørgensen KJ. Screening for breast cancer with mammography. Cochrane Database of Systematic Reviews 2013; Issue 6: Art. No.: CD001877. DOI: 10.1002/14651858.CD001877.pub5.

Olsen 2001


Olsen O, Gøtzsche PC. Screening for breast cancer with mammography. Cochrane Database of Systematic Reviews 2001, Issue 4. Art. No: CD001877. [DOI: [10.1002/14651858.CD001877](https://doi.org/10.1002/14651858.CD001877)]

Additional tables

Table 1				
Examples of varying numbers of women in the Swedish trials				
Study	Age range	Study group	Control group	Reference
Malmö	40-74	21242	21240	Andersson 1980
	40-74	21242	21244	Andersson 1983
	40-74	21088	21195	Andersson 1988
Kopparberg	total	47389	22658	Socialstyrelsen 1985
	40-74	39051	18846	Tabar 1985
	40-74	38589	18582	Tabar 1989
	40-74	38562	18478	Nyström 1993
	40-74	38589	18582	Tabar 1995
	40-74	38568	18479	Nyström 2000
	40-74	38588	18582	Nixon 2000
	40-74	data not available	data not available	Nyström 2002
	40-49	9625	5053	Tabar 1988
	40-49	data not available	data not available	Nyström 1993a
	40-49	9582	5031	Tabar 1995
	40-49	9650	5009	Nyström 1997
Östergötland	total	47001	45933	Socialstyrelsen 1985
	40-74	39034	37936	Tabar 1985
	40-74	38491	37403	Tabar 1989
	40-74	38405	37145	Nyström 1993
	40-74	38491	37403	Tabar 1995
	40-74	38942	37675	Nyström 2000
	40-74	39105	37858	Nixon 2000
	40-74	38942	37675	Nyström 2002
	40-49	10312	10625	Tabar 1988
	40-49	data not available	data not available	Nyström 1993a
	40-49	10262	10573	Tabar 1995
	40-49	10240	10411	Nyström 1997
Stockholm	40-64	40318	19943	Frisell 1989a
	40-65 (sic)	38525	20651	Nyström 1993
	40-64	40318	19943	Frisell 1997
	40-69	39139	20978	Nyström 2000


	40-49	data not available	data not available	Nyström 1993a
	40-49	14842	7103	Frisell 1997
	40-49	14303	8051	Nyström 2000
Göteborg	40-59	20724	28809	Nyström 1993
	39-59	21650	29961	Bjurstam 1997a
	40-59	21000	29200	Nyström 2000
	40-49	10821	13101	Nyström 1993a
	39-49	11724	14217	Bjurstam 1997
	40-49	10888	13203	Nyström 2002

Figure 1



Screen4Me Summary Diagram

Figure 2



PRISMA flow diagram of review update.

Figure 3





Figure 4


medRxiv preprint doi: <https://doi.org/10.1101/2024.06.06.24308542>; this version posted June 6, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias): All outcomes	Blinding of outcome assessment (detection bias): All outcomes	Incomplete outcome data (attrition bias): All outcomes	Selective reporting (reporting bias)	Other bias
Canada 1980	+	+	+	+	+	+	+
Canada 1980a	+	+	+	+	+	+	+
Canada 1980b	+	+	+	+	+	+	+
Edinburgh 1978	-	-	+	-	-	?	-
Göteborg 1982	-	-	+	+	+	+	-
Göteborg 1982a	?	?	+	+	+	+	-
Göteborg 1982b	?	?	+	+	+	+	-
Kopparberg 1977	?	-	+	-	-	-	-
Malmö 1976	+	+	+	+	+	+	+
Malmö II 1978	-	-	+	-	-	-	-
New York 1963	-	?	+	-	-	-	-
Östergötland 1978	?	-	+	-	-	-	-
Stockholm 1981	-	-	+	-	-	-	-
Two-County 1977	?	-	+	-	-	-	-
UK age trial 1991	+	+	+	+	+	+	+


Analysis 1.1




Analysis 1.2



Analysis 1.3




Analysis 1.4




Comparison 1: Screening with mammography versus no screening, Outcome 4: Deaths ascribed to breast cancer, 7 years follow up, women at least 50 years of age (Malmö 55)



Analysis 1.5




Analysis 1.6




Analysis 1.7





Analysis 1.9





Analysis 1.10





Analysis 1.11





Analysis 1.13





Analysis 1.15






Analysis 1.17




Analysis 1.19



Analysis 1.21











Click here to access/download
Supplementary material
[CD001877-data-package-info.html](#)





Click here to access/download
Supplementary material
CD001877-data-rows.csv








[Click here to access/download](#)



Supplementary material

CD001877-overall-estimates-and-settings.csv






Click here to access/download
Supplementary material
CD001877-subgroup-estimates.csv








Click here to access/download
Supplementary material
CD001877-additional-references.ris








Click here to access/download
Supplementary material
CD001877-other-published-versions.ris








Click here to access/download
Supplementary material
CD001877-awaiting.ris








Click here to access/download
Supplementary material
CD001877-excluded.ris





Click here to access/download
Supplementary material
CD001877-included.ris





Click here to access/download
Supplementary material
CD001877-risk-of-bias.csv





Click here to access/download
Supplementary material
CD001877-study-information.csv

